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Marrissa Martyn-St James,1 Andrew Rawdin,1 Emma Simpson,1
Ruth Wong,1 Naila Dracup,1 David L Scott2 and Adam Young3
1School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
2King’s College Hospital NHS Foundation Trust, London, UK
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Background: Treat to target (TTT) is a broad concept for treating patients with rheumatoid arthritis (RA).
It involves setting a treatment target, usually remission or low disease activity (LDA). This is often combined
with frequent patient assessment and intensive and rapidly adjusted drug treatment, sometimes based on
a formal protocol.
Objective: To investigate the clinical effectiveness and cost-effectiveness of TTT compared with
routine care.
Data sources: Databases including EMBASE and MEDLINE were searched from 2008 to August 2016.
Review methods: A systematic review of clinical effectiveness was conducted. Studies were grouped
according to comparisons made: (1) TTT compared with usual care, (2) different targets and (3) different
treatment protocols. Trials were subgrouped by early or established disease populations. Study heterogeneity
precluded meta-analyses. Narrative synthesis was undertaken for the first two comparisons, but was not
feasible for the third. A systematic review of cost-effectiveness was also undertaken. No model was
constructed as a result of the heterogeneity among studies identified in the clinical effectiveness review.
Instead, conclusions were drawn on the cost-effectiveness of TTT from papers relating to these studies.
Results: Sixteen clinical effectiveness studies were included. They differed in terms of treatment target,
treatment protocol (where one existed) and patient visit frequency. For several outcomes, mixed results or
evidence of no difference between TTT and conventional care was found. In early disease, two studies
found that TTT resulted in favourable remission rates, although the findings of one study were not
statistically significant. In established disease, two studies showed that TTT may be beneficial in terms of
LDA at 6 months, although, again, in one case the finding was not statistically significant. The TICORA
(TIght COntrol for RA) trial found evidence of lower remission rates for TTT in a mixed population. Two
studies reported cost-effectiveness: in one, TTT dominated usual care; in the other, step-up combination
treatments were shown to be cost-effective. In 5 of the 16 studies included the clinical effectiveness
review, no cost-effectiveness conclusion could be reached, and in one study no conclusion could be drawn
in the case of patients denoted low risk. In the remaining 10 studies, and among patients denoted high
risk in one study, cost-effectiveness was inferred. In most cases TTT is likely to be cost-effective, except
where biological treatment in early disease is used initially. No conclusions could be drawn for
established disease.
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Limitations: TTT refers not to a single concept, but to a range of broad approaches. Evidence reflects this.
Studies exhibit substantial heterogeneity, which hinders evidence synthesis. Many included studies are at
risk of bias.
Future work: Future studies comparing TTT with usual care must link to existing evidence. A consistent
definition of remission in studies is required. There may be value in studies to establish the importance of
different elements of TTT (the setting of a target, the intensive use of drug treatments and protocols
pertaining to those drugs and the frequent assessment of patients).
Conclusion: In early RA and studies of mixed early and established RA populations, evidence suggests that
TTT improves remission rates. In established disease, TTT may lead to improved rates of LDA. It remains
unclear which element(s) of TTT (the target, treatment protocols or increased frequency of patient visits)
drive these outcomes. Future trials comparing TTT with usual care and/or different TTT targets should use
outcomes comparable with existing literature. Remission, defined in a consistent manner, should be the
target of choice of future studies.
Study registration: This study is registered as PROSPERO CRD42015017336.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
This report investigates the value of so-called ‘treat-to-target’ (TTT) strategies in patients with rheumatoidarthritis (RA). Patients with RA, together with the doctors who treat them, can jointly agree targets
that they hope to achieve from treatment. TTT involves monitoring the condition of the patient and
adjusting treatments in order to attempt to reach the target. TTT can involve a more intensive use of drug
treatments and more frequent monitoring and treatment adjustments than normal care. A systematic
literature review was conducted to identify relevant existing studies. Sixteen studies were found. Eleven
studies were in patients who had RA for < 3 years, three studies were in patients who had RA for > 3 years
and two studies mixed both sets of RA patients. The evidence for the benefit of TTT strategies in reducing
the severity of RA is mixed and it is difficult to draw strong conclusions. The studies we identified often
compared TTT strategies that differed from each other in terms of the drugs and doses that patients
received. However, there is some evidence that TTT works better than usual treatment, in terms of the
numbers of patients achieving remission, particularly in those who have had RA for < 3 years. In patients
with more established disease we found some limited evidence that TTT works better in terms of patients
achieving low disease activity.
We also estimated that, in early disease, TTT strategies are likely to offer good value for money.
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Patients with rheumatoid arthritis (RA) have seen dramatic improvements in their care in the last 20 years,
particularly through the development of more targeted biologic disease-modifying antirheumatic drugs
(bDMARDs) and non-bDMARDs. Treat to target (TTT) in rheumatology is a more recent concept encompassing
a range of broad features. The central component of the TTT concept is the setting of a treatment target.
Recommendations in RA typically specify low disease activity (LDA) or remission as an appropriate target,
but, in addition to the setting of a target, there are a range of different features that lead to a continuum of
‘weak’ to ‘strong’ TTT principles. These can include an increased frequency of rheumatology visits for the
assessment of the target and any associated changes in the management of the patient. Treatment changes
within a TTT strategy may also be protocolised, specifying how treatments are to be altered in response to
the target assessment.
Objectives
To identify and evaluate the evidence for the clinical effectiveness and cost-effectiveness of TTT strategies
compared with routine care for adult patients with RA.
Methods
Review methods
Scoping searches were carried out to identify the extent of potentially relevant literature. Databases
including MEDLINE and EMBASE were searched from 2008 to August 2016. A full systematic review of
clinical effectiveness data was then conducted following the general principles recommended in the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. We searched for
evidence from studies of adults with clinically diagnosed RA, which included TTT. At a minimum, TTT had
to include the setting of an explicit target.
Only randomised controlled trials were included. Data were extracted on measures of treatment goals, including
the number/proportion of patients in each arm meeting the target; disease activity; mortality; health-related
quality of life; serious adverse events (SAEs); treatments; and dosages given. The methodological quality of each
included study was assessed.
Evidence examining the clinical effectiveness of TTT was synthesised according to the TTT comparison,
namely (1) TTT compared with usual care; (2) a comparison of different targets against each other; and
(3) a comparison of different treatment protocols against each other. Two trials did not fit into this framework
and so were examined separately under ‘other comparisons’. Trials were further grouped according to
whether or not they used early RA populations (disease duration < 3 years) or established RA populations.
A systematic review of cost-effectiveness was undertaken. Titles and abstracts were examined by one
reviewer and a random 5% were checked by another reviewer. Study selection based on full texts was
decided by two reviewers, with discrepancies resolved by discussion. Data were extracted by one reviewer
using a standardised data extraction form and checked by a second reviewer.
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Evaluation of cost-effectiveness
As study heterogeneity precluded meta-analysis, it was deemed most informative to analyse each
study included in the clinical effectiveness review and to assess the implications of the results for the
cost-effectiveness of each strategy. A simplistic approach was taken and costs that were assumed to be
similar between arms were ignored.
Results
A total of 16,591 records were identified from electronic databases. Forty-two articles describing 16 trials
were included in the review. Eleven trials examined an early RA population. Three trials examined an
established RA population. Two trials examined populations that included both patients with early RA and
those with established RA. The only trial rated as having a low risk of bias was the TICORA (TIght COntrol
for RA) trial, which examined TTT compared with usual care in a mixed population.
Study heterogeneity precluded meta-analyses. This heterogeneity was evident in the substantial differences
between studies in the targets that were set, the nature of the treatment protocol (where one existed) and
the frequency of patient visits.
Overall, the evidence for TTT is mixed. For several outcome measures, studies produced a mixture of results
or found no difference between TTT and conventional care. However, there does seem to be some
support for the use of TTT in specific patient groups for some outcomes.
Two studies in patients with early disease found that TTT resulted in favourable remission rates, though in
one case the findings were not statistically significant: an odds ratio (OR) of 0.52 [95% confidence interval
(CI) 0.21 to 1.28] in the STRategies in Early Arthritis Management (aggressive therapy in patients with early
arthritis results in similar outcome as conventional care) study at 2 years; an OR of 0.43 (95% CI 0.19 to
0.95) for Disease Activity Score, 28 joints (DAS28)-driven TTT at 1 year in the TreaTing to Twin Targets
(T-4) study; and an OR of 0.21 (95% CI 0.10 to 0.47) for DAS28-driven and matrix metalloproteinase 3
(MMP-3)-driven TTT at 1 year in the T-4 study. The T-4 study found usual care to be more effective than
the MMP-3 target (21% vs. 13%; OR 1.72, 95% CI 0.66 to 4.52). There were mixed findings for DAS28/
Disease Activity Score, 44 joints (DAS44) and joint erosion, and no difference between targeted arms and
usual care on Health Assessment Questionnaire (HAQ) score. There were no differences in the proportions
of patients experiencing any adverse event (AE), SAE, death, withdrawals as a result of AEs or specific AEs.
Two studies in patients with established disease found that TTT may be beneficial in terms of LDA at
6 months, although, again, in one case the result was not statistically significant [an OR of 0.42 (95% CI
0.19 to 0.94) in the Fransen et al. study at 6 months; an OR of 0.81 (95% CI 0.45 to 1.45) using a DAS28
target in the Optimisation of Adalimumab study; and an OR of 0.91 (95% CI 0.50 to 1.66) in the same
study using a swollen joint count (SJC) of 0 targets]. There was no difference between TTT and usual care
in terms of DAS28, SJC, tender joint count or HAQ response. The proportion of patients who withdrew as
a result of AEs (as reported in the Optimisation of Adalimumab study) and experienced specific AEs
(dermatological and gastrointestinal AEs as reported in Fransen et al.) was lower in the TTT arms.
Of the trials that included both patients with early disease and those with established disease, only the
TICORA trial found evidence favouring TTT in terms of remission at 18 months (65% vs. 16%; p < 0.0001).
The TICORA trial also reported results in favour of a TTT approach compared with usual care in terms of
American College of Rheumatology 20/50/70 response rates. The evidence, however, was equivocal for
other outcome measures. A smaller proportion of patients reported any and specific AEs (dermatological,
gastrointestinal and infectious AEs, significance not reported) in the TTT arm than the usual-care arm of
the TICORA trial.
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Support for TTT in early disease is stronger if evidence from the TICORA trial, which had an inclusion
criterion of disease duration < 5 years, is considered generalisable to the early RA population.
There was little difference in outcomes where different targets were used as part of TTT strategies
across all RA populations.
Two papers on the cost-effectiveness of TTT were identified. One, related to the Dutch Rheumatoid Arthritis
Monitoring (DREAM) registry, estimated that TTT would be dominant at 3 years. Savings compared with
usual care were estimated at €462 (2011 values). The second, related to the BehandelStrategieën in
Reumatoïde Artritis trial, estimated that step-up combination therapy was the most cost-effective strategy,
even when compared with a strategy that included combination therapy with a biologic drug, and saved
€2743 per patient (2008 values) compared with sequential monotherapy.
Literature relating to 16 studies was found. In five of these studies, and for low-risk patients (criteria not
defined) in one study, no clear conclusion regarding cost-effectiveness could be made. In the remaining
10 studies, and for the high-risk patients (criteria not defined) in one study, we were able to estimate
whether or not the strategy was likely to be cost-effective. Almost all of the estimates from these studies
indicated that TTT would be considered cost-effective other than where the TTT strategy included the use
of bDMARDs in early disease. No conclusions could be made in relation to TTT in established disease.
Discussion
Treat to target refers not to a single concept, but to a range of broad approaches to the treatment of
patients with RA. The evidence reflects this, with studies exhibiting a great degree of heterogeneity,
particularly in relation to the TTT strategies they sought to examine. Studies varied in terms of the
treatment target, treatment protocols and frequency of assessments. Targets were often defined in terms
of Disease Activity Scores, but different variants of the measure (DAS44, DAS28) and different cut-off
points were used. Even in the case of TTT strategies that were broadly similar, the precise therapies used
exhibited significant variation. For example, in those studies that used both a steroid step-down and a
disease-modifying antirheumatic drug (DMARD) step-up combination treatment protocol, the doses of
steroid varied substantially and the specific DMARD and dose also varied. This variation makes it complex
to synthesise evidence and draw general conclusions. This applies equally to the assessment of clinical
effectiveness and cost-effectiveness. This is further weakened by the risk of bias in many included studies.
Despite this, there does seem to be some support for the broad TTT concept in RA, particularly in early RA,
or for patients with a disease duration < 5 years if the TICORA trial is considered representative of early RA
patients. However, it remains unclear which elements of TTT are important or if all are required. It is not
possible to ascertain if it is the setting of a target, the more intensive management of patients or the
treatment protocols that drive better outcomes. Furthermore, we cannot identify if any particular treatment
target is more appropriate.
Owing to the heterogeneity of the evidence and the potential of changes in usual care across time, no
modelling evaluating all strategies within a fully incremental analysis could be performed. For this reason,
only those studies that have been trialled in the same study can be compared. In early RA, the components
of care that together constitute ‘TTT’ are likely to form a cost-effective approach. There were insufficient
studies in established RA to discern a pattern in cost-effectiveness.
Conclusions
Treat to target is a broad concept and does not refer to a single treatment strategy. In early RA there is
some limited evidence to suggest that strategies that have been tested in clinical studies as TTT lead to
better outcomes, particularly in terms of the number of patients achieving remission. In established disease
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there is evidence that TTT leads to more patients achieving LDA. However, it is unclear which of the
various elements of TTT drive these findings.
Intensive drug therapy is frequently included as part of TTT strategies that have been tested in trials.
These trials do seem to indicate that intensive conventional disease-modifying antirheumatic drug (cDMARD)
treatment is more cost-effective than routine practice, particularly in early RA. However, whether or not these
results require the inclusion of a specific target in addition is uncertain. The use of bDMARDs before intensive
cDMARDs as part of a TTT strategy is unlikely to be cost-effective.
Future trials comparing TTT with usual care and/or different TTT targets should use outcomes comparable
with existing literature. Remission, defined in a consistent manner, should be the target of choice of
future studies.
Study registration
This study is registered as PROSPERO CRD42015017336.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Description of health problem
Rheumatoid arthritis (RA) is a common chronic inflammatory disease that typically affects the joints of the
body that are lined with synovium, such as those in the hands and feet. It is characterised by progressive,
irreversible joint damage, impaired joint function and pain and tenderness caused by swelling of the
synovial lining of joints (synovitis), and manifests as increasing disability and reduced quality of life.1 As
RA is a systemic disease, it affects much more than the joints. The primary symptoms are pain, morning
stiffness, swelling, tenderness, loss of movement, fatigue and redness of the peripheral joints.2,3 Fever, sweats
and weight loss may be experienced. More significant inflammatory manifestations may lead to serious
pathology.4 RA has long been reported as being associated with increased mortality,5,6 particularly as a result
of cardiovascular events,7 which may result from reduced mobility and ongoing inflammation. For example,
a 50-year-old woman with RA is expected to die 4 years earlier than a 50-year-old woman without RA.4
The costs of RA are substantial. Treatment costs associated with drug acquisition and hospitalisation are
major components of this. Reduced work productivity is also a significant cost burden in this patient
group.3 The total costs of RA in the UK, including indirect costs and work-related disability, have been
estimated at between £3.8B and £4.75B per year.8
Epidemiology
Symmons et al.9 estimated a prevalence of 0.8% in a study of the population in Norfolk. This leads to an
estimated 400,000 people in England and Wales with RA,10 with approximately 10,000 incident cases per
year.11 The disease is about 2–4 times more common in women (1.16%) than in men (0.44%),11 with the
majority of cases being diagnosed when patients are aged between 40 and 80 years,12 with peak incidence
among those in their seventies.11 Thus, a large proportion of people affected by RA are of working age.
Significance for the NHS
The treatment of RA is costly to the NHS and the wider economy. Many of the treatment options for
patients are based on drug therapy, some of which (particularly biologic therapies) are extremely costly.
The cost of treating patients whose disease is not well controlled from an early stage is also driven
substantially by the need for joint surgery and hospitalisation.
Treat to target (TTT) has the potential to allow more effective treatment strategies to be given to patients.
Given in early disease, this may result in better disease control. Remission has been shown to correlate
strongly with long-term structural damage identifiable on radiographs and with patient function. Disease
control may also allow the tapering of drug doses over time and avoid the need to progress to costlier
biologic therapies.
Current service provision
A series of drug-based treatments have contributed to the rapid improvement in the care of patients with
RA over the last 20 years. Traditionally, patients have been treated with conventional disease-modifying
antirheumatic drugs (cDMARDs), which include methotrexate (MTX), sulfasalazine (SSZ), hydroxychloroquine
(HCQ), leflunomide (LEF), ciclosporin and gold injections, as well as corticosteroids, analgesics and non-
steroidal anti-inflammatory drugs (NSAIDs). More recently, a group of drugs has been developed consisting
of monoclonal antibodies and soluble receptors that specifically modify the disease process by blocking key
protein messenger molecules (such as cytokines) or cells (such as B lymphocytes).4 Such drugs have been
labelled as biologic disease-modifying antirheumatic drugs (bDMARDs).
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Given the number of treatments available, there is a vast number of potential treatment strategies for
patients in both early and established disease.
Clinical guidelines
For people with newly diagnosed RA, the National Institute for Health and Care Excellence (NICE) clinical
guideline number 794 recommends a combination of cDMARDs [including MTX and at least one other
disease-modifying antirheumatic drug (DMARD) plus short-term glucocorticoids (GCs)] as a first-line
treatment, ideally beginning within 3 months of the onset of persistent symptoms. Where combination
therapies are not appropriate (e.g. where there are comorbidities or pregnancy), DMARD monotherapy is
recommended, this was considered a more standard treatment approach prior to the NICE guidelines.
Current National Institute for Health and Care Excellence Technology Appraisal
guidance
The NICE guidance [Technology Appraisal (TA) number 37513] recommends the use of adalimumab (ADA),
etanercept (ETN), infliximab (IFX), certolizumab pegol, golimumab, tocilizumab (TOC) and abatacept, in
combination with MTX, in people with RA only if:
l disease is severe, that is, Disease Activity Score, 28 joints (DAS28) is > 5.1
l disease has not responded to intensive therapy with a combination cDMARDs
l the manufacturers provide certolizumab pegol, golimumab, abatacept and TOC as agreed in their
patient access schemes.
Adalimumab, ETN, certolizumab pegol or TOC can be used as monotherapy for people who cannot take
MTX, because it is contraindicated or because of intolerance, when the above criteria are met.
At least a moderate European League Against Rheumatism (EULAR) response must be achieved at
6 months for treatment to continue.
The NICE has also issued guidance on the treatment of RA after the failure of a tumour necrosis factor
inhibitor (TNFi) (TA195,14 TA22515 and TA24716).
Description of technology under assessment
Dramatic improvements in the treatment of RA have been seen in the last 20 years (see Smolen et al.17),
particularly through the development of more targeted bDMARDs and non-bDMARDs. A more recent
development that has consolidated these improvements is the concept of TTT. Rather than referring to a
single, precise technology or treatment strategy, TTT in rheumatology can be better described as a
treatment ‘paradigm’17 encompassing a range of broad features. The American College of Rheumatology
(ACR)/EULAR have issued a series of recommendations on TTT based on analysis of a series of trials that
test varying treatment strategies. There is therefore no single set of interventions constituting a TTT
treatment approach.
Treat to target has a strong history in the treatment of other chronic diseases, such as diabetes mellitus
and hypertension. Long-term outcome data supporting the TTT approach in these conditions have
motivated the drive for successful TTT approaches in RA.
The central component of the TTT concept is the setting of a treatment target. Recommendations typically
specify low disease activity (LDA) or remission as appropriate targets. This was the case in EULAR’s 2010
recommendations (see Smolen et al.18) and EULAR’s 2016 updated recommendations (see Smolen et al.17),
both of which recommended clinical remission as the primary treatment goal. The ACR/EULAR’s 2011
definition of remission was originally designed specifically to be a predictor of good patient outcomes in
terms of a later lack of radiography-detected joint damage and good, stable function and quality of life for
BACKGROUND
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patients,19 more so than other disease activity states (including LDA).17 These goals have become realistic
targets with the availability of newer drugs.
The ACR/EULAR definition of remission is:
l Boolean-based definition: at any time point, a patient must satisfy all of the following: a tender joint
count (TJC) of ≤ 1, a swollen joint count (SJC) of ≤ 1, a C-reactive protein (CRP) concentration of
≤ 1 mg/dl and a patient global assessment of ≤ 1 (on a scale of 0–10) or
l index-based definition: at any time point, a patient must have Simple Disease Activity Index (SDAI)
of ≤ 3.3.
Low disease activity as an acceptable, alternative therapeutic goal, particularly in long-standing disease,
is a recommendation intended to imply that there are situations where remission may not be a feasible
outcome.
However, TTT, as a concept, is also often described as comprising more than just a treatment goal.
Different commentators refer to different elements of the TTT strategy that aim to take action to reach and
maintain the treatment goal. Common to most is the concept of regular treatment adaptation in response
to the assessment of a patient in comparison to the target. Sometimes treatment adaptation is described
in broad terms;17,18 in other instances reference is made to ‘aggressive treatment’.20 Terminology also
varies, with some referring to ‘tight control’.21
Solomon et al.20 also refers to TTT as a ‘proactive’ treatment approach. In many studies of TTT this is
evident through more frequent assessment of patients than would normally be the case in standard
practice. Assessments are often made as frequently as monthly under TTT principles. The ACR/EULAR’s
recommendations state that assessments should be made ‘as frequently as monthly’ and drug therapy
should be altered at least every 3 months, until the target is reached. Less frequent (6-monthly) monitoring
of patients is required once the target is reached.
Treat to target can therefore be composed of a range of different features that leads to a continuum of
‘weak’ to ‘strong’ TTT principles. We define the entirety of those features as the ‘treatment strategy’.
The inclusion of a treatment target is a necessary condition for a strategy to be considered a TTT strategy.
Additional components of the strategy include the frequency with which patients are assessed against the
target and the provision of a treatment protocol that specifies how treatments are to be changed in
response to assessments. Thus, the weakest TTT strategy would be one where a treatment target is
specified, but no further instruction is provided on which treatment protocols should be used to reach
that goal.
Treat-to-target studies have often focused on the optimal strategy for patients with newly diagnosed RA.
This links to the concept of there being a ‘window of opportunity’ that has emerged in the RA literature,
which posits that the earlier DMARD therapy is introduced, the greater the impact on long-term health
outcomes.21
Additional costs associated with TTT depend on the nature of the overall treatment strategy. Of course,
the setting of a target itself incurs no additional resources, but the increased frequency of visits to a
rheumatologist and the potential for a more intense use of drug treatments can make TTT a more
resource-intensive option for the initial treatment period.
A simplified schematic of operationalising a TTT strategy has been provided in Figure 1.
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FIGURE 1 A simplified conceptual model of TTT.
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Chapter 2 Definition of the decision problem
We aim to systematically review evidence on the use of TTT strategies for the treatment of RAcompared with standard care with non-TTT strategies.
Decision problem
Interventions
The intervention of interest is a TTT approach to care. At a minimum, for a treatment strategy to be
considered TTT in this review it must contain the explicit setting of a target, assessment of that target and
use of that information by the treating clinician. TTT strategies may also include additional elements; for
example, in the frequency of assessment or in providing a treatment protocol that provides instruction to
the treating clinician on treatment changes in the light of assessments. Our review will seek to distinguish
these different types of TTT.
Population including subgroups
Adult patients aged ≥ 18 years with a diagnosis of RA were eligible for the study. We will consider two
groups of patients separately: (1) those with early disease (≤ 3 years since diagnosis) and (2) those with
established disease (> 3 years since diagnosis). We used definitions of early and established RA as defined
in the trials. When no definition was provided, a cut-off point of 3 years was used, which is generally
consistent across the literature (e.g. Scott et al.22), bearing in mind that no fixed consensus exists.
Examining definitions and mean disease durations across trials, a 3-year cut-off point seems appropriate.
Relevant comparators
The comparator is treatment of patients without a TTT strategy. This includes sequential non-bDMARD
therapy in early disease, clinician preference and any treatment protocol that lacks an explicit treatment target.
Outcomes
A number of outcomes were assessed. Primarily, we examined the proportion of patients achieving target,
remission and LDA. We also examined changes in DAS28/ Disease Activity Score, 44 joints (DAS44), SJC,
TJC, Health Assessment Questionnaire (HAQ), joint erosion and quality of life, as well as EULAR and ACR
response.
Overall aims and objectives of assessment
The aim of this review is to identify and evaluate the evidence for the clinical effectiveness and
cost-effectiveness of TTT strategies compared with routine care for adult patients with RA.
Patient and public involvement
Two members of the public who have RA were asked to peer review the following sections of the report:
the abstract; plain English summary; scientific summary; discussion; and conclusions. The full report was
provided to supply further information and the patient and public involvement representatives could
comment on other sections too. The report was then amended based on the comments received to
improve the clarity and readability of the text.
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Chapter 3 Assessment of clinical effectiveness
Methods for reviewing clinical effectiveness
The search for evidence of clinical effectiveness was undertaken systematically following the general
principles recommended in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement (URL: www.prisma-statement.org/; accessed 30 October 2017). Search strategies are
described in Appendix 1.
Identification of studies
There were two search phases conducted for this review.
Phase I scoping searches were carried out to identify the extent of potentially relevant literature, the range
and types of TTT strategies that have been subject to clinical study, the types of clinical study and the
relevance of these strategies to UK NHS practice.
Four databases and one clinical trials registry were searched (Table 1). Terms for RA (see Appendix 2,
statements 1 and 2) were combined with TTT terms (see Appendix 2, statements 4–18). Terms for TTT
were obtained and adapted from the review by Schoels et al.23
TABLE 1 Sources searched in Phases I and II
Source, date searched from




MEDLINE(R) In-Process & Other Non-Indexed Citations and MEDLINE(R)
(via Ovid), from 1948
✓ ✓
EMBASE (via Ovid), from 1980 ✓ ✓
CDSR (via Wiley Online Library), from 1996 ✓ ✗
CENTRAL (via Wiley Online Library), from 1898 ✓ ✓
NHS EED (via Wiley Online Library), from 1995 to 2015 ✓ ✓
HTA database (via Wiley Online Library), from 1995 ✓ ✗
DARE (via Wiley Online Library), from 1995 ✓ ✗
WoS Citation Index Expanded (Thomson Reuters), from 1900 ✓ ✓
WoS Citation Index and Conference Proceedings Index (Thomson Reuters),
from 1990
✓ ✓
BIOSIS Previews (Thomson Reuters), from 1969 ✗ ✓
CINAHL (via EBSCOhost), from 1982 ✗ ✓
EconLit (via Ovid), from 1886 ✗ ✓
EULAR (via Web of Science, Thomson Reuters) ✓ ✗
ACR (via Web of Science, Thomson Reuters)) ✓ ✗
ClinicalTrials.gov (US National Institutes of Health) (www.clinicaltrials.gov) ✓ ✓
ICTRP (www.who.int/ictrp/en/) ✗ ✓
NICE Evidence (www.nice.org.uk/) ✗ ✓
BIOSIS, Bioscience Information Service; CDSR, Cochrane Database of Systematic Reviews; CENTRAL, Cochrane Central
Register of Controlled Trials; CINAHL, Cumulative Index to Nursing and Allied Health Literature; DARE, Database of Abstracts
of Reviews of Effects; EconLit, American Economic Association’s electronic bibliography; HTA, Health Technology Assessment;
ICTRP, International Clinical Trials Registry Platform; NHS EED, NHS Economic Evaluation Database; WoS, Web of Science.
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The search was combined with specific search filters for randomised controlled trials (RCTs) (see Appendix 2,
statements 21 and 22), systematic reviews (see Appendix 2, statements 26–28) and economic evaluations
(see Appendix 2, statements 32–34). The RCT and systematic reviews search was limited by date from 2008
until May 2015, whereas for recent cost-effectiveness studies, the last 2 years were searched (2013–15).
The Phase II search was informed by the literature identified from the Phase I searches to refine and carry
out a full systematic search of the evidence.
Additional free-text terms for TTT were added to the Phase I search strategies to increase the sensitivity
of the search (see Appendix 2). Only RCT and economic evaluations were searched by combining the
strategies with sensitive search filters. Three further databases, one trials registry and a search engine were
searched (see Table 1). No date or language limits were applied in the search. Records retrieved from the
search were combined and duplicate titles were removed from the Phase I search.
The number of records retrieved from the various sources in Phase I and II searches can be found in Table 2.














MEDLINE 475 168 73 3778 294 417
EMBASE 1315 302 290 7633 423 923
CDSR – 81 – – – –
DARE – 79 – – – –
CENTRAL 1588 – – 2243 45 0
HTA database – 7 – – – –
NHS EED – – 9 0 0 45
WoS Citation Index
Expanded and WoS Citation
Index and Conference
Proceedings Index
2179 641 199 5435 245 444
BIOSIS – – – 1753 32 0
CINAHL – – – 789 66 642
EconLit – – – 0 – 6
EULAR 650 – – – – –
ACR 792 – – – – –
ClinicalTrials.gov 122 – – 26 6 0
ICTRP – – – 0 0 0
NICE Evidence – – – 0 – 2
Total retrieved 7121 1278 571 21,657 1115 2479
Unique 4937 946 436 10,093a 635b 913a
BIOSIS, Bioscience Information Service; CDSR, Cochrane Database of Systematic Reviews; CENTRAL, Cochrane Central
Register of Controlled Trials; CINAHL, Cumulative Index to Nursing and Allied Health Literature; EconLit, American
Economic Association’s electronic bibliography; HTA, Health Technology Assessment; ICTRP, International Clinical Trials
Registry Platform; NHS EED, NHS Economic Evaluation Database; SR, systematic review; WoS, Web of Science.
a Records retrieved from the Phase II search were combined and the duplicate titles removed from Phase I search.
b Records retrieved from the Phase II update search were combined and the duplicate titles removed from the earlier
Phase I and Phase II searches.
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Inclusion and exclusion criteria
Population
The population was adults with clinically diagnosed RA, with or without prior cDMARDs or bDMARDs,
commencing or currently undergoing treatment anywhere on the RA treatment pathway.
Intervention
The intervention is the use of TTT strategies to guide treatment decisions for individual patients, as defined
in Methods for reviewing clinical effectiveness. Sufficient description of the intervention needed to be
reported for a study to be included in the review.
Comparators
The following comparators were permitted: (1) usual care, in which TTT strategies were not used, (2) a
different TTT strategy, in which an alternative target was used and (3) a different TTT strategy, in which an
alternative treatment protocol was used.
Outcomes
A number of outcomes were assessed. Primarily, we examined the proportion of patients achieving target,
remission and LDA. We also examined score changes in the DAS28/DAS44, SJC, TJC and HAQ, joint
erosion and quality of life, as well as EULAR and ACR response. According to the TTT ACR/EULAR
international task force, TTT strategies should use composite measures that include joint counts to assess
disease activity as related to the target.17
Study design
Randomised controlled trials were included. The reference lists of any systematic reviews identified through
the searches were checked for potentially relevant trials.
Exclusion criteria
l Animal models.
l Pre-clinical and biological studies.
l Narrative reviews, editorials, opinions.
l Non-English-language papers.
l Reports published as meeting abstracts only, where insufficient methodological details are reported to
allow critical appraisal of study quality.
l Trials of personalised medicine.
l Non-randomised clinical trials and other study types, such as cohort studies.
l Trials designed to test an active drug versus placebo (PBO) where both arms pursue the same target
and treatment strategy.
Study selection
Titles and abstracts were examined by one reviewer and 5% were checked by another reviewer. Study
selection based on full texts was decided by two reviewers, with discrepancies resolved by discussion.
Data extraction strategy
Data relevant to the decision problem were extracted from all studies by one reviewer using a standardised
data extraction form. Data on the study characteristics (population, type of comparison, study type, method
of RA diagnosis, sample size, treatment arms relevant to the review, duration of RCT phase, duration of
follow-up, primary outcome, geographical location and funding source); population characteristics (mean
age, number and percentage female, number and percentage rheumatoid factor positive, mean disease
duration, mean baseline DAS28, mean baseline SJC, mean baseline TJC, mean baseline pain score, mean
baseline HAQ score); TTT characteristics (target, treatment protocol, frequency of assessment); and key
outcomes (number and percentage completing randomised phase, reasons for withdrawal, number and
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percentage meeting study target, number and percentage attaining LDA, number and percentage attaining
remission, treatment adaptations, total dose of each drug given over the trial period, mean DAS28, mean
DAS44, mean SJC, mean TJC, EULAR response, ACR 20/50/70 response, mean HAQ, joint erosion, quality
of life), including adverse events (AEs) [proportion of patients experiencing any AE, any serious adverse
event (SAE), death, withdrawal as a result of an AE, musculoskeletal AEs, endocrine and metabolic AEs,
cardiovascular AEs, dermatological AEs, ophthalmological AEs, gastrointestinal AEs, infectious AEs,
psychological AEs and other AEs] were extracted.
All data extracted were checked thoroughly by a second reviewer, who checked the first reviewer’s
extraction against the article(s). Data were extracted without blinding to authors or journal. Discrepancies
were discussed and an agreement was reached. We planned that a third reviewer would be consulted
when no consensus could be reached; however, this was not necessary in any instance.
Quality assessment strategy
The methodological quality of each included study was assessed by one reviewer, and checked by a
second reviewer, who checked the first reviewer’s quality assessment against the article(s). Discrepancies
were discussed and an agreement was reached. We planned that a third reviewer would be consulted
when no consensus could be reached; however, this was not necessary in any instance.
The methodological quality of RCTs, identified from the literature search for inclusion, was assessed using
the Cochrane Collaboration risk-of-bias assessment criteria. This tool addresses specific domains, namely
sequence generation; allocation concealment; blinding of participants and personnel; blinding of outcome
assessment; incomplete outcome data; and selective outcome reporting.24 Judgements for domains are
made as low, high, or unclear risk of bias. For cluster RCTs we also included three additional domains for
recruitment bias (were participants recruited prior to clusters being randomised), risk of baseline differences
between clusters and attrition of clusters. We classified RCTs as being at overall ‘low risk’ of bias if they
were rated as ‘low’ for each of three key domains – allocation concealment, blinding of outcome
assessment and completeness of outcome data (> 10% attrition25). RCTs judged as being at ‘high risk’ of
bias for any of these domains were judged as overall ‘high risk’. RCTs not judged as being at ‘high risk’
for any of these domains, or ‘low risk’ for all of these domains, were judged as overall ‘unclear risk’.
Methods of analysis/synthesis
Evidence examining the clinical effectiveness of TTT was reported according to the TTT comparison,
namely (1) TTT compared with usual care, (2) a comparison of different targets against each other and
(3) a comparison of different treatment protocols against each other. Two trials did not fit into this
framework and so were examined separately, under ‘other comparisons’. Within these comparisons, trials
were further grouped according to whether they used early RA populations or established RA populations,
as patients with early and established RA may respond to treatment differently.17,18,22 We used definitions
of early and established RA as defined in the trials, and, when no definition was provided, a cut-off point
of 3 years was used, which is generally consistent across the literature (e.g. Scott et al.22), bearing in mind
that no fixed consensus exists. Examining definitions and mean disease durations across trials, a 3-year
cut-off point seems appropriate. Two trials used populations with both early and established RA patients, so
these trials were reported separately from those with early RA and those with established RA populations.
Statistical meta-analysis was planned where the evidence allowed. Because of the heterogeneity in
treatment protocols, the data from trials in comparison 3 were not narratively combined and examined by
outcome, as with the previous two comparisons, and results were reported separately by trial.
Results
Quantity and quality of research available
A total of 16,591 records were identified from electronic databases for the clinical effectiveness systematic
review, following deletion of duplicates. The study selection process is represented as a PRISMA flow
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diagram (Figure 2). A total of 16,412 records were excluded at title and abstract level and 137 articles
(reporting 53 separate studies) were excluded in the full-paper sift (see Appendix 3 for a comprehensive list
with rationale for exclusion). A total of 42 articles describing 16 trials were included in the review (Table 3).
Table 3 displays the characteristics of the studies included in this review. Eleven trials26–36,38–49,51,54–60,62,64–67
examined an early RA population (defined as disease duration of < 3 years; see Chapter 4, Inclusion and
exclusion criteria) [i.e. BehandelStrategieën in Reumatoïde Artritis (BeSt),26–34,64–66 the Computer-Assisted
Management in Early Rheumatoid Arthritis (CAMERA) studies,35,36,67 Care in early Rheumatoid Arthritis
(CareRA) trial,38–43 the COmBination theRApy with rheumatoid arthritis (COBRA)-light trial,44,45 FINnish
Rheumatoid Arthritis Combination therapy (FIN-RACo) trial,46–49 Hodkinson et al.,51 Saunders et al.,54 the
STRategies in Early Arthritis Management (STREAM) trial,55 the TreaTing to Twin Targets (T-4) study,56,57 the
Treatment of Early Aggressive Rheumatoid arthritis (TEAR) trial58–60 and the early rheumatoid arthritis treated
with tocilizumab, methotrexate or their combination (U-Act-Early) trial62], three trials9,50,52,53 examined an
established RA population [i.e. British Rheumatoid Outcome Study Group (BROSG) trial,9 Fransen et al.50 and
the Optimisation of Adalimumab study52,53] and two trials61,63 examined populations that include both patients
with early RA and those with established RA [i.e. the TIght COntrol for RA (TICORA) trial61 examined patients
with a disease duration of < 5 years and van Hulst et al.63 reported including both newly diagnosed
patients and those with established disease (and did not report on the findings for these patients separately
at all)]. Six studies50,52,53,55–57,61,63 compared one or more TTT approaches with usual care (i.e. Fransen et al.,50
the Optimisation of Adalimumab study,52,53 the STREAM trial,55 the T-4 study,56,57 the TICORA trial61 and
van Hulst et al.63), four studies51–53,56–60 compared different targets against each other (Hodkinson et al.,51 the
Optimisation of Adalimumab study,52,53 the T-4 study56,57 and the TEAR trial58–60) and six studies26–34,38–42,44–49,54,58–60
compared different treatment protocols against each other (BeSt,26–34 the CareRA trial,38–42 the COBRA-light
trial,44,45 the FIN-RACo trial,46–49 Saunders et al.54 and the TEAR trial58–60). Two studies9,35,36,67 made other
comparisons which did not seem to fit with any of the above comparisons (i.e. the BROSG trial9 and the
Included
(n = 42 articles of 16 RCTs)
Records excluded at title and abstract level
(n = 16,412)
Full-text articles assessed for
eligibility
(n = 179 articles)
Articles excluded at full text
(n = 137 articles of 53 studies)
Reasons
• Not TTT, n = 103 articles (of 29 trials)
• Not a RCT, n = 14 articles (of 11 studies)
• Conference abstract with insufficient detail, n = 5
   articles (of 4 trials)
• No new data (from the update search), n = 4 articles
• No relevant outcomes reported, n = 3 articles (of 3 trials)
• No data available for one arm, n = 3 articles (of 1 trial)
• No study results available yet, n = 2 articles (of 2 trials)
• Separate data for the two arms not reported, n = 1 article
   (of 1 trial)
• Numbers stepping up not reported, n = 1 article (of 1 trial)
• Paper unobtainable, n = 1 article (of 1 trial)
Records identified through database searching with
duplicates removed
(n = 16,591 records)
FIGURE 2 Flow diagram of study inclusion.
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CAMERA trial35,36,67). The BROSG trial9 had two arms: intensive management, which used a DAS44 of ≤ 2.4
target and employed a seven-step treatment protocol based on the target, where patients were seen in a
hospital setting; and a routine management arm, which had no target and patients were seen in the
community as well as in the clinic, with treatment escalation based on clinical opinion. The CAMERA35,36,67 trials
employed a conventional strategy group and an intensive strategy group, which used (different) compound
improvement-based targets, different frequencies of assessment and the same treatment protocol.
Most studies specified a RA diagnosis based on ACR 1987 or 2010 criteria; however, the STREAM trial55
required patients to have 2–5 swollen joints (and did not require an ACR diagnosis), the TICORA trial61 required
a DAS44 of > 2.4 and RA diagnosis was not reported in the Optimisation of Adalimumab study,52,53 Saunders
et al.54 or van Hulst et al.63 Sample sizes ranged from 82 to 755 participants and study durations (randomised
phase) ranged from 24 weeks to 3 years. Six trials took place in the Netherlands,26–37,44,45,50,55,62,63 three in the
UK,9,54,61 one in Flemish countries (actual countries were not stated),38–43 one in Finland,46–49 one in South
Africa,51 one in Canada,52,53 one in Japan56,57 and one in the USA.58–60
Risk-of-bias assessment
Risk-of-bias judgements for included non-cluster randomised controlled trials
A summary of the risk-of-bias judgements for the included non-cluster RCTs is presented in Figure 3,
with details presented in Table 4.
None of the included non-cluster RCTs was rated as being at high risk of bias for random sequence
generation. Only one RCT was rated as being at low risk of bias for allocation concealment.58 The
remaining RCTs were rated as having an unclear risk for this domain.9,30,36,41,44,46,51,54,55,57,61 Nine RCTs were
rated as having a high risk of bias for blinding of participants and personnel,9,36,41,44,46,54,55,57,61 and one RCT
was rated as having an unclear risk for this domain.30 Only one RCT was rated as having a low risk for this
domain.58 It should, however, be borne in mind that in most cases it would be difficult for patients to be
blinded, given the differences in treatment approach between trial arms in most trials. Seven RCTs were
rated as having a low risk of bias for blinded outcome assessment,9,30,44,54,55,58,61 four RCTs were rated as
having a high risk of bias41,46,51,57 and one RCT36 was rated as having an unclear risk for this domain.
Four RCTs reported withdrawals of > 10% and were rated as having a high risk of attrition bias.9,36,57,58
The remaining RCTs were rated as having a low risk of bias for this domain.9,36,57,58 Trial protocols were
unavailable for six RCTs that were rated as having an unclear risk of selective reporting.9,36,46,51,57,61 Three
RCTs were rated as having a low risk of bias for this domain30,41,54 and three were rated as having a high
risk of bias, as some outcomes were not reported in either the protocol44,55 or the methods section of the
trial report58. Based on the judgements for allocation concealment, blinded outcome assessment and
attrition domains (see Quality assessment strategy), six RCTs were rated as having an overall high risk of
bias36,41,46,51,57,58 and five RCTs were rated as having an overall unclear risk of bias.9,30,44,54,55 Only one RCT
was rated as having an overall low risk of bias.61
Risk-of-bias judgements for included cluster randomised controlled trials
A summary of the risk-of-bias judgements for the included cluster RCTs is presented in Figure 4, with the
details presented in Table 5.
Two of the included cluster RCTs were rated as being at low risk of bias for random sequence
generation50,52 and one63 was rated as being at unclear risk for this domain. All three cluster RCTs were
rated as being at unclear risk of bias for allocation concealment.50,52,63 All three cluster RCTs were rated as
being at high risk of bias for blinding of participants and personnel.50,52,63 One cluster RCT was rated as
being at high risk of bias for blinded outcome assessment,63 whereas the other two cluster RCTs were
rated as being at unclear risk for this domain.50,52 All three cluster RCTs were rated as being at high risk of
attrition bias (> 10% participants withdrawing).50,52,63 A trial protocol was not available for two cluster
RCTs that were rated as being at unclear risk of bias for selective reporting.50,63 One cluster RCT was rated
as being at high risk of bias for this domain, as AEs that were reported as an outcome in the trial protocol
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were not included in the trial report.52 Two RCTs reported that participant recruitment occurred after
clusters were randomised to treatment allocation, thus these trials were rated as being at high risk of bias
for cluster recruitment bias.50,52 The remaining cluster RCT was rated as being at unclear risk of bias for this
domain.63 Two cluster RCTs reported statistical methods to accommodate for baseline differences across
clusters and rated as being at low risk of bias for cluster baseline differences.50,52 The remaining cluster RCT
was rated as being at unclear risk for this domain.63 One cluster RCT reported that DAS28 outcomes were
available for only a subset of the original clusters that were randomised. This RCT was rated as being at high
risk of bias for cluster attrition.50 The other two cluster RCTs were rated as being at unclear risk for this
domain.52,63 All three included cluster RCTs rated as being at an overall high risk of bias.50,52,63
+ ? – + + ? +
+ + + + – – –
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FIGURE 3 Risk-of-bias judgements for included non-cluster RCTs. +, low risk of bias; –, high risk of bias; ?, unclear
risk of bias.
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Assessment of characteristics of individual study arms
We considered the features of each arm of the included studies, with a view to drawing out common
features across them. If strategies in different study arms are considered sufficiently similar, that would
allow a grouping of TTT ‘types’ and subsequent analysis at this group level, drawing on evidence from
more than one study.
Tables 6–13 display information about each of the study types. We report information on (1) the treatment
target, (2) the treatment protocol and (3) the frequency of clinician contacts with the patient. For point 3,
the focus is on the frequency of visits during the period while the patient has not achieved the target,
as less frequent assessment is often required once target is achieved. These are considered to be the key
distinguishing features of ‘TTT’ strategies as a whole.
In addition, study arms were grouped together using a broad categorisation of the treatment protocol.
This approach was taken by the NICE clinical guideline for RA,4 where the focus was purely on treatment
protocols using conventional DMARDs in early disease. We used the following eight classification categories.
Sequential monotherapy without a treatment target
Study arms in this classification would typically be control arms in studies compared with other TTT
strategies. The arms identified within this classification category are included in Table 6.
Sequential disease-modifying antirheumatic drug monotherapy, or no treatment
protocol, with a treatment target
This refers to study arms that could be seen as comprising only a limited component of ‘TTT’, the weakest
form of TTT strategy feasible under our definition of TTT. The arms identified within this classification
category are included in Table 7.
van Hulst 201063
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FIGURE 4 Risk-of-bias judgements for included cluster RCTs. +, low risk of bias; –, high risk of bias; ?, unclear risk
of bias.
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Steroid step-down, disease-modifying antirheumatic drug step-up combination
Study arms classified in this group involved initial combination therapy with steroids and non-bDMARDs
(either alone or in combination), with the option of increasing the dose or adding in DMARDs. The steroid
dose is tapered downwards over time. The arms identified within this classification category are included in
Table 8.
TABLE 6 Categorisation of included study arms: sequential monotherapy (or no protocol provided) with a target
Trial acronym or
first author and
year of publication Description of target Protocol Frequency of assessments
BeSt26–34 Treatment adjustments
were made every
3 months in an effort
to obtain a DAS44 of
≤ 2.4. Remission was
defined as a DAS44 of
< 1.6
1. 15 mg/week of MTX, increased to
25–30mg/week if the DAS44 was > 2.4.
Subsequent steps for patients with an
insufficient response were:
2. 2000–3000mg/day of SSZ monotherapy
3. 20 mg/day of LEF monotherapy
4. 3–10mg/kg of MTX with IFX every
8 weeks intravenously (IFX)
5. 50 mg/week intramuscular gold
with 120 mg of intramuscular
methylprednisolone
6. 2.5 mg/kg/day of MTX with ciclosporin A





A DAS28 of < 2.6 in
the DAS-targeted arm
and a SJC of 0 in the
SJC-targeted arm
1. There was no specified drug algorithm for
any physician, as many patients had tried
two or more DMARDs before receiving
ADA in routine care
2. Physicians were encouraged to make
treatment changes in patients when the
target was not achieved
3. The dose of ADA was not increased
beyond 40mg subcutaneously every
2 weeks, as that is the approved dose in
Canada
Therefore, much of the targeted treatment
was expected to be intensification of
DMARDs, intra-articular steroid injections
and oral or intramuscular steroids
0, 6, 12 and 18 months.
Assessments at 2, 4 and




To control joint pain,
stiffness and related
symptoms
NSAIDs, intra-articular steroid injections
(up to a maximum of one per month),
DMARDs (antimalarials, SSZ, intramuscular
gold, penicillamine, azathioprine, MTX, LEF)
and low-dose steroids (≤ 7.5 mg daily).
Non-drug modalities, such as physiotherapy
referral, were also used as the GP felt
appropriate. DMARD therapy was monitored
using the standard guidelines in current use




A DAS28 of ≤ 3.2 Systematic monitoring of disease activity by
assessment of the DAS28 by the treating
rheumatologist. According to the study
guidelines the aim was to reach a DAS28 of
≤ 3.2 (LDA) by changing DMARD treatment
if the score was > 3.2
Systematic monitoring of
disease activity was carried
out at weeks 0, 4, 12
and 24
van Hulst et al.,
201063
A DAS28 of ≤ 3.2 None 3 months
DAS, Disease Activity Score; GP, general practitioner; PDN, prednisone.
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TABLE 7 Categorisation of included study arms: sequential monotherapy without a target
Trial acronym or
first author and
year of publication Target Protocol Frequency of assessments
TICORA61 A DAS44 of ≤ 2.4 DMARD monotherapy was given in patients
with active synovitis. Failure of treatment
(because of toxic effects or lack of effect)
resulted in a change to alternative
monotherapy, or addition of a second or
third drug at the discretion of the attending
rheumatologist. Intra-articular injections of
corticosteroid were given to patients
assigned routine care with the same
restrictions as those in the intensive group
3 months
T-4 study56,57 A DAS28 of < 2.6
(DAS-targeted arm);a
MMP-3 concentration
of < 121 ng/ml (men)/
< 59.7 ng/ml (women)
(MMP-3-targeted arm);
and a DAS28 of
< 2.6 and a MMP-3
concentration of
< 121 ng/ml (men)/
< 59.7 ng/ml (women)
(combined DAS- and
MMP-3-targeted arm)
1. 1 g/day SSZ plus 4 mg/week of MTX
(the dosage of was not changed if the
patient had responded compared with
the previous visit) otherwise
2. The dosage was increased in a stepwise
manner to a maximum of 8 mg/week if
patient had not responded. Change of
therapy based on improvement in the
number of tender joints (0–28), swollen
joints (0–26) and concentration of
CRP from pre-assessment values,
without access to current DAS28 and
MMP-3 values
3. If the maximum tolerable dose of MTX
that introduced a dose-dependent side
effect was reached and the patient still
did not fulfil sustained response, TNF
blockers were allowed. If patients with
the administration of TNF blockers did
not show improvement compared with
the previous measurement, TNF blockers
were changed to another biological
agent, or the TNF blocker dose increased,
or the interval for TNF administration was
shortened
DMARDs (including bucillamine,a
intramuscular gold, sodium thiomalate,
tacrolimus and LEF) were given as allowed by
the rheumatologist at all times. Combination
therapy with DMARDs other than MTX
was allowed for two kinds of agents.
Intra-articular GC (to a maximum of 10mg
of triamcinolone acetonide on a single visit)
was permitted for persistently swollen and
tender joints
20, 24, 28, 32, 36, 40, 44,
48, 52 and 56 weeks
CAMERA35,36,67 1. The starting dose of oral MTX was
7.5 mg/week. In both groups, the dosage
of MTX was not changed if patients had
responded compared with the previous
visit otherwise
2. The dosage was increased stepwise by
5 mg/week, to a maximum of
30mg/week
3. If the maximum (tolerable) dose of MTX
was reached and patients did not fulfil
the criteria for sustained response
3 months
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TABLE 7 Categorisation of included study arms: sequential monotherapy without a target (continued )
Trial acronym or
first author and
year of publication Target Protocol Frequency of assessments
4. MTX was administered subcutaneously.
For patients on subcutaneous MTX
having an inadequate response,
ciclosporin was added to the MTX, while
the dosage of MTX was reduced to
15mg/week. The starting dose of
ciclosporin was 2.5 mg/kg/day, this was
increased stepwise by 0.5 mg/kg/day to a
maximum of 4 mg/kg/day, if no response
was reached
If patients fulfilled the criteria for sustained
response, MTX was reduced stepwise by
2.5 mg/week as long as patients met these
criteria, otherwise the dose of MTX was
continued or increased again according to
protocol
STREAM55 The following order of drugs was suggested





No guideline to adapt treatment strategy
was supplied
van Hulst et al.,
201063
3 months
FIN-RACo46–49 1. Prednisolone up to 10mg was allowed in
patients with continuously active disease,
but simultaneous use of multiple
DMARDs was not allowed. The decision
to use prednisolone was made by the
treating physician. The patients were
treated continuously with one DMARD
alone, with or without prednisolone and,
if a more beneficial effect was needed,
the dose was increased or the DMARD
was changed
2. SSZ (2 g daily) was used as the initial drug
in all patients and the dose was increased
to 3 g daily at 3 months if clinically
indicated
3. If an AE occurred, or if the clinical
response was < 25% at 6 months, SSZ
was replaced with MTX (7.5–15mg
weekly). As the third DMARD,
azathioprine (2 mg/kg daily), auranofin,
HCQ, injectable gold, penicillamine or
podophyllotoxin could be used
alternatively after azathioprine
Baseline and at months 1,
3, 4, 5, 6, 9, 12, 18 and 24
DAS, Disease Activity Score; MMP-3, matrix metalloproteinase 3; TNF, tumour necrosis factor.
a Bucillamine is similar to penicillamine.
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Step-up disease-modifying antirheumatic drugs to biologics
In this classification the treatment protocols start patients on non-bDMARDs and outline increases in dose
and/or combinations with other DMARDs, with the option of switching to bDMARDs as part of the
sequence. The arms identified within this classification category are included in Table 9.
Step-up combinations not including to biologics
Similar to the previous set of treatment protocols, study arms in this category start patients on a
non-bDMARD and subsequently allow increases in dose and/or combinations with other non-bDMARDs
and steroids. The arms identified within this classification category are included in Table 10.
Combination disease-modifying antirheumatic drugs plus steroids
Patients are treated from the outset with two non-bDMARDs and steroids. Adjustments to treatments do
not allow bDMARDs. The arms identified within this classification category are included in Table 11.
Disease-modifying antirheumatic drug and biologic combinations
Treatments for patients from the beginning of the protocol include both bDMARDs and non-bDMARDs in
combination. The arms identified within this classification category are included in Table 12.
Triple disease-modifying antirheumatic drug therapy
Three non-bDMARDs are used in combination from the outset. The arms identified within this classification
category are included in Table 13.
Even with this relatively large number of TTT treatment strategy classifications (which are designed to differ
in terms of the treatment protocol, except for the control arms of studies), there is substantial variation.





target Protocol Frequency of assessments
den Uyl et al.,
201369
A DAS44 of < 1.6 60mg/day prednisolone (tapered to
7.5mg/day in 6 weeks), 7.5mg/week of MTX
and 1 g/day of SSZ (increased to 2 g/day after
1 week). MTX increased to 25mg/week after
13 weeks of treatment if the DAS44 was ≥ 1.6
3 months
A DAS44 of < 1.6 1. 30 mg/day of prednisolone, tapered to
7.5 mg/day in 9 weeks and 10mg/week
of MTX with stepwise increments in all
patients to 25 mg/week in 9 weeks
2. Parenteral MTX after 13 weeks if the
DAS44 is ≥ 1.6
3 months
CareRA42 A DAS28-CRP of
< 3.2
15mg of MTX weekly, 2 g of SSZ daily and
a weekly step-down scheme of oral GCs
(60 mg to 40mg to 25mg to 20mg to
15mg to 10mg to 7.5 mg PDN)
Baseline, 4, 8 and
16 weeks. If a treatment
adjustment was required at
week 8, an optional visit
was held at week 12
A DAS28-CRP of
< 3.2
15mg of MTX weekly with a weekly
step-down scheme of oral GCs (30 mg to




15mg of MTX weekly, 10 mg of LEF daily
and a weekly step-down scheme of oral
GCs (30 mg to 20mg to 12.5 mg to 10mg
to 7.5 mg to 5mg PDN)
DAS28-CRP, Disease Activity Score, 28 joints with C-reactive protein concentration; PDN, prednisone.
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TABLE 9 Categorisation of included study arms: step-up DMARDs, including to biologics
Trial acronym Description of target Protocol Frequency of assessments
T-4 study57,57 A DAS28 of < 2.6 1. 1 g/day of SSZ plus oral 4 mg/week of
MTX – the dosage of was not changed
if the patient had responded compared




of < 121 ng/ml for men
and < 59.7 ng/ml for
women
2. The dosage of oral MTX was increased
in a stepwise manner to a maximum
of 8 mg/week if patient had not
responded. Change of therapy based on
improvement in the number of tender
joints (0–28), swollen joints (0–26)
and concentration of CRP from
pre-assessment values, without access
to current DAS28 and MMP-3 values
A DAS28 of < 2.6 and a
MMP-3 concentration
of < 121 ng/ml for men
and < 59.7 ng/ml for
women
3. If the maximum tolerable dose of MTX
that introduced a dose-dependent side
effect was reached and the patient still
did not fulfil a sustained response, TNF
blockers were allowed. If patients on the
administration of TNF blockers did not
show improvement compared with the
previous measurement, TNF blockers
were changed to another biological
agent, or the TNF blocker dose increased,
or the interval for TNF administration was
shortened. Maximum dosages were
1 g/day of SSZ, 20mg/day of LEF,
300mg/day of bucillamine,a 25mg/week
of gold sodium thiomalate, 3 mg/day of
tacrolimus hydrate, 10mg/kg bimonthly
or 6 mg/kg monthly of IFX, 50mg/week
of ETN, 40mg of ADA fortnightly and
8mg/kg of TOC monthly. DMARDs
including bucillamine,a gold sodium
thiomalate, tacrolimus and LEF were
given, as allowed by the rheumatologist
at all times. Combination therapy with
DMARDs other than MTX was allowed
for two kinds of agents. Intra-articular
GC (to a maximum of 10mg of
triamcinolone acetonide on a single visit)
was permitted for persistently swollen
and tender joints
STREAM55 Remission (a DAS44 of
< 1.6)
Treatment was started with
15 mg/week of oral MTX. If the DAS was
≥ 1.6 at a given time point:
1. There was an increase in MTX to 25mg/
week; 25 mg/week of MTX combined
with 40 mg/2 weeks of ADA
2. 25 mg/week of MTX combined with
40 mg/week of ADA
3. A combination of 25 mg/week of MTX,
2000mg/day of SSZ and 400mg/day
of HCQ
4. A combination of 25 mg/week of MTX,
2000mg/day of SSZ, 400 mg/day of
HCQ and 7.5 mg/day of PDN
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TABLE 9 Categorisation of included study arms: step-up DMARDs, including to biologics (continued )
Trial acronym Description of target Protocol Frequency of assessments
If the DAS was < 1.6 at one time point the
treatment remained unchanged. If the DAS
was < 1.6 at two consecutive time points
the following actions were taken,
depending on the stage of the treatment
protocol:
1. 15 mg/week of MTX was decreased
from 2.5 mg/2 weeks to 0 mg/week
after 3 months
2. 25 mg/week of MTX was decreased
from 2.5 mg/2 weeks to 10 mg/week
after 3 months
3. 40 mg/2 weeks of ADA was stopped
4. 40 mg/week of ADA was decreased to
40mg/2 weeks
5. HCQ was decreased from 200mg/
8 weeks to 0 mg
If remission was sustained after 3 months,
SSZ was decreased subsequently from
500mg/4 weeks to 0 mg. If remission was
sustained after 3 months:
1. MTX was decreased from 2.5 mg/
2 weeks to 0 mg
2. 7.5 mg/day of PDN was decreased to
0 mg in 7 weeks
3. LEF was decreased to 10mg/day
If remission was sustained after 3 months:
1. LEF was stopped
2. Gold was decreased to 50mg/2 weeks
If DAS remained < 1.6, gold was decreased
to 50mg/4 weeks; if remission was
sustained, gold was stopped. If at any time
point the DAS was ≥ 1.6, the last effective
treatment was restarted. In case of
intolerance to a DMARD, the highest
tolerated dose was used and, if the DAS
was ≥ 1.6 at the next visit, the patient went
on to the next step
TEAR58–60 A DAS28-ESR of ≥ 3.2 Oral MTX, escalated to a dosage of
20 mg/week or to a lower dosage if
treatment resulted in no active tender/
painful or swollen joints by week 12.
Corticosteroid use at entry tapered. If the
DAS28-ESR was ≥ 3.2 at week 14, patients
were stepped up to MTX plus SSZ at a
dosage of 500 mg twice daily, escalated
(if tolerated) to 1000mg twice daily at
6 weeks, plus HCQ at a dosage of 200 mg
twice daily
DAS, Disease Activity Score; DAS28-ESR, Disease Activity Score, 28 joints with erythrocyte sedimentation rate;
MMP-3, matrix metalloproteinase 3; PDN, prednisone; TNF, tumour necrosis factor.
a Bucillamine is similar to penicillamine.
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TABLE 10 Categorisation of included study arms: step-up combinations not including to biologics
Trial acronym or
first author and
year of publication Description of target Protocol Frequency of assessments
BeSt26–34 Treatment adjustments
were made every
3 months in an effort
to obtain a DAS44 of
≤ 2.4. Remission was
defined as a DAS44
of < 1.6
1. 15mg/week of MTX, increased to
25–30mg/week if the DAS44 was > 2.4.
If response to therapy was still insufficient,
SSZ was added, followed by the addition of
2. 400 mg/day of HCQ and then by PDN
Patients whose disease failed to respond to the
combination of these four drugs subsequently
switched to MTX with IFX, MTX with
ciclosporin and PDN, and finally to 20mg/day
LEF
3 months
TICORA61 A DAS44 of ≤ 2.4 Escalation of DMARDs in patients with
persisting disease activity:
1. 500mg of SSZ daily, increasing every week
to a target dose of 40mg/kg per day
2. 40mg/kg per day of SSZ; 7.5mg/week of
MTX; 5mg per week of folic acid;
200–400mg/day of HCQ
3. Triple therapy with monthly increments of
MTX by 2.5–5.0mg per week (maximum
25mg/week)
4. Triple therapy with weekly 500-mg
increments of SSZ dose (maximum 5 g/day
in divided doses if tolerated)
5. Addition of prednisolone in enteric-coated
tablets, 7.5mg daily
6. Change triple therapy to 2–5mg/kg per day
of ciclosporin; 25mg/week of MTX; and
5mg/week of folic acid. Change to DMARD
(LEF or sodium aurothiomalate; dose NR,
route of administration NR)
Monthly
FIN-RACo46–49 ACR remission Combination therapy started with:
1. 500mg of SSZ twice daily, 7.5mg of MTX
weekly, 300mg of HCQ daily and 5mg
daily of prednisolone for 3 months
2. If the clinical improvement was < 50%
in at least two of swollen joints, tender
joints and ESR or CRP, then MTX and
prednisolone increased to 10mg weekly
and 7.5mg daily
3. The protocol allowed flexible subsequent
dose adjustments to mimic clinical practice.
The highest dose at 9 months and
thereafter was 2 g daily of SSZ, 15mg
weekly of MTX, 300mg daily of HCQ and
10mg daily of prednisolone
4. If remission was achieved during the first
year with the initial combination, the drug
doses were tapered and prednisolone and
MTX could even be discontinued at 9 and
18 months. SSZ (1 g daily) and HCQ
(300mg daily) had to be continued until
the end of the study
Baseline and at months 1,
3, 4, 5, 6, 9, 12, 18 and 24
continued
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TABLE 10 Categorisation of included study arms: step-up combinations not including to biologics (continued )
Trial acronym or
first author and
year of publication Description of target Protocol Frequency of assessments
5. If remission was achieved during the first
year, but not with the initial combination,
drug doses were gradually tapered to those
of the second year
6. If the induced remission was lost, DMARD
doses were increased with the intention of
reaching remission. If one or several
components of the combination had to be
discontinued, a combination of three
DMARDs was restarted by replacing SSZ
and HCQ with auranofin (3–6mg daily)
and MTX with azathioprine (2mg/kg daily).




A DAS28 of < 3.2 1. SSZ (target dosage 40 mg/kg/day in
divided doses)
2. After 3 months, if the DAS28 remained
> 3.2, MTX was added (7.5 mg/week,
increased monthly to a maximum of
25mg/week, as above). After the
maximum tolerated dose of MTX was
reached, 400 mg/day HCQ was added in
patients with persistent disease activity
Monthly
CAMERA35,36,67 20%, 50% responses
based on ESR, SJC,
TJC and VAS of overall
well-being
1. The starting dose of oral MTX was
7.5 mg/week. In both groups, the dosage
of MTX was not changed if patients had
responded compared with the previous
visit; otherwise
2. The dosage was increased stepwise by
5 mg/week, to a maximum of
30mg/week
3. If the maximum (tolerable) dose of MTX
was reached and patients did not fulfil
the criteria for sustained response
4. MTX was administered subcutaneously.
For patients on subcutaneous MTX
having an inadequate response,
ciclosporin was added to the MTX, while
the dosage of MTX was reduced to
15mg/week. The starting dose of
ciclosporin was 2.5 mg/kg/day; this was
increased stepwise by 0.5 mg/kg/day to a
maximum of 4 mg/kg/day, if no response
was reached
If patients fulfilled the criteria for sustained
response, MTX was reduced stepwise by
2.5 mg/week as long as patients met these
criteria, otherwise the dose of MTX was
continued or increased again according to
protocol
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TABLE 11 Categorisation of included study arms: combination DMARDs plus steroids
Trial acronym Protocol Frequency of assessments
BeSt26–34 Treatment adjustments
were made every 3 months
in an effort to obtain a
DAS44 of ≤ 2.4. Remission
was defined as a DAS44 of
< 1.6
1. 7.5 mg/week of MTX, 2000 mg/day
of SSZ and 60mg/day of PDN
(the last of which was tapered in
7 weeks to 7.5 mg/day). If DAS44
was > 2.4
2. MTX was augmented to
25–30mg/week and, if the response
was still insufficient, the combination
was replaced by MTX with ciclosporin
and PDN, followed by MTX with IFX,
LEF monotherapy, gold with
methylprednisolone, and finally by
2–3mg/kg/day azathioprine with PDN
In the case of a persistent DAS44 of
> 2.4, first PDN was tapered to 0 mg
after 28 weeks and then MTX was
tapered to 0 mg after 40 weeks
3 months
PDN, prednisone.
TABLE 10 Categorisation of included study arms: step-up combinations not including to biologics (continued )
Trial acronym or
first author and
year of publication Description of target Protocol Frequency of assessments
Symmons et al.,
20059








twice the upper limit
of normal
NSAIDs, intra-articular steroid injections (up
to a maximum of one per month), DMARDs
(antimalarials, SSZ, intramuscular gold,
penicillamine, azathioprine, MTX, LEF) and
low-dose steroids (≤ 7.5 mg daily) plus, if
necessary, ciclosporin, parenteral steroids,
medium-dose oral steroids (up to 10mg
daily) and cyclophosphamide
Every 4 months
TEAR58–60 A DAS28-ESR of ≥ 3.2 Oral MTX, escalated to a dosage of 20 mg/
week or to a lower dosage if treatment
resulted in no active tender/painful or
swollen joints by week 12. Corticosteroid
use at entry tapered. If the DAS28-ESR was
≥ 3.2, patients were stepped up to triple
therapy (MTX + SSZ+ HCQ)
Every 6 weeks for 48 weeks,
then every 12 weeks
Hodkinson et al.,
201551
A SDAI of ≤ 11 (LDA) 15 mg/week of MTX, increased to 20mg
and then 25mg
Monthly (3 months) then
every 3 months
A CDAI of ≤ 10 (LDA) If this failed, triple therapy of 1000 mg/day
of SSZ and 200mg/day of chloroquine in
combination with 25 mg/week of MTX was
introduced
CDAI, Clinical Disease Activity Index; DAS28-ESR, Disease Activity Score, 28 joints with erythrocyte sedimentation rate;
ESR, erythrocyte sedimentation rate; NR, not reported; PDN, prednisone; VAS, visual analogue scale.
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TABLE 12 Categorisation of included study arms: DMARD biologic combination
Trial acronym Description of target Protocol Frequency of assessments
BeSt26–34 Treatment adjustments
were made every 3 months
in an effort to obtain a
DAS44 of ≤ 2.4. Remission
was defined as a DAS44 of
< 1.6
1. 25–30mg/week of azathioprine with
3 mg/kg of azathioprine at weeks 0,
2 and 6 and every 8 weeks
thereafter. After 3 months, if DAS44
was > 2.4:
2. IFX was increased to 6 mg/kg every
8 weeks. Extra DAS44 calculations for
dose adjustments were performed
every 8 weeks within 1 week before
the next infusion of IFX. If the DAS44
was > 2.4
3. The dose of the next infusion was
increased to 7.5 mg/kg every 8 weeks
and then to 10mg/kg every 8 weeks
If patients still had a DAS44 of 2.4 while
receiving MTX with 10mg/kg of IFX,
they switched to SSZ, then to LEF,
then to the combination of MTX,
ciclosporin, and PDN, then to gold with
methylprednisolone, and, finally, to
azathioprine with PDN. If three was a
persistent good response of DAS44 of
< 2.4 for at least 6 months, IFX was
reduced from 10mg/kg to 7.5 mg/kg to






A DAS28 of < 2.6 in
the DAS-targeted arm
and a SJC of 0 in the
SJC-targeted arm
1. There was no specified drug
algorithm for any physician because
many patients had tried two or more
DMARDs before receiving ADA in
routine care
2. Physicians were encouraged to make
treatment changes in patients when
the target was not achieved
3. The dose of ADA was not increased
beyond subcutaneous 40 mg every
2 weeks, as that is the approved dose
in Canada. Therefore, much of the
targeted treatment was expected
to be intensification of DMARDs,
intra-articular steroid injections and
oral or intramuscular steroids
0, 6, 12 and 18 months.
Assessments at 2, 4 and
9 months were also
recommended
A SJC of 0 1. Physicians were encouraged to make
treatment changes in patients when
the target was not achieved
2. The dose of ADA was not increased
beyond 40mg subcutaneously every
2 weeks, as that is the approved dose
in Canada. Therefore, much of the
targeted treatment was expected to
be intensification of background
therapies (DMARDs, intra-articular
steroid injections and oral or
intramuscular steroids)
DAS, Disease Activity Score; PDN, prednisone.
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
30
Tables 6–13 show that, within each classification group, study arms exhibit significant differences.
These can be seen within each grouping in terms of the treatment target and the frequency of assessment.
For example, within the group of study arms classified as ‘step-up non-biologic combination therapy’, the
frequency of assessments was monthly in some studies (e.g. the TICORA trial,61,63 Saunders et al.54) and
every 3 months in others (e.g. BeSt26–34). Within the same classification group, treatment targets varied
enormously. A DAS44 of ≤ 2.4 was used in two studies (BeSt26–34,65,68 and TICORA61,63). A range of different
measurement scales [ACR, SDAI, Clinical Disease Activity Index (CDAI), DAS28 and other multifaceted
measures] and cut-off points (remission, other measures of response) were used in the other study arms.
Differences are also apparent in the details of the treatment protocols within each broad grouping. Study
arm treatment protocols exhibit substantial variation in the study drugs used, the combinations in which
they may be used, the doses used (both initially and when changing dose in response to assessment of
treatment response), and the ordering of study drugs in the sequence of the protocol.
This variation would be present even if an alternative classification approach were to be adopted. For these
reasons, it is not considered desirable to conduct analyses that synthesise results quantitatively across
different sets of studies. The extent of variation between study arms would make interpretation of results
difficult and potentially result in misleading conclusions.
Assessment of effectiveness
Population characteristics and treat-to-target characteristics
Trials examining early rheumatoid arthritis populations
Eleven trials reported on early RA populations (BeSt,26–34,64–66 CAMERA,35,36,67 CareRA,38–43 COBRA-light,44,45
FIN-RACo,47–49,70 Hodkinson et al.,51 Saunders et al.,54 STREAM,55 T-4 study,56,57 TEAR58–60 and U-Act-Early62).
Population characteristics are presented in Table 14. The mean age of trial participants ranged from 46 to
62 years and trial arm samples ranged from 58% to 84% female and from 23.4% to 91.7% rheumatoid
factor positive. Mean disease duration at baseline ranged from just < 2 weeks to just > 1 year. The mean
DAS28 at baseline ranged from 4.4 to 6.9, indicating moderate to severe RA at baseline among the early
RA population. The mean SJC (on 66 joints) ranged from 10.0 to 14.0 and the mean TJC (0–68 joints)
ranged from 12.3 to 20.0, across all trial arms. The mean HAQ score at baseline ranged from 0.92 to 2.0.
Characteristics of the TTT features of the early RA trials are presented in Table 15. Targets included LDA
[a DAS44 of ≤ 2.4 (BeSt26–34,64–66); a Disease Activity Score, 28 joints with C-reactive protein concentration
(DAS28-CRP) of ≤ 3.2 (CareRA38–43); a SDAI of ≤ 11 (Hodkinson et al.51); a CDAI of ≤ 10 (Hodkinson et al.51);
TABLE 13 Categorisation of included study arms: triple DMARD from start
First author
and year of
publication Description of target Protocol Frequency of assessments
Saunders et al.,
200854
A DAS28 of < 3.2
(to correspond with a
EULAR good response)
1. MTX (7.5 mg/week), SSZ (500 mg twice a day)
and HCQ (200 mg daily)
2. The MTX dosage was escalated each month
in 2.5- to 5-mg increments until good disease
control was obtained (up to a maximum of
25mg/week) or side effects occurred
3. Thereafter, if good disease control was not
achieved (i.e. if the DAS28 remained > 3.2),
SSZ was increased to 40mg/kg/day in divided
doses and, subsequently, if disease control
remained inadequate, the dosage of HCQ
was increased to 400 mg/day
Monthly
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126 54 (13) 86/126
(68)
84/126 (67) 2 (1–5) weeksa,b DAS44, 4.5
(0.9)







121 54 (13) 86/121
(71)
77/121 (64) 2 (1–4) weeksa,b DAS44, 4.5
(0.8)








133 55 (14) 86/133
(65)
86/133 (65) 2 (1–4) weeksa,b DAS44, 4.4
(0.9)







128 54 (14) 85/128
(66)
82/128 (64) 3 (1–5) weeksa,b DAS44, 4.3
(0.9)






151 54 (14) 104/151
(69)
89/151 (66) NR 5.6 (1.2),
n= 102
14 (6) 15 (7) 51 (26) 1.2 (0.7)
Conventional
strategy group
148 53 (15) 97/148
(66)
77/148 (62) NR 5.6 (1.0),
n= 103


























































COBRA Classic 98 53.2 (11.9) 64/98
(65)














COBRA Slim 98 51.8 (131) 63/98
(64)
















93c 51.2 (12.8) 64/93
(69)

















MTX-TSU 47 51.0 (14.0) 38/47
(81)






















COBRA Slim 43 51.4 (14.4) 33/43
(77)






















COBRA-light44,45 COBRA 81 53 (13) 54/81
(67)
47/81 (58) 16 (9–28)
weeksa
5.67 (1.13) 13 (10–17)a 17 (12–24)a NR 1.36 (0.66)
COBRA-light 83 51 (13) 58/81
(70)
48/83 (58) Median 17
(8–33) weeksa
















































































































































































































48 (20–65)h 65 (66) 65 (66) 8.6 (2–23)d NR 14 (7) 20 (10) NR NR
Hodkinson
et al., 201551





6.1 (1.2) 11 (5.7) 12.5 (8.5) 66.7 (22.6) HAQ-DI, 1.7 (0.8)










49 55 (15) 37/49
(76)
34/49 (69) 10 (9) 6.8 (0.9) 12 (4) 18 (6) 71 (26) 1.9 (0.7)
Step-up therapy 47 55 (11) 37/47
(79)
34/47 (72) 13 (12) 6.9 (0.9) 13 (5) 18 (6) 65 (22) 2.0 (0.7)
STREAM55 Aggressive
group
42 48 (13) 24/42
(58)
20/42 (48) 6 (3–10)a DAS44, 2.2
(0.5)
NR NR NR 0.50 (0.25–0.88)a
Conventional
care
40 46 (12) 32/40
(79)
13/40 (33) 6 (4–9)a DAS44, 2.4
(0.7)
NR NR NR 0.69 (0.32–1.06)a





































































































TEAR58–60 Immediate ETN 244 50.7 (13.4) 181/244
(74)
216/244 (89) 3.5 (6.4) DAS28-(ESR),
5.8 (1.1)







132 48.8 (12.7) 101/132
(77)
121/132 (92) 4.1 (7.2) DAS28-(ESR),
5.8 (1.1)





Step-up ETN 255 48.6 (13.0) 176/255
(69)
232/255 (91) 2.9 (5.6) DAS28-(ESR),
5.8 (1.1)






124 49.3 (12.0) 87/124
(70)
108/124 (87) 4.5 (7.6) DAS28-(ESR),
5.9 (1.1)




















































CCP, cyclic citrullinated peptide; DAS, Disease Activity Score; DAS28-ESR, Disease Activity Score, 28 joints with erythrocyte sedimentation rate; D-HAQ, Dutch version of the Health
Assessment Questionnaire; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability Index; ITT, intention to treat; mHAQ, modified Health Assessment
Questionnaire; MMP-3, matrix metalloproteinase 3; MTX-TSU, methotrexate tight step-up; NR, not reported; PDN, prednisone; RF, rheumatoid factor; SD, standard deviation; SJC28, swollen
joint count, 28 joints; TJC28, tender joint count, 28 joints; VAS, visual analogue scale.
a Median (interquartile range).
b From diagnosis to inclusion.
c n= 94 in Verschueren et al.42
d Mean (range).
e Reported in Verschueren et al.42
f Median (range).
g Reported in Verschueren et al.40


















































































































































































126 A DAS44 of ≤ 2.4 1. 15 mg/week of MTX, increased to 25–30mg/
week if the DAS44 was > 2.4. Subsequent
steps for patients with an insufficient
response were:
2. 2000–3000mg/day of SSZ monotherapy
3. 20 mg/day of LEF monotherapy
4. MTX with 3–10mg/kg IFX every 8 weeks
(intravenously)
5. 50 mg/week of gold (intramuscularly) with
120 mg of methylprednisolone (intramuscularly)






121 1. 15 mg/week of MTX, increased to 25–30mg/
week if the DAS44 was > 2.4. If response to
therapy was still insufficient, SSZ was added,
followed by the addition of:
2. 400 mg/day of HCQ and then by PDN. Patients
whose disease failed to respond to the
combination of these four drugs subsequently
switched to
3. MTX with IFX, MTX with ciclosporin and PDN,
and finally to 20 mg/day LEF
Initial combination
therapy with PDN
133 1. 7.5 mg/week of MTX, 2000mg/day of SSZ and
60mg/day of PDN (the last of which was
tapered in 7 weeks to 7.5 mg/day). If the
DAS44 was > 2.4
2. MTX was augmented to 25–30mg/week
and if the response was still insufficient, the
combination was replaced by:
3. MTX with ciclosporin and PDN, followed by
MTX with IFX, LEF monotherapy, gold with
methylprednisolone and finally by
2–3mg/kg/day azathioprine with PDN. In the
case of a persistent DAS44 of > 2.4, first PDN
was tapered to 0 mg/day after 28 weeks and






























participants Target Treatment protocol Frequency of assessment
Initial combination
therapy with IFX
128 1. 25–30mg/week of MTX with 3 mg/kg of IFX at
weeks 0, 2 and 6 and every 8 weeks thereafter.
After 3 months, if DAS44 > 2.4:
2. IFX was increased to 6 mg/kg every 8 weeks.
Extra DAS44 calculations for dose adjustments
were performed every 8 weeks within 1 week
before the next infusion of IFX. If the DAS44
was > 2.4:
3. The dose of the next infusion was increased to
7.5 mg/kg every 8 weeks and then to 10mg/kg
every 8 weeks. If patients still had a DAS > 2.4
while receiving MTX with 10 mg/kg of IFX, they
switched to SSZ, then to LEF, then to the
combination of MTX, ciclosporin and PDN, then
to gold with methylprednisolone, and, finally,
to azathioprine with PDN. If there is a persistent
good response of the DAS44 of < 2.4 for at
least 6 months, then:
4. IFX is reduced from 10mg/kg to 7.5 mg/kg to
6 mg/kg and then to 3 mg/kg every next
infusion until stopped
CAMERA35,36,67 Other comparisons Conventional
strategy group
151 Response (> 20%
improvement in SJC,
> 20% improvement in any





for SJC and ≤ 50%
improvement from baseline
for two of ESR, TJC and
VAS general well-being)
1. The starting dose of oral MTX was 7.5 mg/week.
In both groups, the dosage of MTX was not
changed if patients had responded compared
with the previous visit, otherwise:
2. The dosage was increased stepwise by
5 mg/week to a maximum of 30mg/week
3. If the maximum (tolerable) dose of MTX was
reached and patients did not fulfil the criteria
for sustained response MTX was administered
subcutaneously. For patients on subcutaneous
MTX having an inadequate response,
ciclosporin was added to the MTX, while the














































































































































































participants Target Treatment protocol Frequency of assessment
The starting dose of ciclosporin was 2.5 mg/kg/
day, this was increased stepwise by 0.5 mg/kg/
day to a maximum of 4 mg/kg/day, if no
response was reached
4. If patients fulfilled the criteria for sustained
response, MTX was reduced stepwise by
2.5 mg/week as long as patients met these
criteria, otherwise the dose of MTX was




148 Response (decrease in SJC,
if SJC unchanged,
assessors’ judgement
looking at TJC, ESR and
VAS general well-being),
avoiding inadequate
response (SJC ≥ 6, number
of painful joints ≥ 3, ESR










COBRA Classic 98 DAS28-CRP ≤ 3.2 15mg of MTX weekly, 2 g of SSZ daily and a
weekly step-down scheme of oral GCs (60 mg to
40mg to 25mg to 20mg to 15 mg to 10mg to
7.5 mg of PDN), then:
1. Weekly increase of MTX dose to 20mg
2. SSZ dose increase to 3 mg (then considered a
strategy failure)
Screening: baseline, weeks
4, 8 and 16. If a treatment
adjustment was required at
week 8, an optional visit
was held at week 12
COBRA Slim 98 15mg of MTX weekly with a weekly step-down
scheme of oral GCs (30 mg to 20mg to 12.5 mg
to 10mg to 7.5 mg to 5mg of PDN), then:
1. Weekly increase of MTX dose to 20mg




93a 15 mg of MTX weekly, 10 mg of LEF daily and a
weekly step-down scheme of oral GCs (30 mg to
20mg to 12.5 mg to 10mg to 7.5 mg to 5mg of
PDN), then:
1. Weekly increase of MTX dose to 20mg




































MTX-TSU 47 A DAS28-CRP of ≤ 3.2 15mg of MTX weekly, no oral steroids allowed,
then:
1. MTX dose increase to 20mg weekly
2. Addition of LEF 10 mg daily (then considered an
efficacy failure)
Screening: baseline, weeks
4, 8 and 16. If a treatment
adjustment was required at
week 8, an optional visit
was held at week 12
COBRA Slim 43 15mg of MTX weekly with a step-down scheme of
daily oral GCs (30-20-12.5-10-7.5-5 mg of PDN).
From week 28, GCs were tapered on a weekly
basis by leaving out one daily dose each week over
a period of 6 weeks until complete discontinuation,
then:
1. MTX dose increase to 20mg weekly





COBRA 81 A DAS44 of < 1.6 1. 60mg/day of prednisolone, tapered to 7.5mg/day
in 6 weeks, 7.5mg/week of MTX and 1 g/day of
SSZ, increased to 2 g/day after 1 week
2. MTX increased to 25mg/week after 13 weeks
of treatment if the DAS44 was ≥ 1.6
Every 3 months
COBRA-light 83 1. 30 mg/day of prednisolone, tapered to
7.5 mg/day in 9 weeks and 10mg/week MTX
with stepwise increments in all patients to
25 mg/week in 9 weeks




















































































































































































99 (97 in ITT) Remission – a modified
version of ACR 1981
defined remission (Pinals
et al.71) – on any drug
treatment, no swollen or
tender joints (modified by
excluding fatigue and
duration definition)
1. Combination therapy started with:
2. 500 mg of SSZ twice daily, 7.5 mg of MTX
weekly, 300 mg of HCQ daily and 5 mg of
prednisolone daily for 3 months
3. If the clinical improvement was < 50% in at
least two of SJC, TJC and ESR or CRP, the MTX
and prednisolone increased to 10mg weekly
and 7.5 mg daily
4. The protocol allowed flexible subsequent dose
adjustments to mimic clinical practice. The
highest dose at 9 months and thereafter was
2 g daily of SSZ, 15 mg weekly of MTX, 300 mg
daily of HCQ and 10mg daily of prednisolone
5. If remission was achieved during the first year
with the initial drug combination, the drug
doses were tapered, and prednisolone and MTX
could even be discontinued at 9 and 18 months.
SSZ (1 g daily) and HCQ (300mg daily) had to
be continued until the end of the study
6. If remission was achieved during the first year
but not with the initial drug combination, drug
doses were gradually tapered to those of the
second year
7. If the induced remission was lost, DMARD
doses were increased with the intention of
reaching remission
8. If one or several components of the
combination had to be discontinued, a
combination of three DMARDs was restarted by
replacing SSZ and HCQ with auranofin (3–6mg
daily) and MTX with azathioprine (2 mg/kg
daily). Other DMARDs could also be used
as substitutes
Baseline and at months 1,





























participants Target Treatment protocol Frequency of assessment
Single-drug
treatment
100 (98 in ITT) 1. Prednisolone (up to 10mg) was allowed in
patients with continuously active disease
(decision to use made by the treating
physician), but simultaneous use of multiple
DMARDs was not allowed. The patients were
treated continuously with one DMARD alone,
with or without prednisolone and, if a more
beneficial effect was needed, the dose was
increased or the DMARD was changed
2. SSZ (2 g daily) was used as the initial drug in all
patients and the dose was increased to 3 g daily
at 3 months, if clinically indicated
3. If an AE occurred, or if the clinical response was
< 25% at 6 months, the SSZ was replaced with
MTX (7.5–15mg weekly)
4. As the third DMARD, azathioprine (2 mg/kg
daily), auranofin, HCQ, injectable gold,






SDAI arm 42 A SDAI of ≤ 11 (LDA) 15 mg/week of MTX, then if not achieving a SDAI
of ≤ 11:
1. Increased oral MTX to 20mg and then
to 25mg
2. Triple therapy (1000 mg/day of SSZ, 200 mg/day
of chloroquine, 25 mg/week of MTX)
3. LEF in combination with MTX. Low-dose oral
corticosteroids (PDN 7.5 mg/day) were
prescribed to all patients for the initial 6
months and were tapered and stopped after
the 6-month visit if LDA was achieved
Monthly for the first
3 months then every














































































































































































participants Target Treatment protocol Frequency of assessment
CDAI arm 60 A CDAI of ≤ 10 (LDA) 15 mg/week of MTX, then if not achieving a CDAI
of ≤ 10:
1. Increased oral MTX to 20mg, then 25mg
2. Triple therapy (1000 mg/day of SSZ, 200 mg/day
of chloroquine, of 25 mg/week MTX)
3. LEF in combination with MTX. Low-dose oral
CSs (PDN 7.5 mg/day) were prescribed to all
patients for the initial 6 months and were









47 A DAS28 of < 3.2 1. MTX (7.5 mg/week), SSZ (500mg twice a day)
and HCQ (200mg daily). 5 mg/week folic acid
was co-prescribed 4 days after MTX dosing
2. The MTX dosage was escalated each month in
2.5- to 5-mg increments until good disease
control was obtained (up to a maximum of
25mg/week) or side effects occurred
3. Thereafter, if good disease control was not
achieved (i.e. if the DAS28 remained > 3.2),
SSZ was increased to 40mg/kg/day in divided
doses; subsequently:
4. If disease control remained inadequate, the
dosage of HCQ was increased to 400 mg/day.
If there is persistent disease activity despite
maximal drug therapy or drug-related toxicity,
then alternative DMARDs or biologic agents
could be used singly or in combination in order
to control disease activity































participants Target Treatment protocol Frequency of assessment
Step-up therapy 49 1. SSZ (target dosage 40mg/kg/day in divided doses)
2. After 3 months, if the DAS28 remained > 3.2,
MTX was added (7.5 mg/week, co-prescribed
with 5 mg/week of folic acid 4 days after MTX
dosing, increased monthly to a maximum of
25mg/week, as above)
3. After the maximum tolerated dose of MTX was
reached, 400 mg/day of HCQ was added in
patients with persistent disease activity
STREAM55 TTT vs. usual care Aggressive group 42 Remission (a DAS44 of
< 1.6)
Treatment was started with 15 mg/week of oral
MTX. If the DAS was ≥ 1.6 at a given time point:
1. Increase in MTX to 25mg/week; 25mg/week of
MTX combined with 40mg of ADA every 2 weeks
2. 25 mg/week of MTX combined with 40 mg/
week of ADA
3. A combination of 25 mg/week of MTX,
2000mg/day of SSZ and 400mg/day of HCQ
4. A combination of 25 mg/week of MTX,
2000mg/day of SSZ, 400 mg/day of HCQ and
7.5 mg/day of PDN
5. 20 mg/day of LEF (100 mg at days 1, 8 and 15)
and 50mg/week of intramuscular gold
If the DAS was < 1.6 at one time point, the
treatment remained unchanged. If the DAS was
< 1.6 at two consecutive time points, the following
actions were taken:
1. 15mg/week of MTX was decreased from 2.5 mg
every 2 weeks to 0mg/week after 3 months
2. 25mg/week of MTX was decreased from 2.5 mg
every 2 weeks to 10mg/week after 3 months
3. 40 mg of ADA every 2 weeks was stopped
4. 40 mg/week of ADA was decreased to 40mg
every 2 weeks
5. HCQ was decreased from 200mg every














































































































































































participants Target Treatment protocol Frequency of assessment
If remission was sustained after 3 months, SSZ was
decreased subsequently from 500mg every
4 weeks to 0 mg. If remission was sustained after
3 months:
1. MTX was decreased from 2.5 mg every 2 weeks
to 0 mg
2. 7.5 mg/ day of PDN was decreased to 0 mg in
7 weeks
3. LEF was decreased to 10mg/day
If remission was sustained after 3 months
1. LEF was stopped
2. Gold was decreased to 50mg every 2 weeks
If DAS remained < 1.6 and gold was decreased to
50mg every 4 weeks; if remission was sustained,
gold was stopped. If at any time point the DAS
was ≥ 1.6 the last effective treatment was
restarted. In case of intolerance to a DMARD, the
highest tolerated dose was used and, if the DAS
was ≥ 1.6 at the next visit, the patient went on to
the next step
Conventional care 40 Not prompted to make
treatment decisions based
on DAS. The treating
physician could only
change therapy if the DAS
was > 2.4 at the 3-month
assessment
The rheumatologist had access to the DAS, but
was not prompted to make treatment decisions
based on the DAS. The following order of drugs
was suggested to the treating rheumatologist:
HCQ (or MTX after 2005 with 25 patients





























participants Target Treatment protocol Frequency of assessment
T-4 study56,57 TTT vs. usual care;
comparison of
different targets
Routine care 62 No target All groups received 1 g/day of SSZ. Change of
therapy in the routine care group was based on
the treating physician’s clinical judgement
according to the improvement in the number of
tender joints (0–28), swollen joints (0–26) and
value of serum CRP from pre-assessment values,
without access to current DAS28 and MMP-3
values
Weeks 0, 2, 4, 6, 8, 12,
16, 20, 24, 28, 32, 36, 40,
44, 48, 52 and 56
DAS28-driven
therapy
60 A DAS28 of < 2.6 1. 1 g/day of SSZ plus 4 mg/week of MTX:b the
dosage was not changed if the patient had
responded compared with the previous
visit; otherwise:
2. The dosage was increased in a stepwise
manner to a maximum of 8 mg/weekc if patient
had not responded. Change of therapy based
on improvement in the number of tender joints
(0–28), swollen joints (0–26) and value of CRP
from pre-assessment values, without access to
current DAS28 and MMP-3 values
3. If the maximum tolerable dose of MTX that
introduced a dose-dependent side effect was
reached and the patient still did not fulfil
sustained response, TNF blockers were allowed.
If patients with the administration of TNF
blockers did not show improvement compared
with the previous measurement, TNF blockers
were changed to another biological agent, or
the TNF blocker dose increased, or the interval
for TNF administration was shortened. DMARDs
including bucillamine,c gold sodium thiomalate,
tacrolimus and LEF were given, as allowed, by
the rheumatologist at all times. Combination
therapy with DMARDs other than MTX was
allowed for two kinds of agents. Intra-articular
GC (to a maximum of 10mg of triamcinolone
acetonide on a single visit) was permitted for
persistently swollen and tender joints
MMP-3-driven
therapy
60 A MMP-3 concentration of
< 121 ng/ml for men or




61 A DAS28 of < 2.6 and a
MMP-3 concentration of
< 121 ng/ml for men or



















































































































































































Immediate ETN 244 No target Oral MTX, escalated to 20mg/week or to a lower
dosage if treatment resulted in no active tender/
painful or swollen joints by week 12, plus
subcutaneous 50 mg/week of ETN. Corticosteroid
use at entry tapered
Every 6 weeks during the
first 48 weeks and every




132 Oral MTX, escalated to 20mg/week or to a lower
dosage if treatment resulted in no active tender/
painful or swollen joints by week 12, plus 500mg
twice daily of SSZ, escalated (if tolerated) to
1000 mg twice daily at 6 weeks, plus 200 mg twice
daily of HCQ. Corticosteroid use at entry tapered
Step-up ETN 255 A DAS28-ESR of < 3.2 Oral MTX, escalated to 20mg/week or to a lower
dosage if treatment resulted in no active tender/
painful or swollen joints by week 12 plus an ETN
PBO. Corticosteroid use at entry tapered. If DAS28-
ESR was ≥ 3.2 at week 24, patients were stepped
up to MTX plus subcutaneous 50 mg/week of ETN
Step-up triple
therapy
124 Oral MTX, escalated to 20mg/week or to a lower
dosage if treatment resulted in no active tender/
painful or swollen joints by week 12 plus a triple-
therapy PBO. Corticosteroid use at entry tapered.
If DAS28-ESR was ≥ 3.2 at week 24, patients were
stepped up to MTX plus 500 mg twice daily of SSZ,
escalated (if tolerated) to 1000mg twice daily at

































TOC +MTX 105 A DAS28 of < 2.6 and a
SJC28 of ≤ 4
1. 8 mg/kg of TOC (maximum 800mg) every
4 weeks; the number of infusions could differ
depending on achievement of sustained
remission, at which the point infusions were
tapered down in dose according to protocol
and eventually discontinued. MTX started at
10 mg per week orally and increased stepwise
every 4 weeks by 5 mg to a maximum of 30mg
per week, until remission or dose-limiting
toxicity. Patients received 5mg of folic acid
orally twice per week
2. If remission was not achieved at the maximum
dose or maximum tolerated dose of MTX,
200 mg of HCQ twice per day orally for
3 months was added to the regimen
3. If remission was not achieved after HCQ
step-up, the initial treatment regimens ended
and standard of care therapy was started at the
discretion of the treating physician, typically
MTX combined with a TNF inhibitor
4. If sustained remission was achieved, the dose of
MTX was reduced stepwise by 5 mg every
4 weeks until 10 mg, then discontinued as the
next step; 4 weeks thereafter, TOC was tapered
to 4 mg/kg, and after 3 months of 4 mg/kg per
4 weeks, TOC was discontinued, provided
sustained remission persisted
There was no fixed number
of weeks or visits per
patient. SJC, TJC, pain,
general health, ESR and
CRP assessed at baseline
and every 4 weeks














































































































































































participants Target Treatment protocol Frequency of assessment
TOC + PBO–MTX 103 1. 8 mg/kg of TOC (maximum 800mg) every
4 weeks; the number of infusions could differ
depending on achievement of sustained
remission, at which point the infusions were
tapered down in dose according to the protocol
and eventually discontinued. The same scheme
was followed for PBO–MTX as the TCO +MTX
arm. Patients received 5 mg of folic acid orally
twice per week
2. If remission was not achieved at the maximum
dose or maximum tolerated dose of PBO–MTX,
200 mg of HCQ twice per day orally for
3 months was added to the regimen
3. If remission was not achieved after HCQ
step-up, the initial treatment regimens ended
and MTX was started in place of PBO–MTX and
stepped up in accordance the protocol
4. If remission was not achieved after switching to
the active MTX treatment and stepping up,
standard of care therapy was initiated, typically
MTX combined with a TNF inhibitor
5. If sustained remission was achieved, the dose of
PBO–MTX was reduced stepwise by 5 mg every
4 weeks until 10 mg, then discontinued as the
next step; 4 weeks thereafter, TOC was tapered
to 4 mg/kg, and after 3 months of 4 mg/kg per






























participants Target Treatment protocol Frequency of assessment
MTX + PBO–TOC 108 1. MTX started at 10 mg per week orally and
increased stepwise every 4 weeks by 5 mg to a
maximum of 30mg/week, until remission or
dose-limiting toxicity. The same scheme was
followed for PBO–TOC as the TCO +MTX arm.
Patients received 5mg of folic acid orally twice
per week
2. If remission was not achieved at the maximum
dose or maximum tolerated dose of PBO–TOC,
200 mg of HCQ twice per day orally for
3 months was added to the regimen
3. If remission was not achieved after HCQ
step-up, the initial treatment regimens ended
and TOC was started in place of PBO–TOC and
stepped up according to the protocol
4. If remission was not achieved after switching to
the active TOC treatment and stepping up,
standard of care therapy was initiated, typically
MTX combined with a TNF inhibitor
5. If sustained remission was achieved, the dose of
MTX was reduced stepwise by 5 mg every
4 weeks until 10 mg, then discontinued as the
next step; 4 weeks thereafter, PBO–TOC was
tapered to 4 mg/kg and after 3 months of
4 mg/kg per 4 weeks, PBO–TOC was
discontinued, provided sustained
remission persisted
DAS, Disease Activity Score; DAS28-ESR, Disease Activity Score, 28 joints with erythrocyte sedimentation rate; ESR, erythrocyte sedimentation rate; ITT, intention to treat; MMP-3, matrix
metalloproteinase 3; MTX-TSU, methotrexate tight step-up; PDN, prednisone; SJC28, swollen joint count, 28 joints; TNF, tumour necrosis factor; VAS, visual analogue scale.
a n= 94 in Verschueren et al.42
b This small dose of MTX is unique to Japanese patients and much higher doses are required in other populations.




































































































































































a DAS28 of < 3.2 (Saunders et al.54); a Disease Activity Score, 28 joints with erythrocyte sedimentation rate
(DAS28-ESR) of < 3.2 (TEAR58–60)], remission [a DAS44 of < 1.6 (COBRA-light44,45 and STREAM55); modified ACR
1981 definition (FIN-RACo46–49); a DAS28 of < 2.6 (T-4 study56,57 and Optimisation of Adalimumab study52,53);
a DAS28 of < 2.6 and a SJC (28 joints) of ≤ 4 (U-Act-Early62)] response [defined by thresholds of SJC, TJC,
erythrocyte sedimentation rate (ESR) and general well-being visual analogue scale (VAS) (CAMERA35,36,67)]:
and matrix metalloproteinase 3 (MMP-3) concentration (< 121 ng/ml for men or < 59.7 ng/ml for women;
T-4 study56,57). Treatment protocols for attaining the target varied considerably across studies in terms of the
number of steps in the treatment protocol and the treatments used at each step, the only similar ones being
in the COBRA Classic arms of the CareRA40,42,43 and COBRA-light44,45 trials (which were similar, but not
exactly alike). Assessments were made every 3 months or less in all trials with an early RA population.
Trials examining established rheumatoid arthritis populations
Three trials9,50,52,53 reported on established RA populations (i.e. BROSG trial,9 Fransen et al.50 and the
Optimisation of Adalimumab study52,53). Population characteristics are presented in Table 16. The mean age
of trial participants ranged from 51.5 to 60.8 years, and trial arm samples ranged from 62% to 83.5%
female and from 62% to 93.5% rheumatoid factor positive. The mean disease duration at baseline ranged
from 4 to 12.6 years. The mean DAS28 at baseline ranged from 4.5 to 5.8, indicating moderate to severe
RA at baseline among the established RA population. The mean SJC (on 66 joints) ranged from 10.5 to
11.1 and mean TJC (0–68 joints) ranged from 11.3 to 13.5, across all trial arms. The mean HAQ score at
baseline ranged from 1.25 to 1.6.
Characteristics of the TTT features of the established RA trials are presented in Table 17. Targets included
LDA (DAS28 of ≤ 3.250), remission (DAS28 of < 2.652,53), SJC of 0,52,53 control of joint pain, stiffness and
related symptoms, and suppression of clinical and laboratory evidence of inflammation, plus CRP below twice
the upper limit of normal.9 Two9,50 of the three trials examining an established RA population (BROSG9 trial
and Fransen et al.50) did not employ a specific treatment protocol for reaching the target. The Optimisation
of Adalimumab study52,53 used the same treatment protocol for both the DAS28 of < 2.6- and the SJC of
0-targeted arms. Only the Fransen et al.50 trial had assessments every 3 months or less (0, 4, 12 and 24 weeks),
whereas the BROSG9 trial had assessments every 4 months and the Optimisation of Adalimumab study52,53
had assessments every 6 months (although visits every 2 months until 6 months and then every 3 months until
12 months were recommended for the two targeted arms).
Trials examining both early and established rheumatoid arthritis populations
Two trials61,63 examined both early and established RA populations combined (TICORA61 and van Hulst et al.63).
Population characteristics are presented in Table 18. The mean age of trial participants ranged from 51 to
60 years, and trial arm samples ranged from 60% to 71% female and 73% to 79% rheumatoid factor
positive. The mean disease duration at baseline ranged from 19 months to 8.9 years. The mean DAS28 at
baseline ranged from 3.9 to 4.2 (and DAS44 ranged from 4.6 to 4.9). The mean SJC (on 66 joints) ranged
from 11 to 12 and the mean HAQ score at baseline ranged from 1.1 to 2.0.
The characteristics of the TTT features of the trials with populations containing both patients with early RA
and those with established RA are presented in Table 19. LDA targets were used by both trials (a DAS44 of
≤ 2.461 and a DAS28 of ≤ 3.263) (with no target in the usual-care arms). The van Hulst et al.63 trial did not
employ a specific treatment protocol for reaching the target. The TICORA61 trial used a specific treatment
protocol for the intensive management arm, but not for the routine management arm. Both trials had
assessments every 3 months.
Effectiveness of treat to target compared with usual care
Heterogeneity in the treatment protocols used, and outcomes reported, precluded statistical meta-analysis
and, therefore, the findings of the trials examining TTT compared with usual care were combined and
examined narratively by outcome. Where it was possible, some comparisons were examined using forest
plots, with odds ratios (ORs) and confidence intervals (CIs) calculated.
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
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233 60.8 (11.3) [62.5
(30.1–87.4)]a




































NR NR NR NR
Usual care 179 Main sample,
n= 179: 59 (13),
58 (50–70)a
Subsample
























Routine care 109 56.0 (12.9) 91/109 (84) NR NR 5.7 (1.0) 10.6 (6.0) 11.3 (6.9) NR 1.6 (0.6)
DAS28
target
100 55.3 (13.7) 82/100 (82) NR NR 5.7 (1.1) 11.1 (5.3) 13.0 (7.9) NR 1.4 (0.7)
SJC target 99 51.5 (13.2) 77/99 (78) NR NR 5.8 (1.3) 10.5 (5.7) 13.5 (7.3) NR 1.5 (0.6)
NR, not reported; SD, standard deviation.
a Mean (range).













































































































































































participants Target Treatment protocol Frequency of assessment
BROSG trial9 Other comparisons Symptomatic
treatment
(shared care)
233 To control joint pain, stiffness
and related symptoms
Managed predominantly in the primary care setting.
NSAIDs, intra-articular steroid injections (up to a maximum
of one per month), DMARDs (antimalarials, SSZ,
intramuscular gold, penicillamine, azathioprine, MTX and
LEF) and low-dose steroids (≤ 7.5 mg daily). Non-drug
modalities, such as physiotherapy referral, were also
used as the GP felt appropriate. DMARD therapy was
monitored using the standard guidelines in current use in
the five centres
Seen at home every 4
months by a rheumatology
specialist nurse and annually
by the rheumatologist,
encouraged to visit the GP if




233 To control joint pain, stiffness
and related symptoms and to
suppress clinical and laboratory
evidence of inflammation. CRP
concentrations below twice the
upper limit of normal
Managed predominantly in the hospital clinic setting.
Symptomatic treatment group drugs plus, if necessary,
ciclosporin, parenteral steroids, medium-dose oral steroids
(up to 10mg daily) and cyclophosphamide
Every 4 months (or more
often if clinically indicated)
Fransen et al.,
200550
TTT vs. usual care DAS28 205 A DAS28 of ≤ 3.2 (for
subsample of 142 patients with
DAS assessment)
Systematic monitoring of disease activity by assessment of
DAS28 by the treating rheumatologist. The aim was to
reach a DAS28 of ≤ 3.2 (LDA) by changing DMARD
treatment if the score was > 3.2
0, 4, 12 and 24 weeks
Usual care 179 No target No systematic monitoring of disease activity was done and





TTT vs. usual care;
comparison of
different targets
RC 109 No target No treatment protocol 0, 6, 12 and 18 months
DAS28 target 100 A DAS28 of < 2.6 1. There was no specified drug algorithm for any
physician, as many patients had tried two or more
DMARDs before receiving ADA in RC
2. Physicians were encouraged to make treatment
changes in patients when the target was not achieved
3. The dose of ADA was not increased beyond 40mg
subcutaneous every 2 weeks, as that is the approved
dose in Canada. Therefore much of the targeted
treatment was expected to be intensification of
DMARDs, intra-articular steroid injections and oral or
intramuscular steroids
0, 6, 12 and 18 months.
Assessments at 2, 4 and
9 months were also
recommended
SJC target 99 SJC of 0



























































55 51 (15) 39/55 (71) 41/55 (75) 19 (16) DAS44: 4.9 (0.9) 12 (4)
(0–44)
NR 62 (20) 2.0 (0.8)
Routine
management
55 54 (11) 38/55 (69) 40/55 (73) 20 (16) DAS44: 4.6 (1.0) 11 (4)
(0–44)
NR 59 (20) 1.9 (0.7)




144 59 (13) 87/144 (60) 105/144 (75) 8.9 (0–32) yearsa 4.2 (1.3) NR NR NR 1.3 (0.7)
Usual-care
group
104 60 (13) 71/104 (68) 80/144 (79) 5.8 (0–40) yearsa 3.9 (1.3) NR NR NR 1.1 (0.7)












































































































































































participants Target Treatment protocol Frequency of assessment




55 A DAS44 of
≤ 2.4
Escalation of DMARDs in patients with persisting disease
activity:
1. 500 mg daily of SSZ, increasing every week to target
dose of 40 mg/kg per day
2. 40 mg/kg per day of SSZ, 7.5 mg/week of MTX, 5 mg
per week of folic acid, 200–400mg/day of HCQ
(< 6.5 mg/kg per day)
3. Triple therapy with monthly increments of MTX by
2.5–5.0 mg per week (maximum 25mg per week)
4. Triple therapy with weekly 500-mg increments of SSZ
dose (maximum 5 g per day in divided doses if tolerated)
5. Addition of prednisolone in enteric-coated tablets,
7.5 mg daily
6. Change triple therapy to 2–5mg/kg per day
ciclosporin, 25 mg/week of MTX and 5mg/week of
folic acid





55 No target Clinical decision-making not aided by formal composite
measures of disease activity
DMARD monotherapy was given in patients with active
synovitis, and failure of treatment (because of toxic
effects or lack of effect) resulted in a change to
alternative monotherapy, or addition of a second or third
drug at the discretion of the attending rheumatologist.
Intra-articular injections of corticosteroid were given with
the same restrictions as those in the intensive group






144 A DAS28 of
≤ 3.2
No protocol: DAS28 provided on paper to the
rheumatologist. Rheumatologist advised to aim for their
patients to reach a DAS28 of ≤ 3.2
Every 3 months (more if
needed)






















Trials examining early rheumatoid arthritis populations
Table 20 summarises the TTT outcomes for the comparison of TTT with usual care for the early RA population.
Details of treatment adaptations and dose of drugs given are summarised in Appendix 4, Table 51. Both trials
(i.e. STREAM55 and T-4 study57) reported the proportion of patients meeting the target for at least one of the
study arms (although the T-4 study reported only the number and proportion of patients meeting the DAS28
target and not the MMP-3 target or the combined DAS28 and MMP-3 target). The number meeting the
target was 38% in the DAS28 of < 2.6 arm of the T-4 study.57 The number meeting the target in the STREAM
trial was slightly higher in the conventional care group (65%) than in the aggressive group (54%) at 1 year
and then slightly higher in the aggressive group (66%) than in the conventional care group (49%) at 2 years,
although the statistical significance of these comparisons was not reported [our calculated OR is 1.66 (95% CI
0.67 to 4.12) at 1 year and 0.52 (95% CI 0.21 to 1.28) at 2 years]. Neither trial reported the proportion of
patients attaining LDA at follow-up. In the STREAM trial, the proportion of patients in remission was slightly
higher in the usual-care arm (65%) than in the TTT arm (54%) at 1 year and slightly higher in the TTT arm
(66%) than the usual-care arm (49%) at 2 years, although the statistical significance of these comparisons
was not reported.55 In the T-4 study, the proportion of patients attaining DAS28 remission was highest in the
combined DAS28 and MMP-3 target group (56%; OR 0.21, 95% CI 0.10 to 0.47) vs. routine care], still
significantly higher in the DAS28 of < 2.6 target group (38%; OR 0.43, 95% CI 0.19 to 0.95) vs. routine care]
than the MMP-3 target group (13%), which in turn was significantly lower than in the routine care arm
(21%;57 OR 1.72, 95% CI 0.66 to 4.52). Visualised data in Figure 5 show some evidence of a benefit of TTT
on remission at 1 year, when some targets may be more beneficial than others.
Specific disease activity outcomes are summarised in Table 21. In the T-4 study,57 the mean decrease in
DAS28 score between baseline and 56 weeks was significantly greater in one of the three TTT arms
{the DAS28-targeted arm: –2.5 [standard deviation (SD) 3.1]} than in the usual care arm [–1.3 (SD 2.7)],
although there was no significant difference between either of the other arms (the MMP-3-targeted arm
or the combined DAS28 and MMP-3-targeted arm) and the usual-care arm. Nor in the STREAM trial55 was
there any difference in the DAS44 score between the TTT arm and the usual-care arm at 2 years. In neither
study was there any significant difference in mean change from baseline in HAQ score/modified Health
Assessment Questionnaire (mHAQ) score between the targeted arm and the usual-care arm (measured at
2 years in the STREA trial55 and at 56 weeks in the T-4 study57). In the T-4 study,57 the mean change in
erosion score from baseline to 56 weeks was significantly better in the combined DAS28 and MMP-3
target group [in which erosion score was reduced by –0.8 (SD 4.8)] than in the routine care group [in which
the erosion score increased by 0.8 (SD 1.4)], but differences in the change in erosion score between either of
the other arms (the DAS28-targeted arm or MMP-3-targeted arm) and usual care were not significant.
Similarly, the increase in joint space narrowing (JSN) score at 56 weeks was significantly lower in the
combined DAS28 and MMP-3 target group [0.3 (SD 2.1)] than in the routine care group [1.4 (SD 2.7)]. In
addition, in the T-4 study,57 the mean change in Sharp/van der Heijde score (SHS) from baseline to 56 weeks
was better in the combined DAS28 and MMP-3 target group [a reduction in total score of –0.6 (SD 5.9)] than
in the routine care group [an increase in total score [2.0 (SD 2.1)]. In the STREAM trial, however, there was no
significant difference in the proportion of patients without erosions at baseline who developed new erosions
over the course of the trial, or in the median increase in SHS from baseline at 2 years.55 SJC, TJC, EULAR
response, ACR response and quality of life were not reported in any trial comparing TTT with usual care in an
early RA population.
In summary, among trials examining an early RA population, there is no clear evidence either in favour of or
against the clinical effectiveness of a TTT approach, in comparison with usual care, overall. There is some
evidence to suggest that TTT may be more effective than usual care in terms of remission at 1 year. The
STREAM55 trial found usual care to be more effective at 1 year, but TTT to be more effective at 2 years, in
terms of the proportion of patients meeting the target and attaining remission. The T-4 study57 found usual
care to be more effective than the MMP-3 target, but the combined DAS28 and MMP-3-targeted arm to be
more effective than usual care, in terms of the proportion of patients attaining remission. There were mixed
findings in relation to DAS28/DAS44 (the T-4 study57 found greater benefit for the DAS28-targeted arm
than for usual care, but no difference between the MMP-3 or combined targeted arms and usual care;
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42 2 years 1 year 41/42 (98) Remission
(DAS44 of < 1.6)
22b (54) NR 22b (54)





40 1 year 38/40 (95) No target 21b (65)c NR 21b (65)
(DAS44 of < 1.6)
Aggressive
group
42 2 years 41/42 (98) Remission
(DAS44 of < 1.6)
27b (66) NR 27b (66)





40 2 years 38/40 (95) No target 19b (49)c NR 19b (49)
(DAS44 of < 1.6)
T-4 study56,57 Routine care 62 56 weeks 56 weeks 55/62 (89)
available for
analysis
No target NA NR 13/62 (21) (DAS28
of < 2.6);d,e 9/62 (15)




60 56 weeks 56/60 (93)
available for
analysis
A DAS28 of < 2.6 23/60
(38%)
NR 23/60 (38) (DAS28
of < 2.6);d 19/60 (32)





60 56 weeks 53/60 (8%)
available for
analysis
A MMP-3 concentration of
< 121 ng/ml for men or
< 59.7 ng/ml for women
NR NR 8/60 (13) (DAS28
of < 2.6);d,h 8/60 (13)






61 56 weeks 58/61 (95)
available for
analysis
A DAS28 of < 2.6 and a
MMP-3 concentration of
< 121 ng/ml for men or
< 59.7 ng/ml for women
NR NR 34/61 (56) (DAS28
of < 2.6);e,h 28/61
(46) (SDAI of ≤ 3.3)d,f
0.21
(0.10 to 0.47)g
NA, not applicable; NR, not reported.
a Randomised.
b Calculated.





























M–H, fixed, 95% CI
OR










1.66 (0.67 to 4.12)
Conventional care vs. aggresive therapy, 










0.43 (0.19 to 0.95)
Routine care vs. DAS28-driven therapy, 










1.72 (0.66 to 4.52)
Routine care vs. MMP-3 targeted therapy, 










0.21 (0.10 to 0.47)
Routine care vs. DAS-28 and MMP-3  targeted 
therapy, 56 weeks T-4 study; Urata 201257









































































































































































































score (SD) Joint erosion Quality of life
STREAM55 Aggressive
group
42 2 years 2 years NR 1.4 (0.7) NR NR NR NR 0.09
(0.50)b,c
New erosions in







40 2 years NR 1.7 (0.8) NR NR NR NR 0.25
(0.59)b,c
New erosions in 8 out







Routine care 62 56 weeks 56 weeks –1.3 (2.7);c,e
n= 55






JSN score: 1.4 (2.7)c,g
Total score: 2.0 (2.1)c,h
DAS28-driven
therapy
60 56 weeks –2.5 (3.1);c,e
n= 56






JSN score: 1.4 (2.8)c,i
Total score: 1.6 (4.3)c,f
MMP-3-driven
therapy
60 56 weeks –1.3 (2.4);c
n= 53






JSN score: 0.7 (2.0)c























































61 56 weeks –2.0 (2.2);c
n= 58












c Change from baseline.
d Median (interquartile range).
e p< 0.05.
f p< 0.005.
g p< 0.05 (routine care vs. combined DAS28 and MMP-3-targeted arm).
h p< 0.001.




































































































































































the STREAM55 trial also found no difference), and in relation to joint erosion (the T-4 study57 found greater
benefit for the combined target arm than with usual care in terms of SHS, but no difference between the
DAS28- or MMP-3-targeted arms and usual care; the STREAM55 trial also found no difference). There was no
difference between TTT arms and usual care on HAQ score (assessed in the STREAM trial55 and the T-4 study57).
Impact of target among trials comparing treat to target with usual care in an early rheumatoid
arthritis population Among trials with early RA populations that used a remission target (DAS44 of
< 1.655 and DAS28 of < 2.657), there was mixed evidence in terms of the proportion of patients meeting
the target and the proportion attaining remission (the STREAM trial55 found usual care to be more effective
at 1 year, but TTT to be more effective at 2 years) and DAS28/DAS44 (the T-4 study57 found TTT to be
more effective than usual care, but the STREAM trial55 found no difference), with no difference on HAQ
score55,57 or joint erosion.55
The one trial examining a MMP-3 normalisation target in an early RA population found evidence in favour
of usual care in terms of the proportion of patients attaining remission,57 but no difference between the
MMP-3 normalisation-targeted arm and usual care on HAQ score progression.57
The one trial examining a combined remission and MMP-3 normalisation target in an early RA population
found evidence in favour of TTT in terms of the proportion of patients attaining remission and joint
erosion,57 but no difference between the combined DAS28 remission and MMP-3 normalisation-targeted
arm and usual care on HAQ score progression.57
In summary, comparing trials by target, there is no clear evidence in favour of any specific target being
more effective than usual care in an early RA population.
Trials examining established rheumatoid arthritis populations
Table 22 summarises the TTT outcomes for the comparison of TTT with usual care for the established RA
population. Details of treatment adaptations and doses of drugs given are summarised in Appendix 4,
Table 65. In the Fransen et al.50 trial, the proportion of patients who met the study target at 24 weeks
was significantly greater in the DAS28-targeted arm (31%) than in the usual-care arm (16%), as was the
proportion who attained LDA at 24 weeks (remission was not reported). In the Optimisation of Adalimumab
study there were no significant differences between the usual-care arm and each of the two targeted arms
at 6, 12 or 18 months in terms of the proportion of patients meeting the target (for both a DAS28 of < 2.6
and SJC of 0), attaining LDA or attaining remission.52,53 The data depicted in Figure 6 show some evidence
of a benefit of TTT on LDA at 6 months, in that some targets may be more beneficial than others. This
became more evident at 12 and 18 months, certainly for the DAS28-targeted arm compared with routine
care [OR 0.74 (95% CI 0.42 to 1.31) at 12 months and OR 0.34 (95% CI 0.19 to 0.61) at 18 months].
Table 23 summarises the disease activity outcomes for the comparison of TTT with usual care for the
established RA population. There were no significant differences in mean DAS28 at 6, 12 or 18 months
between either of the targeted arms and the routine care arm in the Optimisation of Adalimumab
study,52,53 nor between the targeted and usual-care arms of the Fransen et al.50 trial at 24 weeks. Similarly,
there were no significant differences in mean SJC or TJC at 6, 12 or 18 months between either of the
targeted arms and the routine care arm in the Optimisation of Adalimumab study52,53 (the Fransen et al.50
trial did not report SJC or TJC). The proportion of patients with a good or moderate EULAR response was
significantly different across the three arms of the Optimisation of Adalimumab study, with higher
proportions in the DAS28-targeted arm (63.0%) and SJC-targeted arm (53.5%) than in the usual-care arm
at 18 months, but not at 6 or 12 months.52,53 There were no significant differences in mean change from
baseline in the HAQ score at 6, 12 or 18 months between either of the targeted arms and the routine care
arm in the Optimisation of Adalimumab study52,53 (the Fransen et al.50 trial did not report HAQ scores).
The DAS44, ACR 20/50/70 responses, joint erosion and quality of life were not reported by either trial
examining TTT compared with usual care in an established RA population.
ASSESSMENT OF CLINICAL EFFECTIVENESS
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DAS28 205 24 weeks 4 weeks NA A DAS28 of
≤ 3.2
NR NR NR –
Usual care 179 4 weeks NA No target NR NR NR –
DAS28 205 12 weeks NA A DAS28 of
≤ 3.2
NR NR NR –
Usual care 179 12 weeks NA No target NR NR NR –
DAS28 205 24 weeks 189/205 (82) A DAS28 of
≤ 3.2
19/61 (31)b 19/61 (31)
(DAS28 of ≤ 3.2)b
NR 0.42
(0.19 to 0.94)
Usual care 179 24 weeks 159/179 (89) No target 13/81 (16)b,c 13/81 (16)





Routine care 109 18 months 6 months NA No target 17%
(DAS28 of < 2.6);c
22% (SJC= 0)c
28%
(DAS28 of < 3.2)
17%
(DAS28 of < 2.6)
–
DAS28 target 100 6 months NA A DAS28 of
< 2.6
24% 33%
(DAS28 of < 3.2)
24%
(DAS28 of < 2.6)
0.81
(0.45 to 1.45)d
SJC target 99 6 months NA A SJC of 0 24% 30%
(DAS28 of < 3.2)
16%
(DAS28 of < 2.6)
0.91
(0.50 to 1.66)d
Routine care 109 12 months NA No target 21%
(DAS28 of < 2.6);c
23% (SJC= 0)c
32%
(DAS28 of < 3.2)
21%
(DAS28 of < 2.6)
–
DAS28 target 100 12 months NA A DAS28 of
< 2.6
28% 39%
(DAS28 of < 3.2)
28%
(DAS28 of < 2.6)
0.74
(0.42 to 1.31)d
SJC target 99 12 months NA A SJC of 0 26% 31%
(DAS28 of < 3.2)
26%










































































































































































































(DAS28 of < 3.2)
16%
(DAS28 of < 2.6)
–
DAS28 target 100 18 months 73/100 (73) A DAS28 of
< 2.6
38% 47%
(DAS28 of < 3.2)
38%
(DAS28 of < 2.6)
0.91
(0.50 to 1.66)d
SJC target 99 18 months 77/99 (77.8) A SJC of 0 26% 27%
(DAS28 of < 3.2)
22%
(DAS28 of < 2.6)
0.79
(0.42 to 1.49)d
NA, not applicable; NR, not reported.
a Randomised.
b p= 0.028.
c This refers to the proportion of control arm participants meeting the target set for patients in the intervention arm.
























M–H, fixed, 95% CI
OR










0.42 (0.19 to 0.94)











0.81 (0.45 to 1.45)
Routine care vs. DAS28 target, 6 months










0.91 (0.50 to 1.66)
Routine care vs. SJC-0 target, 6 months
Optimisation of Adalimumab study; Pope 201352















































































































































































































erosion Quality of life
Fransen et al.,
200550
DAS28 205 24 weeks 24 weeks –0.40 (1.0)b,c NR NR NR NR NR NR NR NR





















































































NR, not reported; SEM, standard error of the mean.
a Randomised.
b Mean (SD).
c Change from baseline.
d Mean.






















In summary, among trials examining an established RA population, there is no clear evidence either in favour
of or against the clinical effectiveness of a TTT approach, in comparison with usual care, overall. There is
some evidence to suggest that TTT may be more effective than usual care in terms of LDA at 6 months. There
was evidence in favour of a TTT approach compared with usual care in the Fransen et al. trial50 in terms of the
proportion of patients meeting the target and attaining LDA, but no difference between TTT and usual care
in the Optimisation of Adalimumab study52 in terms of the proportion of patients meeting the target and
attaining LDA and remission. There was evidence in favour of a TTT approach compared with usual care in
terms of EULAR response in the Optimisation of Adalimumab study52 (both the DAS28- and SJC-targeted
arms were found to be more effective than usual care in terms of attaining a good or moderate EULAR
response at 18 months, although there was no difference at 6 or 12 months). There was, however, no
difference between TTT and usual care in terms of DAS28 in the Fransen et al.50 trial and the Optimisation of
Adalimumab study,52 nor in terms of SJC, TJC or HAQ response in the Optimisation of Adalimumab study.52
Impact of target among trials comparing treat to target with usual care in an established
rheumatoid arthritis population The one trial examining a LDA target (DAS28 of ≤ 3.2), in an
established RA population, found evidence in favour of TTT in terms of the proportion of patients meeting
the target and the proportion attaining remission.50
The one trial examining a remission target (DAS28 of < 2.6) in an early RA population found evidence in
favour of TTT in terms of EULAR good/moderate response,52 but no difference between the DAS28 remission-
targeted arm and usual care on the proportion of patients meeting the target, the proportion of patients
attaining LDA,52 the proportion of patients attaining remission, DAS28, SJC, TJC or HAQ score progression.52
The one trial examining a SJC of zero target in an early RA population found evidence in favour of TTT in
terms of EULAR good/moderate response,52 but no difference between the SJC of zero-targeted arm and
usual care on the proportion of patients meeting the target, the proportion of patients attaining LDA,
the proportion of patients attaining remission, DAS28, SJC, TJC or HAQ score progression.52
In summary, when the evidence is examined by target there is evidence in favour of TTT [using a LDA
target (DAS28 of ≤ 3.2)], compared with usual care in an established RA population.50 However, the
evidence is mixed with regard to remission (DAS28 of < 2.6) and SJC (SJC of 0) targets,52 although only
one trial used each of these targets and this related only to one outcome reported in the case of the LDA
target.50 The remission and SJC targets impacted on the same outcomes in the same way, although
findings were from the same (single) trial.52
Trials examining both early and established rheumatoid arthritis populations
Table 24 summarises the TTT outcomes for the comparison of TTT with usual care for the trials with
populations containing both patients with early RA and those with established RA. Details of treatment
adaptations and dose of drugs given are summarised in Appendix 4, Table 53. Neither the TICORA61 nor the
van Hulst et al.63 trial reported the proportion of patients meeting the study target or the proportion of
patients attaining LDA, and the van Hulst et al.63 trial did not report the proportion of patients attaining
remission. In the TICORA trial, the proportion of patients who attained remission at 18 months was
significantly greater in the intensive management arm (65%) than in the routine management arm (16%).61
Table 25 summarises the disease activity outcomes for the comparison of TTT with usual care for the trials with
populations containing both patients with early RA and those with established RA. In the van Hulst et al.63 trial
there was no significant difference in mean DAS28 between the intervention group and usual-care group at 3,
6, 9, 12, 15 or 18 months, or in the mean change from baseline in DAS28 at 18 months. The TICORA61 trial
did not report the DAS28. At 3, 6, 9, 12, 15 and 18 months, the mean DAS44 was significantly lower in the
intensive management arm than the routine management arm. In addition, there was a significantly greater
mean change from baseline in the DAS44 in the intensive management arm [–3.5 (SD 1.1)] than in the routine
management arm [–1.9 (SD 1.4)] of the TICORA trial at 18 months.61 The DAS44 was not reported in the
van Hulst et al. trial.63 There was a significantly greater mean change from baseline in the SJC in the intensive
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55 18 months 18 months 53/55 (96) A DAS44 of ≤ 2.4 NR NR 36 (65)b (EULAR




55 18 months 50/55 (91) No target NR NR 9 (16)b (EULAR
remission – a DAS44
of < 1.6)
van Hulst et al.,
201063
Intervention group 144 18 months 18 months 138/144 (96) A DAS28 of ≤ 3.2 NR NR NR
Usual-care group 104 18 months 92/104 (88) No target NR NR NR
NR, not reported.
a Randomised.























































(SD) Joint erosion Quality of life
TICORA61 Intensive
management
55 18 months 3 months NR 2.67 (1.38)b,c NR NR NR NR NR NR NR
Routine
management
55 3 months NR 3.65 (1.40)b,c NR NR NR NR NR NR NR
Intensive
management
55 6 months NR 2.29 (1.43)b,c NR NR NR NR NR NR NR
Routine
management
55 6 months NR 3.32 (1.70)b,c NR NR NR NR NR NR NR
Intensive
management
55 9 months NR 2.07 (1.30)b,c NR NR NR NR NR NR NR
Routine
management
55 9 months NR 3.08 (1.48)b,c NR NR NR NR NR NR NR
Intensive
management
55 12 months NR 1.77 (1.13)b,c NR NR NR NR NR NR NR
Routine
management
55 12 months NR 2.78 (1.46)b,c NR NR NR NR NR NR NR
Intensive
management
55 15 months NR 1.50 (0.96)b,c NR NR NR NR NR NR NR
Routine
management
55 15 months NR 2.66 (1.36)b,c NR NR NR NR NR NR NR
Intensive
management




































































































































































































































(SD) Joint erosion Quality of life
Routine
management


































144 18 months 3 months 4.06
(3.84 to 4.28)c,n
NR NR NR NR NR NR NR NR
Usual-care
group
104 3 months 3.87
(3.66 to 4.11)c,n
NR NR NR NR NR NR NR NR
Intervention
group
144 6 months 3.87
(3.65 to 4.08)c,n
NR NR NR NR NR NR NR NR
Usual-care
group
104 6 months 3.60
(3.35 to 3.87)c,n
NR NR NR NR NR NR NR NR
Intervention
group
144 9 months 3.68
(3.45 to 3.86)c,n
NR NR NR NR NR NR NR NR
Usual-care
group
104 9 months 3.40
(3.17 to 3.64)c,n
NR NR NR NR NR NR NR NR
Intervention
group
144 12 months 3.74
(3.54 to 3.98)c,n
NR NR NR NR NR NR NR NR
Usual-care
group
104 12 months 3.53
(3.28 to 3.80)c,n
NR NR NR NR NR NR NR NR
Intervention
group
144 15 months 3.61
(3.37 to 3.81)c,n






















































(SD) Joint erosion Quality of life
Usual-care
group
104 15 months 3.39
(3.13 to 3.66)c,n
NR NR NR NR NR NR NR NR
Intervention
group
144 18 months 3.55
(3.33 to 3.76);c,n
–0.66e,o











104 18 months 3.24
(2.99 to 3.49);c,n
–0.69e,o









NR, not reported; SF-12, Short Form questionnaire-12 items.
a Randomised.
b p< 0.0001.
c Converted from graphical data.
d Mean (SD).














































































































































































management arm [–11 (SD 5)] than in the routine management arm [–8 (SD 5)] at 18 months in the TICORA
trial; however, there was no significant difference in mean change from baseline in the SJC between the
intervention group and usual-care group at 18 months in the van Hulst et al. trial.63 There was a significantly
greater mean change from baseline in the TJC in the intensive management arm [–20 (SD 5)] than in the
routine management arm [–12 (SD 12)] at 18 months in the TICORA trial; however, there was no significant
difference in mean change from baseline in the TJC between the intervention group and usual-care group at
18 months.61
In the TICORA61 trial at 18 months, the proportion of patients who attained a EULAR good response was
significantly greater in the intensive management arm (82%) than in the routine management arm (44%);
however, in the van Hulst et al. trial63 at 18 months, the proportion of patients who attained a EULAR good
response, a moderate response and no response were similar in the intervention group and usual-care group
(statistical significance not reported). In the TICORA trial,61 the proportions of patients who attained an ACR
20, ACR 50 and ACR 70 at 18 months were significantly greater in the intensive management arm (90%,
84% and 71%, respectively) than in the routine management arm (64%, 40% and 18%, respectively); in
the van Hulst et al. trial,63 however, ACR response was not reported. In the TICORA trial,61 at 18 months,
mean change in the HAQ score from baseline was a significantly greater in the intensive management arm
[–0.97 (SD 0.8)] than in the routine management arm [–0.47 (SD 0.9)];61 in the van Hulst et al. trial,63
however, there was no significant difference at 18 months in mean change from baseline in HAQ score
between the intervention group and usual-care group.
In the TICORA61 trial, median increase from baseline in the SHS erosion score and total SHS were significantly
lower in the intensive management arm [SHS erosion score: 0.5, interquartile range (IQR) 0–3.4; total SHS:
4.5, IQR 1–9.9] than in the routine management arm (SHS erosion score: 3, IQR 0.5–8.5; total SHS: 8.5, IQR
2.0–15.5), but no significant difference in SHS JSN score between the arms was found at 18 months. Erosion
was not reported in the van Hulst et al. trial.63 Mean change from baseline in the Short Form questionnaire-36
items (SF-36) Physical Summary score was significantly greater in the intensive management arm [9.3 (SD 12.0)]
than in the routine management arm [4.0 (SD 11.0)]. Furthermore, at 18 months, there was no significant
difference in mean change from baseline in the SF-36 Mental Health Summary score between the TTT and
usual-care arms.61 Quality of life was not reported in the van Hulst et al. trial.63
We identified an abstract also relating to the TICORA trial (i.e. Porter et al.72); however, there is a
discrepancy between the data reported in the abstract and those reported in the Grigor et al.61 paper in
terms of EULAR good response, EULAR remission, ACR 20, ACR 70, CRP and SHS erosion score. We used
the data from the Grigor et al.61 paper in our synthesis.
In summary, among trials with populations including both patients with early RA and those with
established RA, there is no clear evidence either in favour of or against the clinical effectiveness of a TTT
approach in comparison with usual care. TICORA,61 which was the only trial in the systematic review that
was rated as having a low risk of bias, demonstrated evidence in favour of a TTT approach in terms of the
proportion of patients attaining remission. There was also evidence in favour of a TTT approach rather
than usual care in terms of ACR 20/50/70 response in the TICORA61 trial. The evidence, however, was
equivocal for DAS28/DAS44 score, SJC, TJC, EULAR response and HAQ score progression, with the
TICORA61 trial reporting TTT to be more effective than usual care and the van Hulst et al.63 trial reporting
no difference between TTT and usual care. In terms of joint erosion and quality of life, evidence from the
TICORA61 trial was ambiguous, with some subscales showing benefit for TTT over usual care and some
demonstrating no difference.
Impact of target among trials comparing treat to target with usual care in a population
containing both patients with early rheumatoid arthritis and those with etablished rheumatoid
arthritis Both trials examining populations including both patients with early RA and those with established
RA61,63 examined a LDA target (DAS44 of ≤ 2.461 or DAS28 of ≤ 3.263). Thus, the findings described and
summarised above relate only to a LDA target for this comparison and this population group.
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Comparison of different targets
Heterogeneity in the treatment protocols used, and outcomes reported, precluded statistical meta-analysis
and, therefore, the findings of the trials comparing different targets were combined and examined
narratively by outcome.
Trials examining early rheumatoid arthritis populations
Table 26 summarises the TTT outcomes for the comparison of different targets for the early RA population.
Details of treatment adaptations and doses of drugs given are summarised in Appendix 4, Table 54.
Only one of the three trials (i.e. TEAR58) reported the proportion of patients meeting the target (while
Hodkinson et al.51 and the T-4 study57 did not). This was lower for both DAS28 of < 3.2-targeted arms
combined (28%) than for the immediate ETN and immediate triple-therapy arms without a target (41%
and 43%, respectively) at 24 weeks.58 Similar proportions of patients attained LDA and remission in the
Hodkinson et al. trial,51 whereas in the TEAR trial a significantly greater proportion of patients in each of
the immediate ETN (41%) and immediate triple-therapy (43%) arms attained LDA according to DAS28
criteria than both step-up arms combined at 24 weeks (28%); however, the proportions of participants
attaining remission at 102 weeks were not significantly different between the two DAS28 < 3.2 targeted
arms and the two immediate therapy arms without a target.58 In the T-4 study, the proportion of patients
attaining DAS28 remission was highest in the combined DAS28 and MMP-3-targeted group (56%).
The proportion of patients attaining DAS28 remission was significantly higher than in the DAS28 of
< 2.6 target group (38%) or the MMP-3 target group (13%), the proportion in this last group being
significantly lower than in the routine care arm (21%).57
Table 27 summarises the disease activity outcomes for the comparison of different targets for the early
RA population. There were no significant differences in DAS28 or decrease in DAS28 between arms with
different targets in any of the three trials to examine the comparison of different targets in an early
RA population. In the TEAR trial,58 the mean SJC was slightly higher in the two targeted step-up arms
[4.4 (SD 3.1) and 4.4 (SD 2.8) for step-up the ETN and step-up triple-therapy arms, respectively] than in
either immediate treatment arm with no target [2.2 (SD 3.9) and 2.3 (SD 3.3) for the immediate ETN and
immediate triple-therapy arms, respectively] at 102 weeks (although the statistical significance between
groups was not reported). In the Hodkinson et al. trial,51 however, there was no significant difference in
the mean SJC at 12 months between the SDAI- and CDAI-targeted arms. There was little difference in the
mean TJC between the two DAS28-targeted (step-up) arms and the two immediate treatment arms with
no target, at 102 weeks, in the TEAR trial.58 In addition, there was no significant difference in the mean
TJC at 12 months between the SDAI- and CDAI-targeted arms in the Hodkinson et al. trial.51
There was no significant difference in the proportion of patients between the CDAI- and SDAI-targeted
arms with EULAR good response at 12 months in the Hodkinson et al. trial51 (the T-4 study57 and TEAR
trial58 did not report EULAR response). In the TEAR trial,58 the proportion of patients achieving ACR
20/50/70 response at 6 months was significantly higher in the immediate treatment arms with no target
(56.28%, 32.14% and 11.13%, respectively, and 55.88%, 31.33% and 7.97%, respectively, for the
immediate ETN and immediate triple-therapy arms) thanin the two DAS28-targeted (step-up) arms
(40.12%, 19.51% and 2.84%, respectively, and 39.32%, 17.53% and 3.62%, respectively, for the
step-up ETN and step-up triple-therapy arms). There was no significant difference in ACR 20/50/70
response between the two DAS28-targeted (step-up) arms and the immediate treatment arms with no
target at 2 years. ACR response was not reported in the Hodkinson et al.51 trial or the T-4 study.56,57
There were no significant differences in the mean HAQ score or change in HAQ score between arms
with different targets in the Hodkinson et al. trial,51 T-4 study57 or TEAR trial58 at 1 or 2 years.
In the T-4 study,57 mean change from baseline in the SHS JSN score and total SHS were significantly lower
in the combined DAS28 and MMP-3-targeted group [0.3 (SD 2.1) and –0.6 (SD 5.9), respectively] than in
the DAS28-targeted group [1.4 (SD 2.8) and 1.6 (SD 4.3), respectively] at 56 weeks. There was no
significant difference between the DAS28-targeted, MMP-3-targeted and combined DAS28 and MMP-3-
targeted arms in the mean change from baseline in SHS erosion score at 56 weeks. Similarly, in the TEAR
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SDAI arm 42 12 months 12 months 41/42 (98) A SDAI of ≤ 11 (LDA) NR 13(32) (DAS28b) 14 (34) (DAS28b)
CDAI arm 60 12 months 57/60 (95) A CDAI of ≤ 10 (LDA) NR 17 (30) (DAS28b) 19 (33) (DAS28b)
T-4 study56,57 Routine care 62 56 weeks 56 weeks 55/62 (89)
available for
analysis
No target NA NR 13/62 (21)
(DAS28 of < 2.6)c,d
9/62 (15)
(SDAI of ≤ 3.3)e
DAS28-driven
therapy
60 56 weeks 56/60 (93)
available for
analysis
A DAS28 of < 2.6 23/60 (38) NR 23/60 (38)
(DAS28 of < 2.6)f
19/60 (32)
(SDAI of ≤ 3.3)g
MMP-3-driven
therapy





< 121 ng/ml for men
or < 59.7 ng/ml for
women
NR NR 8/60 (13)
(DAS28 of < 2.6)h
8/60 (13)




61 56 weeks 58/61 (95)
available for
analysis
A DAS28 of < 2.6
and a MMP-3
concentration of
< 121 ng/ml for men
or < 59.7 ng/ml for
women
NR NR 34/61 (56)
(DAS28 of < 2.6)
28/61 (46)


















































TEAR58–60 Immediate ETN 244 102 weeks 24 weeks See below No target 100/244 (41) 100/244 (41)




132 24 weeks See below 65/152 (43) 65/152 (43)
(DAS28-ESR of ≤ 3.2)
NR
Step-up ETN 255 24 weeks See below A DAS28-ESR of
< 3.2
105/376 (28) 105/376 (28)i




124 24 weeks See below NR
Immediate ETN 244 102 weeks 168/244 (69)
(159 with DAS28)





132 102 weeks 82/132 (62)
(76 with DAS28)
45/76 (59)d NR 45/76 (59)j
(DAS28-ESR of
≤ 2.6)









124 102 weeks 81/124 (65)
(75 with DAS28)
42/75 (57)d NR 42/75 (57)j
(DAS28-ESR of
≤ 2.6)
NA, not applicable; NR, not reported.
a Randomised.
b No further details reported.
c Treatment arms not reported.
d Assuming proportion of completers with DAS28.
e p < 0.05 vs. DAS28-driven therapy group.
f p < 0.0005 vs. DAS28 and MMP-3-driven therapy group.
g p < 0.05 vs. DAS28 and MMP-3-driven therapy group.
h p < 0.005 vs. MMP-3-driven therapy group.
i p < 0.001 vs. DAS28 and MMP-3-driven therapy group.


































































































































































































score (SD) Joint erosion Quality of life
Hodkinson
et al., 201551












T-4 study56,57 Routine care 62 56 weeks 56 weeks –1.3 (2.7);b
n= 55












60 56 weeks –2.5 (3.1);b
n= 56












60 56 weeks –1.3 (2.4);b
n= 53













61 56 weeks –2.0 (2.2);b
n= 58




























































score (SD) Joint erosion Quality of life
TEAR58–60 Immediate
ETN





132 6 months NR NR NR NR NR ACR 20: 55.88%h,i NR NR NR
ACR 50: 31.33%h,i
ACR 70: 7.97%h,i















132 2 years NR NR NR NR NR ACR 20: 45.97%h NR NR NR
ACR 50: 31.27%h
ACR 70: 10.66%h










































































































































































































score (SD) Joint erosion Quality of life
Immediate
ETN








































































b Change from baseline.
c p< 0.005.
d p< 0.05 (routine care group vs. combined DAS28 and MMP-3-targeted group).
e p< 0.001.
f p< 0.05 (DAS28-targeted group vs. combined DAS28 and MMP-3-targeted group).
g p< 0.005.
h Converted from graphical data.






















trial, there was no significant difference in mean SHS erosion score, SHS JSN score or total SHS between
both DAS28-targeted (step-up) arms and either immediate treatment arm with no target at 102 weeks.58
The DAS44 and quality of life were not reported in any trial examining TTT compared with usual care in an
early RA population.
In summary, there was mainly no difference in the clinical effectiveness of different targets on the
proportion of patients meeting the target,58 attaining LDA51,58 and attaining remission.51 Only the T-4 study57
(early RA) found differences between targets: the DAS28 of < 2.6 target was more effective than the
MMP-3 target, and the combined DAS28 of < 2.6 and MMP-3 target was more effective than both the DAS28
of < 2.6 target and the MMP-3 target, in terms of the proportion of patients in remission. There was no
difference in the clinical effectiveness of different targets on DAS28/DAS44,51,57,58 TJC,51,58 EULAR response51
and HAQ response.51,57,58 Findings in other outcomes were equivocal. In terms of SJC, a LDA target (DAS28 of
< 3.2) was found to be more effective than immediate treatment with no target in the TEAR trial;58 however,
there was no difference between the two LDA-targeted arms (a CDAI of ≤ 10 and a SDAI of ≤ 11) in the
Hodkinson et al. trial.51 In terms of ACR 20/50/70 response, the immediate treatment arm was more effective
than the LDA arm in the TEAR trial58 at 6 months; however, there were no differences between targets in the
TEAR trial58 at 2 years. In terms of joint erosion, the T-4 study57 found the combined target arm to be more
effective than the DAS28 of < 2.6-targeted arm on SHS JSN score and total score; however, there was no
difference between the combined target arm, DAS28 of < 2.6 arm and MMP-3 normalisation arm on the SHS
erosion score,57 and no difference between the DAS28 of < 3.2 arm and the immediate treatment arm with no
target on SHS erosion score, JSN score and total score in the TEAR trial.58
Trials examining established rheumatoid arthritis populations
Table 28 summarises the TTT outcomes for the comparison of different targets for the established RA
population. Details of treatment adaptations and dose of drugs given are summarised in Appendix 4,
Table 55. Only one trial with an established RA population made comparisons between different treatment
targets. The Optimisation of Adalimumab study found no differences between arms with different targets
in terms of the proportions of patients meeting the target, attaining LDA or attaining remission.52,53
Table 29 summarises the TTT outcomes for the comparison of different targets for the established RA
population. The one trial that compared different targets in an established RA population was the
Optimisation of Adalimumab study.52,53 There were no significant differences in mean DAS28 at 6, 12 or
18 months between the DAS28 of < 2.6- and SJC of 0-targeted arms.52,53 The proportion of patients
with a good or moderate EULAR response was significantly different across the three trial arms, with a
slightly higher proportion in the DAS28 of < 2.6-targeted arm (63.0%) than the SJC of 0-targeted arm
(53.5%).52,53 There were no significant differences in mean change from baseline in HAQ score at 6, 12
or 18 months between the DAS28 of < 2.6- and SJC of 0-targeted arms.52,53 DAS44, ACR 20/50/70
responses, joint erosion and quality of life were not reported in the Optimisation of Adalimumab study.52,53
In summary, there was no difference in the clinical effectiveness of different targets on the proportion
of patients meeting the target, attaining LDA and attaining remission.52 In addition, there was mainly
no difference in the clinical effectiveness of different targets on disease activity outcomes.52 Only the
Optimisation of Adalimumab study52 demonstrated the benefit of a DAS28 of < 2.6 target over a SJC of
0 target and this was only for the proportion of patients with a EULAR moderate/good response.
Comparison of different treatment protocols
Heterogeneity in the treatment protocols used and outcomes reported precluded statistical meta-analysis.
Because of the heterogeneity in treatment protocols, the data from trials in the comparison of different
treatment protocols were not narratively combined and examined by outcome as with the previous two
comparisons; instead, results are reported separately by trial.
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Routine care 109 18 months 6 months NA No target NR (17) (DAS28 of < 2.6);
NR (22) (SJC = 0)
NR (28) (DAS28 of < 3.2) NR (17) (DAS28 of < 2.6)
DAS28 target 100 6 months NA A DAS28
of < 2.6
24% NR (33) (DAS28 of < 3.2) NR (24) (DAS28 of < 2.6)
SJC target 99 6 months NA A SJC of 0 24% 30% (DAS28 of < 3.2) NR (16) (DAS28 of < 2.6)
Routine care 109 12 months NA No target NR (21) (DAS28 of < 2.6);
NR (22.9) (SJC= 0)
NR (32) (DAS28 of < 3.2) NR (21) (DAS28 of < 2.6)
DAS28 target 100 12 months NA A DAS28
of < 2.6
28% NR (39) (DAS28 of < 3.2) NR (28) (DAS28 of < 2.6)
SJC target 99 12 months NA A SJC of 0 26% NR (31) (DAS28 of < 3.2) NR (26) (DAS28 of < 2.6)
Routine care 109 18 months 52/109 (48) No target NR (16) (DAS28 of < 2.6);
NR (21.1) (SJC= 0)
NR (23) (DAS28 of < 3.2) NR (16) (DAS28 of < 2.6)
DAS28 target 100 18 months 73/100 (73) A DAS28
of < 2.6
NR (38.0) NR (47) (DAS28 of < 3.2) NR (38) (DAS28 of < 2.6)
SJC target 99 18 months 77/99 (78) A SJC of 0 NR (26.3) NR (27) (DAS28 of < 3.2) NR (22) (DAS28 of < 2.6)

























































Routine care 109 18 months 6 months 3.26b NR –6.4 (0.7)c,d –7.8 (0.9)c,d Good/moderate
response: 56.9%
NR –0.47 (0.06)c,d NR NR
DAS28 target 100 6 months 3.72b NR –7.6 (0.8)c,d –9.0 (1.0)c,d Good/moderate
response: 62.0%
NR –0.44 (0.06)c,d NR NR
SJC target 99 6 months 3.49b NR –6.9 (0.7)c,d –7.6 (0.9)c,d Good/moderate
response: 62.5%
NR –0.45 (0.05)c,d NR NR
Routine care 109 12 months 3.12b NR –6.5 (0.7)c,d –8.4 (0.9)c,d Good/moderate
response: 51.4%
NR –0.57 (0.06)c,d NR NR
DAS28 target 100 12 months 3.38b NR –8.3 (0.8)c,d –9.4 (1.0)c,d Good/moderate
response: 61.0%
NR –0.47 (0.06)c NR NR
SJC target 99 12 months 3.18b NR –7.2 (0.7)c,d –7.8 (0.9)c,d Good/moderate
response: 50.5%
NR –0.39 (0.06)c,d NR NR
Routine care 109 18 months 3.27b NR –6.5 (0.8)c,d –8.0 (1.0)c,d Good/moderate
response: 35.8%e
NR –0.49 (0.07)c,d NR NR
DAS28 target 100 18 months 3.40b NR –8.3 (0.8)c,d –9.3 (1.0)c,d Good/moderate
response: 63.0%e
NR –0.51 (0.07)c,d NR NR
SJC target 99 18 months 3.16b NR –6.4 (0.8)c,d –7.4 (1.0)c,d Good/moderate
response: 53.5%e
NR –0.41 (0.06)c,d NR NR




d Change from baseline.




































































































































































Trials examining early rheumatoid arthritis populations
Appendix 5, Table 75 summarises the TTT outcomes for the comparison of different treatment protocols
for the early RA population. All seven trials reported the proportion of patients meeting the target. In the
BeSt trial, significantly higher proportions of patients met the target in the initial combination therapy with
prednisone (PDN) (71%) and initial combination therapy with IFX (74%) arms than in the sequential
monotherapy arm (53%) at 12 months.30 However, at the 7- and 8-year follow-ups, the numbers meeting
the target were similar across the four arms.28,29 In CareRA trial, the proportion of patients meeting the
target was not significantly different between the COBRA Classic, COBRA Slim and COBRA Avant-Garde
arms among the high-risk patients,42,43 nor between the methotrexate tight step-up (MTX-TSU) and COBRA
Slim arms40,43 at 16 or 52 weeks. In COBRA-light, there was no significant difference in the proportion
meeting the target between the different treatment protocol arms at 13 weeks and 6 or 12 months.44,45
In the FIN-RACo trial, the proportion of participants meeting the target was significantly higher in the
combination treatment arm (37%) than in the single-drug arm (18%) at 246 and 11 years47 (37% and 19%,
respectively), but not at 5 years (29% and 22%, respectively).47 In the Saunders et al.54 trial, the proportions
of patients meeting the target in the step-up therapy and parallel triple-therapy arms at 12 months were
not significantly different. In the TEAR trial, the proportion of patients meeting the target was similar for the
step-up ETN (52.9%) and step-up triple-therapy (56.5%) arms at 12 weeks, but lower for both the step-up
etanercept and step-up triple-therapy arms combined (28%) than the immediate etanercept and immediate
triple-therapy arms (41% and 43%, respectively) at 24 weeks.58 There was no significant difference in
patients attaining the LDA target among arms using different treatment protocols in the high- or low-risk
patient populations in the CareRA trial at 52 weeks.43 In the U-Act-Early trial, a significantly greater
proportion of patients met the target in the TOC plus MTX (86%) and TOC plus PBO–MTX (88%) arms
than the MTX plus PBO–TOC arm (77%) at 104 weeks.62
Five trials reported the proportion of patients with LDA at follow-up in each arm. In the BeSt trial,
significantly higher proportions of patients attained LDA in the initial combination therapy with PDN (71%)
and initial combination therapy with IFX (74%) arms than in the sequential monotherapy arm (53%) at
12 months,30 but at 7- and 8-year follow-up the proportions attaining LDA were similar across the four
arms. In the CareRA trial, the proportion of patients attaining LDA was not significantly different between
the COBRA Classic, COBRA Slim and COBRA Avant-Garde arms among the high-risk patients,42,43 nor
between the MTX-TSU and COBRA Slim arms among the low-risk patients40,43 at 16 and 52 weeks. In the
Saunders et al.54 trial, there was no significant difference between the proportions of patients attaining
LDA in the step-up therapy and parallel triple-therapy arms at 12 months. In the TEAR trial, a significantly
greater proportion of patients in each of the immediate ETN (41%) and immediate triple-therapy (43%)
arms attained LDA according to DAS28 criteria than both step-up arms combined at 24 weeks (28%).58
All seven trials reported the proportion of patients attaining remission at follow-up in each arm. In the BeSt
trial, the proportions of patients attaining remission in the four arms were not significantly different at 7 or
8 years.28,29 Among the high-risk patients in the CareRA trial, the proportions of patients attaining remission
at 4, 8, 16 and 52 weeks were similar among the different treatment protocol arms.42,43 Similarly, among the
low-risk patients in the CareRA trial, the proportion of patients attaining remission at 16 and 52 weeks was
not significantly different between the COBRA Slim and MTX-TSU arms.40,43 We noted some discrepancies
between the data reported in an abstract and the full text for the CareRA trial. In the De Cock et al.38
abstract, the percentage of patients attaining remission is different from that reported in the Verschueren
et al.42 paper for the COBRA Classic and COBRA Avant-Garde arms among the high-risk patients. We have
used data from the full text42 in our synthesis. In the COBRA-light trial, there was no significant difference
between the different treatment protocol arms in the proportion of patients attaining remission at 13 weeks
and at 6 or 12 months.44,45 In the FIN-RACo trial, the proportion of participants attaining remission was
significantly higher in the combination treatment arm than in the single-drug arm at 246 (37% vs. 18%) and
11 years47 (37% vs. 19%), but not at 5 years (29% vs. 22%).47 In the Saunders et al.54 trial, there was no
significant difference between the proportions of patients attaining remission in the step-up therapy and
parallel triple-therapy arms at 12 months. In the TEAR trial, the proportions of participants attaining remission
at 102 weeks were not significantly different between the step-up etanercept, step-up triple-therapy,
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immediate etanercept and immediate triple-therapy arms.59 In the U-Act-Early trial, the proportion of patients
attaining remission at 104 weeks was significantly greater in the TOC plus MTX (86%) arm and TOC plus
PBO–MTX (88%) arm than in the MTX plus PBO–TOC arm (77%).62
The disease activity outcomes for the trials comparing different treatment protocols for the early RA
population are summarised in Appendix 5, Table 73.
In the BeSt trial, the proportion of patients who attained ACR 20 and ACR 70 response was greater in
the initial combination therapy with PDN and initial combination therapy with IFX arms than in the
sequential monotherapy and step-up combination therapy arms at 3, 6 and 12 months; however, the
statistical significance of this comparison was not reported.30 The Dutch version of the Health Assessment
Questionnaire (D-HAQ) mean score was significantly lower in the initial combination with PDN and initial
combination with IFX arms than in the sequential monotherapy and step-up combination therapy arms at
3, 6 and 9 months, and significantly lower in the initial combination with PDN and initial combination
with IFX arms than in the sequential monotherapy arm at 12 months.30 At 5 years, the mean HAQ scores
were significantly lower in the initial combination therapy with IFX arm than in the three other arms, and
also in the initial combination with PDN arm than in the sequential monotherapy and step-up combination
therapy arms.31 Similarly, at 7 years, HAQ scores were significantly lower in the initial combination with
IFX arm than in the sequential monotherapy and step-up combination therapy arms.29 In addition, at 8 years,
the mean HAQ scores were significantly lower in the initial combination therapy with IFX arm than in the
step-up combination therapy arm.28 There were no significant differences between HAQ scores at 10 years.64
The SHS erosion score and total SHS at 12 months were significantly lower in the initial combination with PDN
[0.9 (SD 1.9) and 2.0 (SD 3.6), respectively] and initial combination with IFX arms [0.7 (SD 2.1) and 1.3 (SD 4.0),
respectively] than in the sequential monotherapy [3.5 (SD 8.2) and 7.1 (SD 15.4), respectively] and step-up
combination therapy arms [2.6 (SD 4.7) and 4.3 (SD 6.5), respectively)] .30 However, there were no differences
among the arms in median change in SHS or mean SHS estimates corrected for baseline SHS at 10 years.64 The
mean improvement from baseline in the SF-36 Physical Components score at 3 and 6 months was significantly
greater in the initial combination therapy with PDN (11.2 and 12.5, respectively) and the initial combination
therapy with IFX (9.6 and 12.4, respectively) arms than in the sequential monotherapy (5.8 and 8.0, respectively)
and the step-up combination therapy (3.9 and 8.5, respectively) arms, with no significant differences between
groups in SF-36 Mental Components score at 3 or 6 months and no significant differences between groups in
either SF-36 score at 12 months30 or 2 years.26 DAS28, DAS44, SJC, TJC and EULAR response were not reported
in the BeSt trial.
In the CareRA trial, there was no significant difference in change from baseline in DAS28-CRP between
the COBRA Classic, COBRA Slim and COBRA Avant-Garde arms among the high-risk patients42 and in the
MTX-TSU and COBRA Slim arms among the low-risk patients40 at 16 or 52 weeks.43 There were no
significant differences in the proportion of patients with a EULAR good response and EULAR moderate
response between the COBRA Classic, COBRA Slim and COBRA Avant-Garde arms among the high-risk
patients42 and between the MTX-TSU and COBRA Slim arms among the low-risk population40 at 16 or at
52 weeks.43 We noted some discrepancies between the data reported in an abstract and the full text. In
the De Cock et al.38 abstract, the percentage of patients with a good EULAR response is different from the
percentage reported in the Verschueren et al.42 paper in all high-risk arms. We have used data from the
full texts in our synthesis. Among the high-risk patients, similar proportions of patients in the COBRA
Classic, COBRA Slim and COBRA Avant-Garde arms had a clinically meaningful HAQ response and a HAQ
of 0 at 16 weeks.42 Among the low-risk patients, the proportion of patients who had a HAQ score of 0 at
16 weeks was significantly greater in the MTX-TSU arm (51.2%) than in the COBRA Slim arm (23.4%),
although there were no significant differences between arms in mean HAQ change at 16 or 52 weeks40,43
or in the proportion of patients with clinically meaningful HAQ change at 16 weeks.40 The change in SHS
was not significantly different between arms using different treatment protocols in the high- and low-risk
populations at 52 weeks.43 The DAS44, SJC, TJC, ACR 20/50/70 response and quality of life were not
reported in the CareRA trial.
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In the COBRA-light trial, there was no significant difference in mean DAS28 at 12 months between the
COBRA and COBRA-light arms. There was no significant difference in mean DAS44 scores, change from
baseline in DAS44 or change from baseline in the Disease Activity Score, 44 joints with C-reactive protein
concentration (DAS44-CRP) between the COBRA and COBRA-light arms at 6 or 12 months.44,45 There
was no significant difference in SJC or TJC at 12 months between the COBRA and COBRA-light arms.45
There was no significant difference in the proportion of patients attaining a EULAR good response or
EULAR non-response between the COBRA and COBRA-light arms at 13 weeks or 6 months.44 There was
no significant difference in the proportion of patients with ACR 70 in the COBRA and COBRA-light arms at
12 months.45 There was no significant difference in mean HAQ scores between the COBRA and COBRA-light
arms at 3, 6 or 12 months.44,45 The difference in change in SHS erosion score between the COBRA [0.18
(SD 0.4)] and COBRA-light [0.30 (SD 0.8)] arms at 12 months approached statistical significance (p = 0.05).45
There were no significant differences in mean SHS JSN scores or total SHSs at 12 months between the
COBRA and COBRA-light arms.45 Quality of life was not reported in the COBRA-light trial.
In the FIN-RACo trial,46–49 there was a significant treatment effect over time (baseline to 11-year follow-up)
for DAS28 in the combination treatment arm compared with the single-drug arm, although the difference
between arms at 11 years was not statistically significant.49 There was no significant difference in mean
change from baseline in the SJC between the combination treatment and single-drug treatment arms at
2 years, or in median SJC at 11 years.49 There was no significant difference in mean change from baseline
in the TJC between the combination treatment and single-drug arms at 2 years,46 or in median TJC at
11 years.49 There was no significant difference between the combination treatment and single-drug arms in the
proportion of patients meeting ACR 20 response criteria at 6 months or 2 years;46 however, the proportion of
patients who met ACR 50 response criteria at 2 years was significantly greater in the combination treatment
arm than in the single-drug arm.46 There was no significant difference between the combination treatment and
single-drug arms in the mean HAQ score at 2,46 547 or 1149 years, the mean change from baseline in Stanford
HAQ score at 2 years46 or the proportion of patients with a HAQ score of 0 or a HAQ score of > 1 at 11
years.47 There was a significantly lower median number of eroded joints (2 eroded joints, IQR 0–5 eroded
joints) and a significantly lower median Larsen score (4, IQR 0–4) in the combination treatment arm than in the
single-drug arm (4 eroded joints, IQR 2–7 eroded joints; Larsen score 12, IQR 4–20) at 2 years.46 There was
also a significantly greater mean increase from baseline in Larsen score in the single-drug arm (27, 95% CI
22 to 33) than in the combination treatment arm (17, 95% CI 12 to 26) at 11 years,49 with no significant
difference in the proportion of patients in both treatment arms having no erosive changes in large joints at this
time point. The DAS44, EULAR response and quality of life were not reported in the FIN-RACo trial.
In the Saunders et al.54 trial, there was no significant difference in mean change from baseline in DAS28
between the parallel triple-therapy and step-up therapy arms at 12 months. There was no significant
difference in the proportion of patients with a EULAR good response between the parallel triple-therapy
and step-up therapy arms at 12 months. There was no significant difference in the proportion of patients
meeting the criteria for ACR 20/50/70 response between the parallel triple-therapy and step-up therapy
arms at 12 months. There was no significant difference in mean change from baseline in HAQ score
between the parallel triple-therapy and step-up therapy arms at 12 months. There was no significant
difference in mean change from baseline in SHS erosion score, SHS JSN score or total SHS between the
parallel triple-therapy and step-up therapy arms at 12 months. There was no significant difference in
mean change from baseline in Short Form questionnaire-12 items (SF-12) score between the parallel
triple-therapy and step-up therapy arms at 12 months. The DAS44, SJC and TJC were not reported in the
Saunders et al.54 trial.
In the TEAR trial, there were no significant differences in the DAS28-ESR between the immediate ETN,
immediate triple-therapy, step-up ETN and step-up triple-therapy arms at 102 weeks.58 The mean SJC was
slightly higher in the step-up ETN [4.4 (SD 3.1)] and step-up triple-therapy [4.4 (SD 2.8)] arms than in the
immediate ETN [2.2 (SD 3.9)] and immediate triple-therapy [2.3 (SD 3.3)] arms at 102 weeks, although
the statistical significance between groups was not reported.58 The mean TJC was similar in the immediate
ETN, immediate triple-therapy, step-up ETN and step-up triple-therapy arms at 102 weeks.58 The proportion
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of patients achieving ACR 20/50/70 response at 6 months was significantly higher in the immediate ETN
(56.28%, 32.14% and 11.13%, respectively) and immediate triple-therapy (55.88%, 31.33% and 7.97%,
respectively) arms than in the step-up ETN (40.12%, 19.51% and 2.84, respectively) and step-up triple-
therapy (39.32%, 17.53% and 3.62, respectively) arms.58 There was no significant difference in ACR
20/50/70 response between the four different treatment arms at 2 years (although there was a significant
effect of drug, in favour of ETN over triple-therapy in terms of ACR 70 response at 2 years).58 There was no
significant difference in mean mHAQ scores between the immediate ETN, immediate triple-therapy, step-up
ETN and step-up triple-therapy arms at 102 weeks.58 There was no significant difference in mean SHS
erosion score, SHS JSN score or total SHS between the immediate ETN, immediate triple-therapy, step-up
ETN and step-up triple-therapy arms at 102 weeks.58 The DAS44, EULAR response and quality of life were
not reported in the TEAR trial.58
There were no significant differences in the DAS28 change from baseline across the study arms in the
U-Act-Early trial at 24, 52 or 104 weeks.62 Patients in the MTX plus PBO–TOC arm had a significantly
higher mean SJC [3.0 (SD 4.4)] and TJC [3.7 (SD 4.8)] than in the TOC plus MTX arm [1.0 (SD 2.1) and 2.8
(SD 4.9), respectively] and the TOC plus PBO–MTX arm [1.6 (SD 2.8) and 3.0 (SD 3.9), respectively] at
24 weeks, but there were no significant differences between the arms with different treatment protocols
at 52 or 104 weeks.62 A significantly greater proportion of patients in the TOC plus MTX (89%) and TOC
plus PBO–MTX (87%) arms attained a EULAR good response at 24 weeks than in the MTX plus PBO–TOC
arm (49%). In addition, the proportion of patients who attained a EULAR moderate response at 24 weeks
was significantly greater in the MTX plus PBO–TOC arm (32%) than in the TOC plus MTX (5%) and TOC
plus PBO–MTX (11%) arms.62 The proportion of patients who attained a EULAR good response at 52 weeks
was significantly greater in the TOC plus PBO–MTX arm (88%) than in the TOC plus MTX (75%) arm or
in the MTX plus PBO–TOC (72%) arm; however, at 104 weeks there were no significant differences
between arms receiving different treatment protocols.62 The proportions of patients who attained ACR
20/50/70/90 responses at 24 weeks and an ACR 90 response at 52 weeks was significantly greater in the
TOC plus MTX and TOC plus PBO–MTX arms than in the MTX plus PBO–TOC arm; however, there were no
significant differences across arms in terms of ACR 20/50/70/90 at 104 weeks.62 The three groups were
significantly different on mean HAQ score at 24 weeks, with a lower score in the TOC plus MTX arm [0.50
(SD 0.55)] than in the TOC plus PBO–MTX arm [0.63 (SD 0.66)] or the MTX plus PBO–TOC [0.65 (SD 0.54)]
arm, with no significant differences at 52 or 104 weeks.62 There was a significantly smaller mean increase
in SHS in the TOC plus MTX arm [0.50 (SD 1.50)] than in the MTX plus PBO–TOC arm [0.96 (SD 2.87)] at
52 weeks, and a significantly smaller mean increase in SHS in the TOC plus MTX arm [1.18 (SD 3.92)] and
the TOC plus PBO–MTX arm [1.45 (SD 4.27)] than in the MTX plus PBO–TOC arm [1.53 (SD 2.42)] at
104 weeks.62 The DAS44 and quality of life were not reported in the U-Act-Early trial.62
Other comparisons
Trials examining early rheumatoid arthritis populations
The CAMERA35,36,67 trial employed a conventional strategy group and an intensive strategy group, which
used (different) compound improvement-based targets, different frequencies of assessment and the same
treatment protocol. The CAMERA35,36,67 trial did not report the proportions of patients attaining the target
or attaining LDA at 1- or 2-year follow-up points (Table 30). The proportions of patients attaining remission
at 1 and 2 years were significantly higher in the intensive strategy group (35% and 50%, respectively) than
in the conventional strategy group (14% and 37%, respectively).36
The mean SJC and TJC were slightly lower in the intensive strategy group than in the conventional strategy
group at 6 months, 1 and 2 years, although the statistical significance of these comparisons was not
reported (Table 31).36 The proportion of patients with a good EULAR response was a significantly higher in
the intensive strategy group (48%) than in the conventional strategy group (25%) and the proportion of
patients with no EULAR response was significantly smaller in the intensive strategy group (12%) than in the
conventional strategy group (32%), with no significant difference between groups in the proportion of
patients with a moderate EULAR response at 6 months.67 The proportion of patients who attained an ACR
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TABLE 30 Treat-to-target outcomes: early RA population – other comparisons
























151 2 years 1 year NA Clinical response
(see Table 15)












151 2 years 92/151 (61) Clinical response
(see Table 15)








NR NR 55/148 (37)d (≥ 1 period
of remission)c
NA, not applicable; NR, not reported.
a Randomised.
b p< 0.001.























TABLE 31 Disease activity outcomes: early RA population – other comparisons
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c Converted from graphical data.
d p= 0.001.





































































































































































50 response at 1 year was significantly greater in the intensive strategy group (58%) than in the conventional
strategy group (43%), although there was no significant difference in the proportion of patients with an
ACR 50 response at 2 years between the intensive strategy group and the conventional strategy group.36
There were similar mean changes from baseline in HAQ score in the intensive strategy group and the
conventional strategy group at 1 and 2 years.36 The Disease Activity Score (DAS), joint erosion and quality of
life were not reported.
Trials examining established rheumatoid arthritis populations
The BROSG9 trial had two arms: intensive management, which used a DAS44 of ≤ 2.4 target and employed a
seven-step treatment protocol based on the target, and in which patients were seen in a hospital setting; and
a routine management arm, which had no target and patients were seen in the community as well as in the
clinic, with treatment escalation based on clinical opinion. The BROSG trial did not report the proportions of
patients attaining the target or attaining LDA or remission (Table 32). By the end of the trial (3 years’ follow-up),
77.1% of patients in the aggressive therapy arm had some change in disease suppressive treatment, compared
with 55.9% in the symptomatic treatment arm (significance not reported).9
The mean SJC, TJC and HAQ scores were similar in the symptomatic treatment arm and aggressive therapy
arm at 3 years in the BROSG trial (Table 33).9 No other disease activity outcomes were reported.
Adverse events
Comparison of treat to target with usual care
Trials examining early rheumatoid arthritis populations Two studies compared TTT with usual care in
the early RA population (Table 34). In the STREAM trial,55 there were significantly more AEs at 2 years in
the aggressive group (62) than in the conventional care group (35). However, there was no significant
difference between the TTT and usual-care arms in the proportion of patients who experienced any AE at
2 years.55 The proportion of patients with any AE was similar in the routine care and targeted arms of the
T-4 study at 56 weeks.57 The proportion of patients with SAEs was not significantly different between the
usual-care and TTT arms in the T-4 study, and was similar in terms of number of deaths and withdrawals
as a result of AEs at 56 weeks.57
Appendix 5, Table 74 summarises the specific AEs reported in trials of TTT compared with usual care in the
early RA population. There was no difference in the proportion of patients with serious infection between
any of the TTT arms and usual care in the T-4 study at 56 weeks.57 No other specific AEs were reported in
the T-4 study57 or STREAM trial.55
In summary, among trials examining an early RA population, there was no difference in the proportion
of patients experiencing any AE,55,57 SAE,57 death,57 withdrawals as a result of AEs57 or specific AEs;57
however, more events (any AE) were experienced in the TTT arm than in the usual-care arm in the
STREAM trial.55
Impact of target among trials comparing treat to target with usual care in an early
rheumatoid arthritis population
Among trials with early RA populations that used a remission target (a DAS44 of < 1.655 and a DAS28 of
< 2.657), there was mixed evidence in terms of the proportion of patients with any AE, with no difference in
the proportion of patients with a SAE,57 deaths,57 withdrawals as a result of AEs57 and specific AEs (serious
infection57). The STREAM55 trial found fewer AEs in the usual-care arm at 2 years, but no difference between
arms in the proportions of patients with any AE at 2 years. The T-4 study57 also found no difference between
the remission-targeted arm and usual care at 56 weeks in the proportions of patients with any AE.
One trial, the T-4 study,57 examining a MMP-3 normalisation target in an early RA population, found no
difference between the MMP-3 normalisation-targeted arm and usual care at 56 weeks in the proportions
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TABLE 34 Adverse events: comparison of TTT vs. usual care
Trial acronym or first







Any AEa Any SAEa,b Death
Withdrawal as a result
of AEsa
Early RA population
STREAM55 Aggressive group NR 2 years 59% patients had
62 AEsc
Five SAEs, including one
patient hospitalised once
and one hospitalised twice
for drug-related SAEs
None reported 0
Conventional care NR 2 years 42% patients had
35 AEsc
Three SAEs, including one
patient hospitalised once
for a drug-related SAE
None reported 0
T-4 study56,57 Routine care 61 56 weeks 41/NR (67) Malignancy, n = 1 (1.6);
serious infection, n= 0 (0)
0 (0) 6
DAS28-driven therapy 59 56 weeks 49/NR (81) Death, n= 0 (0);
malignancy, n= 0 (0);
serious infection, n= 0 (0)
0 (0) 3
MMP-3-driven therapy 59 56 weeks 46/NR (78) Malignancy, n = 0 (0);




61 56 weeks 42/NR (69) Malignancy, n = 1 (1.6);
serious infection, n= 0 (0)
0 (0) 2
Established RA population
Fransen et al., 200550 DAS28 205 24 weeks NR NR NR NR
Usual care 179 24 weeks NR NR NR NR
Optimisation of
Adalimumab study52,53
Routine care 100 18 months NR NR NR 10 (10)
DAS28 target 109 18 months NR NR NR 12 (9.08)d





































































































































































TABLE 34 Adverse events: comparison of TTT vs. usual care (continued )
Trial acronym or first







Any AEa Any SAEa,b Death
Withdrawal as a result
of AEsa
Combined early and established population
TICORA61 Intensive management 55 18 months 32/55 (58) patients
had 46 AEs
NR 1/55 (2) 20/129 (16), new DMARD
courses were stopped
because of toxic effects
Routine management 55 18 months 42/55 (76) patients
had 85 AEs
NR 3/55 (5) 38/89 (43), new DMARD
courses were stopped
because of toxic effects
van Hulst et al., 201063 Intervention group AEs NR NR NR NR NR NR
Usual-care group AEs NR NR NR NR NR NR
NR, not reported.
a Refers to numbers of patients, unless otherwise specified.
b Defined in the trial as a SAE.
c p= 0.034.






















of patients with any AE, the proportion of patients with a SAE, death, withdrawals as a result of AEs and
specific AEs (serious infection).
Similarly, the T-4 study,57 examining a combined remission and MMP-3 normalisation target in an early
RA population, found no difference between the MMP-3 normalisation-targeted arm and usual care at
56 weeks in the proportions of patients with any AE, the proportion of patients with a SAE, deaths,
withdrawals as a result of AEs and specific AEs (serious infection).
In summary, comparing trials by target on AEs, there is no clear evidence in favour of any target being
more or less safe than usual care in an early RA population.
Trials examining established rheumatoid arthritis populations Table 34 summarises the AEs among
trials of patients with established RA comparing TTT with usual care. The proportions of patients with any
AE or a SAE or who died were not reported in either the Fransen et al.50 trial or the Optimisation of
Adalimumab study.52 In the Optimisation of Adalimumab study, the proportion of patients who withdrew
because of AEs was lower in the SJC-targeted arm(4%) than in the routine care arm (10%), although
statistical significance was not reported.52
Appendix 6, Table 75 summarises the specific AEs reported in trials of TTT compared with usual care in an
early RA population. The Fransen et al.50 trial reported that the proportion of patients with dermatological
AEs (rash or itching) was significantly greater in the usual-care arm (11%) than in the TTT arm (4%). In
addition, the proportion of patients who at 24 weeks were reported to have experienced a gastrointestinal
AE was significantly greater in the usual-care arm (9%) than in the TTT arm (4%). Specific AEs were not
reported in the Optimisation of Adalimumab study.52,53
In summary, the findings of trials examining established RA populations suggest that TTT may be more
beneficial to patients than usual care in terms of AE outcomes. A smaller proportion of patients withdrew
because of AEs52 and experienced specific AEs (dermatological and gastrointestinal AEs50) in the TTT arm
than in the usual-care arm.
Impact of target among trials comparing treat to target with usual care in an established
rheumatoid arthritis population
One trial, Fransen et al.,50 examining a LDA target (DAS28 of ≤ 3.2) in an established RA population, found
evidence in favour of TTT in terms of specific AEs at 24 weeks (dermatological and gastrointestinal AEs).
One trial, the Optimisation of Adalimumab study,52 examining a remission target in an established RA
population, found no difference in the number and proportion of patients who withdrew from the trial
because of AEs between the remission-targeted arm (DAS of < 2.6) and the usual-care arm, although the
statistical significance of this comparison was not reported.
The one trial, the Optimisation of Adalimumab study,52 examining a SJC of 0 target in an established RA
population found evidence in favour of TTT in terms of withdrawals as a result of AEs, although the
statistical significance of this comparison was not reported.
In summary, there is evidence in favour of the safety of TTT, using a LDA target, compared with usual care
in an established RA population,50 but of a difference between targeted arms and usual care with regard
to remission (DAS28 of < 2.6) and SJC (SJC of 0) targets,52 although only one trial used each of these
targets and this related to only one outcome reported in the case of the LDA target.50 The remission target
and SJC target impacted on the same outcomes in the same way, although findings were from the same
(single) trial (i.e. the Optimisation of Adalimumab study52).
Trials examining both early and established rheumatoid arthritis populations Table 34 summarises
the AEs among trials with a population of patients with early and established RA comparing TTT with
usual care. In the TICORA trial,61 the proportion of patients who experienced any AE was greater in the
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usual-care arm (76% experienced 85 AEs) than in the TTT arm (58% experienced 46 AEs; statistical
significance not reported), and at 18 months the proportion in each arm who had died was similar to that
in the TTT arm. AEs were not reported for the van Hulst et al. trial.63
Appendix 6, Table 76 summarises the specific AEs reported in trials of TTT compared with usual care in the
early RA population. The TICORA61 trial reported only numbers of AEs and not the numbers and/or
proportions of patients with AEs. There were slightly more dermatological, gastrointestinal and infectious
AEs in the usual-care arm than in the TTT arm, although the statistical significance of this comparison was
not reported. Specific AEs were not reported in the van Hulst et al. trial.63
In summary, the one trial61 reporting on AE outcomes in a population including both patients with early RA
and those with established RA reported mixed findings in terms of AE outcomes. The TICORA trial,61 which
was the only trial rated as being at a low risk of bias, reported that a smaller proportion of patients reported
any AE and specific AEs (dermatological, gastrointestinal and infectious AEs, significance not reported) in
the TTT arm than in the usual-care arm; however, there was no difference in the number of deaths between
the TTT and usual-care arms.61
Impact of target among trials comparing treat to target with usual care in a population
containing both early and established rheumatoid arthritis patients
The one trial61 reporting on AE outcomes in a population including both patients with early RA and those
with established RA examined a LDA target (DAS44 of ≤ 2.4). Thus, the findings described and summarised
above relate only to a LDA target for this comparison and this population group.
Comparison of different targets
Trials examining early rheumatoid arthritis populations The Hodkinson et al.51 trial did not report
AEs. In the two trials comparing different targets in an early RA population, the T-4 study57 and TEAR58
(Table 35), the proportions of patients with AEs or SAEs and of deaths and withdrawals due to AEs were
similar across arms of different targets, including a DAS28 of < 2.6; a MMP-3 concentration of < 121 ng/ml
for men and < 59.7 ng/ml for women; a DAS28 of < 2.6 and a MMP-3 concentration of < 121 ng/ml for
men or < 59.7 ng/ml for women; no target; and a DAS28-ESR of < 3.2.
Appendix 5, Table 72 summarises the specific AEs reported in trials comparing different targets in the early
RA population. The T-4 study57 reported no difference in the proportion of patients with serious infection
between the DAS28-, MMP-3- and combined DAS28 and MMP-3-targeted arms at 56 weeks. No
significant differences in the number of specific AEs were reported in the TEAR trial at 102 weeks.58
In summary, among trials comparing different targets in an early RA population, different targets made no
difference to the proportions of patients with any AE,57,58 SAEs,57,58 deaths,57,58 withdrawals as a result of
AEs57,58 and specific AEs.57,58
Trials examining established rheumatoid arthritis populations Table 35 summarises the AEs among
trials of patients with established RA comparing different targets. In the Optimisation of Adalimumab study,52
the proportion of patients who withdrew because of an AE was greater in the DAS28 of < 2.6-targeted arm
(9%) than in the SJC-targeted arm (4%), although statistical significance was not reported. The proportions
of patients with any AE, a SAE or who died were not reported. No specific AEs were reported.
Comparison of different treatment protocols
Trials examining early rheumatoid arthritis populations Tables 73 and 74 in Appendix 5 examine
AEs among trials of patients with early RA comparing different treatment protocols.
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TABLE 35 Adverse events: comparison of different targets
Trial acronym or first






AE in source, n/N (%)
Any AEa Any SAEa,b Death
Withdrawal as a result
of AEsa
Early RA population
Hodkinson et al., 201551 SDAI arm AEs NR NR NR NR NR NR
CDAI arm AEs NR NR NR NR NR NR
T-4 study56,57 Routine care 61 56 weeks 41 (67.2) Death, n= 0 (0); malignancy,
n= 1 (1.6); serious infection, n= 0 (0)
0 (0) 6
DAS28-driven therapy 59 56 weeks 49 (81.4) Death, n= 0 (0); malignancy,
n= 0 (0); serious infection, n= 0 (0)
0 (0) 3
MMP-3-driven therapy 59 56 weeks 46 (78.0) Death, n= 2 (3.4); malignancy,




61 56 weeks 42 (68.9) Death, n= 0 (0); malignancy,
n= 1 (1.6); serious infection, n= 0 (0)
0 (0) 2
TEAR58–60 Immediate ETN 244 102 weeks 193 (79.1) 35 (14.3) 1 12 (4.9): SAE, n= 8; AE,
n= 3; death, n= 1
Immediate triple therapy 132 102 weeks 101 (76.5) 18 (13.6) 1 7 (5.3): SAE, n= 2; AE,
n= 4; death, n= 1
Step-up ETN 255 102 weeks 187 (73.3) 32 (12.5) 2 9 (3.5): SAE, n= 2; AE,
n= 5; death, n= 2
Step-up triple therapy 124 102 weeks 92 (74.2) 16 (12.9) 0 4 (3.2): SAE, n= 2; AE,




Routine care 100 18 months NR NR NR 10 (10)
DAS28 target 109 18 months NR NR NR 12 (9.08)c
SJC target 99 18 months NR NR NR 4 (4)
NR, not reported.
a Refers to numbers of patients unless otherwise specified.
b Defined in the trial as a SAE.




































































































































































In the BeSt trial, the proportions of patients across the four arms (varying in treatment protocol) who had
experienced any AE or a SAE were similar at 1 year30 and 5 years.31 Similar proportions of patients died in
each arm at 531 and 10 years,33 although this proportion was slightly greater in the two initial combination
therapy arms (15.8% and 15.6%), than in the sequential monotherapy and step-up combination therapy
arms (12.7% and 12.4%, respectively; statistical significance not reported). Withdrawals as a result of AEs
were not reported. Similar proportions of patients had specific AEs in each treatment arm of the BeSt trial
at 1 year (see Appendix 5, Table 74; significance not reported).30 The proportion of patients with specific
AEs were not significantly different across treatment arms at 5 years.31
Among the high-risk patients in the CareRA trial, the proportions of patients with any AE at 16 weeks
were significantly higher in the COBRA Classic (61.2%) and COBRA Avant-Garde (69.9%) arms than in the
COBRA Slim (46.9%) arm.42 Similar numbers of SAEs were reported in the three trial arms and similar
proportions of deaths and withdrawals as a result of AEs across all arms were reported at 16 weeks.42
Among the low-risk patients, there were no significant differences in the proportion of patients with any
AE across arms at 16 weeks, with no SAEs in either arm.40
The proportion of patients with any AE was not significantly different between arms using different
treatment protocols in the high- and low-risk populations of the CareRA trial at 52 weeks; however,
the mean number of AEs per patient differed significantly across groups in the high-risk population of the
CareRA trial, with a higher mean number of AEs per patient in the COBRA Classic [1.9 (SD 2.0)] and
COBRA Avant-Garde [1.9 (SD 1.6)] arms than in the COBRA Slim arm [1.3 [SD 1.4)] at 52 weeks.43 The
number of therapy-related SAEs was similar across arms in the high- and low-risk populations of the
CareRA trial at 52 weeks.43 There were no deaths in either arm of the low-risk population and similar
proportions of patients died in the high-risk population. There were no withdrawals as a result of AEs in
the high- or low-risk population of the CareRA trial.43
Specific AEs were reported only in terms of numbers of events in the CareRA trial for the high-risk patients
at week 16 and for the high- and low-risk patients at week 52 (rather than the proportion of patients
experiencing each AE), and the statistical significance of comparisons across groups was not reported at
16 weeks. There were more dermatological AEs in the COBRA Classic and COBRA Avant-Garde arms than
in the COBRA Slim arm at 16 weeks among the high-risk patients.42 Among the low-risk patients, there
were similar proportions of patients with gastrointestinal and infectious AEs at 16 weeks.40 The numbers of
dermatological, ophthalmological and infectious AEs were similar across trial arms in the high- and low-risk
populations; however, there were more gastrointestinal AEs in the COBRA Avant-Garde arm (67) than in
the COBRA Classic (45) and COBRA Slim (48) arms among the high-risk population at 52 weeks.43 No
other specific AEs were reported.
In the COBRA-light trial, similar proportions of patients had any AE (≥ 1) across the COBRA and COBRA-light
arms at 6 months.44 Twice as many patients in the COBRA-light arm as in the COBRA arm experienced a
SAE (6 vs. 3) at 6 months44 and 12 months (9 vs. 16),45 although the statistical significance was not reported.
Numbers of withdrawals as a result of AEs across arms were similar at 6 months.44 In terms of specific AEs,
in the COBRA-light trial, the proportion of patients who had dermatological AEs at 6 months was slightly
greater in the COBRA-light arm (43%) than in the COBRA arm (37%), although statistical significance was
not reported.44 All other specific AEs were similar across trial arms.
In the FIN-RACo46 trial, the proportion of patients who had any AE or SAEs were similar in the combination
treatment and single-drug arms at 2 years, with no deaths or withdrawals as a result of AEs in either arm
at 2 years. There were no significant differences in the proportions of patients with specific AEs in the
combination treatment and single-drug arms at 2 years.
In the Saunders et al.54 trial, AEs were reported only in terms of number of AEs rather than as number and/or
proportion of patients with AEs. Similar numbers of AEs were reported in the parallel triple-therapy and
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step-up therapy arms at 12 months, with similar numbers of drug withdrawals and no withdrawals from the
trial in either arm. Numbers of specific AEs were similar in the parallel triple-therapy and step-up therapy arms.
In the TEAR trial,58 AEs were reported only in terms of numbers of AEs rather than as number and/or
proportion of patients with AEs. Similar proportions of patients experienced any AE, a SAE, death or
withdrawal as a result of AEs or specific AEs in the four trial arms (immediate ETN, immediate triple
therapy, step-up ETN and step-up triple therapy) at 102 weeks.
The proportion of patients with any AE was not significantly different between arms using different treatment
protocols in the U-Act-Early trial at 104 weeks.62 The proportion of patients with a SAE was not significantly
different between arms at 104 weeks, and there were no deaths in either arm.62 There was no significant
difference in withdrawals as a result of AEs across groups in the U-Act-Early trial.62 The proportion of patients
with specific AEs was similar across arms at 104 weeks.62
Other comparisons
Trials examining early rheumatoid arthritis populations There were similar proportions of patients with any
AE in the intensive strategy group and conventional strategy group in the CAMERA trial (Table 36).36 More
SAEs (graded as severe by the rheumatologist) were reported in the intensive strategy arm (n = 35) than in
the conventional strategy arm (n = 10), although the statistical significance of this comparison was not
reported.35 Likewise, there was a greater proportion of withdrawals as a result of AEs in the intensive
strategy arm (18%) than in the conventional strategy arm (7%), although the statistical significance was
not reported.36 In terms of specific AEs (see Appendix 6, Table 75), a significantly greater proportion of
patients in the intensive strategy group experienced dermatological AEs (53.7%), gastrointestinal AEs
(66.4%), central nervous system AEs (59.1%), hepatic AEs (55.0%) and haematological AEs (25.5%) than
in the conventional strategy group (40.0%, 53.6%, 38.6%, 35.0% and 10.7%, respectively) at 2 years.35
Trials examining established rheumatoid arthritis populations AEs were not reported for the
BROSG trial.9
Discussion
This section focuses on the main outcomes of the proportion of patients meeting the target, attaining LDA
and attaining remission. Overall, across populations, there is no clear evidence either in favour of or against
the clinical effectiveness of a TTT approach, in comparison with usual care, in terms of the proportion of
patients meeting the target, attaining LDA or attaining remission. However, there does seem to be some
limited support for TTT among the early RA population, in terms of remission, among the established RA
























a Refers to numbers of patients unless otherwise specified.
b Defined in the trial as a SAE.
c Graded as severe according to the rheumatologist.
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population, in terms of LDA, and among trials that included populations of patients with both early and
established RA, in terms of remission. Similarly, there is no clear evidence either in favour of or against the
clinical effectiveness of a TTT approach, in comparison with usual care, in terms of the DAS28/DAS44
response, SJC, TJC, EULAR response, HAQ score, erosion and quality of life across populations, when overall
findings are considered;50,52,55,57,61,63 however, there does seem to be some limited support for TTT on some
clinical outcomes. Similarly, comparing trials by target, there is no clear evidence in favour of any target being
more or less effective than usual care across population groups, as measured by the proportion of patients
meeting the target, attaining LDA and attaining remission. There is also no clear evidence in favour of one
particular target over all others in relation to DAS28/DAS44 response, SJC, TJC, EULAR response, HAQ score,
erosion and quality of life across populations, when overall findings are considered. Specifically, we found no
difference in the clinical effectiveness of different targets on DAS28/DAS44,51,57,58 TJC51,58 and HAQ score
response51,58 among the trials reviewed and equivocal evidence for SJC,51,58 EULAR response,51,52 ACR 20/50/70
response58 and joint erosion.57,58 All trials comparing different targets were rated as being at high risk of bias.
Adverse events appear to have been experienced differently by different population groups in the
comparison of TTT with usual care. Among trials examining an early RA population, evidence was mixed,
favouring the usual-care arm. Among trials examining established RA populations, the evidence favoured
the TTT arm and was mixed in the only trial reporting on these outcomes in a population containing both
early and established RA patients (i.e. the TICORA trial61), slightly favouring TTT.
Overall, when the evidence comparing trials by target on AEs is considered across all population groups,
there is no clear evidence in favour of any target being more or less safe than usual care, or more or less
safe than any other target. Caution is warranted, however, in interpreting these findings, given the small
number of studies reporting AE data in each population group. In addition, the same AEs were not
considered in all studies and AEs were recorded/reported seemingly erratically in the original papers, with
little systematic consideration of AEs. Future trials should systematically record and report on an agreed
range of AEs, to build the evidence base of AEs within TTT. This is an important issue to address, given
that the intensity of TTT as a treatment plan is typically greater than that usual care.
The quality of the included studies will have inevitably had an impact on the findings of our review. The risk
of bias, as assessed with the Cochrane risk-of-bias instrument,24 was rated as being high in six RCTs and
three cluster RCTs, and unclear in five RCTs; this was generally because of the judgements for allocation
concealment, blinded outcome assessment and attrition domains. Only one RCT (i.e. the TICORA trial61) was
rated as being at low risk of bias.
In trials rated as being at high or unclear risk of bias, findings were generally equivocal or demonstrated no
difference between arms. The one trial rated as being at low risk of bias,61 which compared TTT against usual
care in a population that included both patients with early RA and those with established RA, by the criterion
of this review (patients with a disease duration of < 5 years) demonstrated evidence that was generally in
favour of a TTT approach, with favourable results in terms of the proportion of patients attaining remission,
DAS44 response, change in SJC and TJC, EULAR good response, ACR 20/50/70 response, HAQ score
progression, change in joint erosions (as measured by the SHS erosion score and total SHS) and SF-36
Physical Summary score (and no difference between TTT and usual care in terms of SHS JSN score and SF-36
Mental Health Summary score).61
There are, however, some elements of the design of the TICORA trial61 that require consideration in
interpreting findings. The TTT arm had more intensive assessments, more frequent visits and a higher dose
of steroids than the usual-care arm; therefore, it is unclear whether the effects on outcomes were because
of TTT or the increased assessment or escalation of therapy. The issue of unbalanced steroid use also applies
to the FIN-RACo trial,46–49 in which more patients in the intensive treatment arm received prednisolone; as a
result, it is difficult to untangle the effects of TTT from the effects of the steroid. Future trials are needed
in which TTT is the only variable that differs between arms and in which all other aspects of care are held
constant, as far as is practicable. In addition, the STREAM trial,55 which appears frequently in the current
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review because of the large number of outcomes it contributed, had a small sample size and uneven
distribution of some baseline variables, such as rheumatoid factor (which was also relatively low at baseline).
The current systematic review is the most comprehensive review to date to examine the clinical effectiveness
of TTT. We have synthesised findings on TTT compared with usual care and a comparison of different targets.
Synthesis of different treatment protocols was precluded (even in terms of a narrative integration of findings)
by heterogeneity and lack of comparability between treatment protocols, although we have provided a
comprehensive summary of the findings of trials that compare different treatment protocols. The current
review is also the only systematic review to examine findings by population, which is important in this context
as the recommendations for TTT differ slightly for early and established RA patients, as the treatment
prognosis and implications of TTT may be different in these populations.17,18 Another strength of the current
review is the focus on RCTs, which reduces the impact of selection bias on the review findings.
The main limitation of the current review is the small number of trials within each comparison, in each
population group. Trials showed much heterogeneity in targets, treatment protocols, frequency of contact,
outcomes and follow-up time points, even within the same population group, in each comparison. Risk of
bias was rated to be high in the majority of included trials. Another consideration is that many trials used
a DAS28 of < 2.6 to assess clinical remission as an outcome; however, doubts have been raised as to
whether or not this is true remission, as it is now known that active disease and radiological progression
can be present in patients with a DAS28 of < 2.6.73–78
The systematic reviews by Schoels et al.23 (initial review) and Stoffer et al.79 (update of the Schoels et al.
review), designed to inform the international task force recommendations for treating to target,17,18 both
concluded that TTT was more effective than usual care. Similarly, Jurgens et al.21 examined the effectiveness
of TTT on remission rates and found results in favour of TTT, Schipper et al.80 compared the effectiveness of
TTT with usual care on mean change in DAS28 and found TTT to be more effective than usual care and
Bakker et al.81 found evidence of the effectiveness of TTT in terms of remission, but did not synthesise the
evidence (findings were reported individually by study). The Knevel et al.82 review, which also analysed RCTs
and non-randomised studies, found no evidence to recommend one particular target over others, similar to
the findings of the current review. The Knevel et al.82 review also reported no particular benefit of TTT
among patients with established RA, but an overall benefit of TTT among early RA patients. It is unclear
whether or not the reviews by Schoels et al.,23 Stoffer et al.79 and Knevel et al.82 reported on all outcomes
reported in all included studies; the current review provides an explicit and comprehensive overview of all
measured outcomes. All five previous reviews examined data from RCTs and non-randomised studies
together, whereas the current review focused on RCTs only, to reduce the possibility of selection bias.
Although the search strategy for this assessment report was comprehensive, the possibility of a publication
bias cannot be discounted. It was not possible to undertake a formal assessment of publication bias, as
there were too few trials per comparison to assess funnel plot asymmetry.
From the evidence reviewed here, we consider that the evidence for TTT is mixed but, in early RA, there does
seem to be some limited support for TTT, particularly in terms of the numbers of patients achieving remission.
This is particularly true if the TICORA trial,61 which was the only trial in the review rated as being at low risk
of bias, is interpreted as providing evidence relevant to the early RA population (inclusion criterion for the
TICORA trial was disease duration of < 5 years). We also found no clear evidence to support the clinical
effectiveness of one particular target over others. There is also no clear evidence of a greater likelihood of
AEs in a TTT approach compared with usual care (or of the use of one target in particular), suggesting that
such an approach is no more harmful (and may, indeed, be less harmful, as some of the evidence suggests).
Caution is warranted in interpreting this conclusion, however, as there were only small numbers of trials
within each comparison, in each population group, and there was much heterogeneity in terms of targets,
treatment protocols, frequency of contact, outcome and follow-up time points. In addition, only one trial
(i.e. the TICORA trial61) was rated as being at low risk of bias; the rest were rated as being unclear or high
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risk of bias, mainly because of the lack of blinding in outcome assessment and attrition bias (and, in addition,
elements of design make the attribution of the TICORA trial’s61 findings to TTT less clear).
According to the current review findings, there is a weak basis for recommending TTT in the routine care
of RA and TTT does not appear to confer any significant harms, although AEs were not examined in a
consistent way across trials. Despite this uncertainty, it is not immediately clear that additional research on
TTT should be conducted because there are many different aspects to the TTT concept. If such research is
to be conducted, there should be a focus on well-conducted trials comparing TTT with usual care and/or
different TTT targets, which are adequately blinded (in terms of participants, study personnel and outcome
assessment), with low rates of attrition and adequate allocation concealment, designed to control for all
other variables than TTT/different targets, reporting on the proportion of patients meeting the target and
being in remission.
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Chapter 4 Assessment of cost-effectiveness
Systematic review of existing cost-effectiveness evidence
The objective of this review was to identify and evaluate studies exploring the cost-effectiveness of TTT
strategies in the treatment of RA.
Identification of studies
Electronic databases
Studies were identified by searching the following electronic databases on the 14 January 2016:
l MEDLINE(R) In-Process & Other Non-Indexed Citations and MEDLINE(R) (via Ovid) 1948 to present
l EMBASE (via OvidSP) 1980 to present
l Web of Science Science Citation Index Expanded (via Thomson Reuters) from 1900 to present
l Web of Science Conference Proceedings Index (via Thomson Reuters) from 1990 to present
l Cumulative Index to Nursing and Allied Health Literature (CINAHL) (via EBSCOhost) 1982 to present
l NHS Economic Evaluation Database (via The Cochrane Library) 1995 to 2015
l American Economic Association’s electronic bibliography (via Ovid) from 1886 to present.
Sensitive keyword strategies using free text and, where available, subject headings or thesaurus terms for
RA and TTT were combined in the electronic database searches. Searches in MEDLINE, EMBASE, Web
of Science and CINAHL were limited by study design by combining the results with economic- and
cost-related search terms (see Appendix 2 for full search strategies). Date limits or language restrictions
were not used on any of the database searches.
Inclusion and exclusion criteria
Studies were selected according to predetermined inclusion and exclusion criteria. Studies were included if
they reported the cost-effectiveness of TTT strategies in RA estimating the health-related benefits in terms
of quality-adjusted life-years (QALYs) gained; life-years gained; DAS; SHS; percentage of patients achieving
remission; percentage of patients achieving LDA; percentage of patients achieving treatment response;
change in patient utility (VAS or SF-36 scores); or any other clinical measure of disease progression/activity
or health-related quality of life. Studies that did not report costs but in which the treatment protocols were
described in sufficient detail to allow the incremental cost between treatment arms to be assumed or
approximated were also included. Papers not published in the English language were excluded.
One reviewer (AR) independently screened all titles and abstracts. When there was uncertainty in the
decision, a second reviewer (MDS) was used and a consensus through discussion was obtained. Full papers
were obtained for any titles/abstracts that were considered relevant or where the title/abstract information
was not sufficient to make a decision.
Quality assessment strategy
The quality of the economic evaluation studies that met the inclusion criteria was assessed using the
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist.83,84 The use of this
checklist ensures a consistent approach to assessing the quality of each economic evaluation. This can be
found in Appendix 5.
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Results of the cost-effectiveness review
The systematic searches identified 1231 potentially relevant citations. Of the titles and abstracts screened,
two relevant full-text papers were retrieved and assessed in detail. A PRISMA flow diagram describing the
process of identifying relevant literature can be found in Appendix 4.
Two eligible studies were found to be relevant: Vermeer et al.85 and van den Hout et al.86 Vermeer et al.85
conducted an economic evaluation of TTT compared with usual care in patients in the Dutch Rheumatoid
Arthritis Monitoring (DREAM) registry: the DREAM remission induction cohort (TTT) and the Nijmegen
early-RA-inception cohort. Adult patients with an ACR classification criterion for RA, with symptom duration
of < 1 year and who had had no previous DMARDs were included.
The TTT strategy included regular assessment of patients (weeks 0, 8, 12, 20, 24, 36 and 52, and every
3 months thereafter) against the target of remission (DAS28< 2.6). A treatment protocol of DMARD
monotherapy, followed by a step-up to combination DMARD therapy, followed by anti-tumour necrosis
factor (TNF), was adopted. The usual-care group did not have the DAS28 released to the treating
rheumatologist. Treatment was not provided in accordance with a protocol, but left to the discretion
of the rheumatologist. In general, patients were treated with step-up or sequential monotherapy with
cDMARDs and/or a biologic, notably anti-TNF.
The costs used were those applicable in 2011 in the Netherlands. Results were expressed in terms of cost
per remission and cost per QALY using 2-year follow-up data and an extended analysis using 3-year
follow-up for a smaller proportion of patients with available data.
The authors found that TTT was associated with an incremental cost of €3591 per remission at 2 years and
after 3 years was dominant (cost saving and more patients in remission). Similarly, at 2 years the cost per QALY
for TTT compared with usual care was €19,410 and it was dominant at 3 years (more QALYs, cost saving).
This suggests that TTT has higher costs in the short term (as the strategy requires more intensive drug therapy
and more frequent assessment of patients), but it is more effective and, in the longer term, this greater
effectiveness offsets some of the initial extra costs and may more than offset them. For example, patients in
remission are less likely to progress to costly biologic therapies or require hospitalisation. However, it may be
the case that TTT simply delays rather than avoids these cost-incurring events completely. This would become
apparent only with longer follow-up.
van den Hout et al.86 conducted an economic evaluation as part of the BeSt study.26–34 This was a
randomised trial of patients (n = 508) with early-onset RA randomised to (1) DMARD monotherapy,
(2) step-up combination therapy (including to treatment with IFX), (3) DMARD and steroid combination
therapy stepped up (including to treatment with IFX) or (4) initial IFX and DMARD combination therapy.
DASs were measured every 3 months and used to change treatments according to the protocol the patient
was randomised to. Costs and utilities were measured over 2 years to allow cost per QALY estimates to be
made from a Dutch perspective. Productivity costs were included using both friction cost and human
capital approaches.
The primary analysis used British tariffs to generate utility scores for the EuroQol-5 Dimensions (EQ-5D)
and the friction cost method for costing productivity losses. The most effective strategy in terms of
QALYs generated was strategy 4, but the additional cost meant that this was unlikely to be considered
cost-effective: the incremental cost-effectiveness ratio (ICER) compared with the next most effective
strategy was €130,000. Strategy 2 was most likely to be cost-effective for willingness-to-pay values up to
€74,000 per QALY and strategy 3 for willingness-to-pay values between €74,000 and €130,000 per QALY.
These general findings did not change in sensitivity analysis, except when the human capital approach to
valuing productivity losses was taken. Then, strategy 4 became highly cost-effective.
ASSESSMENT OF COST-EFFECTIVENESS




We considered how economic modelling could best be undertaken to be of use to decision-makers in
relation to TTT strategies. As noted above, TTT does not represent a specific intervention or technology,
but is a term that encompasses a range of different treatment strategies. Various aspects of TTT – the
setting of a treatment target, frequent assessment of that target, changes to therapy informed by patient
performance against the target and protocols for switching or amending drug therapy according to patient
performance – have been tested in clinical trials but not in a consistent manner.
As all trials vary in terms of the aspects of TTT they test, one means of providing generalisable results is to
pool similar studies together. In Chapter 3, Assessment of characteristics of individual study arms, an
illustrative grouping of studies was provided on the basis of the treatment protocols used to adjust drug
therapies according to the patient assessments. A similar approach to this was taken in the economic
modelling undertaken to help inform the NICE clinical guideline in RA.4 The NICE guideline considered the
optimal use of non-bDMARDs and steroids in patients with early RA. Trial arms were categorised by
treatment protocol and a similar approach was taken here for studies identified as TTT trials. It can be seen
that, even within studies that used treatment protocols that were broadly similar within TTT approaches,
there remains substantial heterogeneity. The precise details of the treatment protocols differ: cDMARDs
used are different, doses vary and the timings with which treatment changes are made also are different.
There are also differences between studies in terms of the frequency of assessment and the treatment
target. For these reasons it was not considered feasible to pool study arms together in the assessment of
clinical effectiveness. Those same concerns remain valid when considering the appropriate method for
assessing cost-effectiveness.
There are additional issues to be considered in relation to cost-effectiveness methods. To conduct an
economic evaluation, even within the follow-up period of any of the single trials identified, requires
substantial information about the experiences of patients. For example, unlike standard technologies,
TTT trials typically have a complex treatment protocol that specifies how drug treatments are to be amended,
and how the frequency of visits can be amended, by taking the assessment of patients into account. To
estimate resource use that will vary by patient because of these factors requires a level of reporting of results
that is typically absent from published papers. Indeed, in most cases such data will not have been collected.
The importance of extrapolation beyond the trial study period is critical in this area. Vermeer et al.85 show
how cost-effectiveness estimates vary substantially between their 2- and 3-year analyses. Extrapolation is
critical in this area because TTT typically involved higher upfront costs – patients are treated in a more intense
fashion and assessments are made more frequently. The expectation is that better control of patients gained
from this more intense management will provide benefits both to patients and to the health system in the
longer term. This can be achieved because it is often the case that patients in continued remission of LDA
can have their drug treatments reduced or eliminated entirely, even if only for a short period.87 This may not
be apparent within the short follow-up periods of clinical trials. It is also the case that better disease control
is likely to reduce or eliminate the requirement for joint replacement surgery and hospitalisations.88 Finally,
and critically, the lifetime cost-effectiveness of any treatment strategy is likely to be dominated by the extent
to which biologic drugs are used. Current eligibility for biologic drug treatment in the UK NHS requires the
failure of at least two cDMARDs. It is not feasible to estimate the rate at which drug failures occur within
clinical trials in order to then construct a model that moves patients to biologic drugs in the extrapolation
period. Even if it was, such is the importance of the use of biologics on cost-effectiveness that it is entirely
feasible that this would dominate any influence of the TTT element of the treatment strategy. In the extreme
case, one could imagine a case where biologics themselves were not considered to be cost-effective. In this
case, treatment strategies in early RA that resulted in the greatest delay in patients failing two DMARDs
(and, therefore, moving to biologics) would become the optimal strategy. This could lead to perverse results.
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Owing to the combination of these factors, a standard economic analysis conducted in terms of cost per QALY
was not deemed feasible or useful for informing decision-making. Owing to a lack of validity in synthesising
the data, an approach of a single model that compares all identified treatment strategies simultaneously was
not considered appropriate. Instead, each study identified within the clinical effectiveness review was
considered in isolation, with an ICER being extracted if the authors provided a measure of cost-effectiveness, or
estimated by the authors of this report, if possible. Where insufficient data were provided to allow an estimate
of the ICER, a narrative account of the relative cost-effectiveness of the treatment arms contained within
each study is provided. The data provided in the papers were often insufficient to allow a robust estimate of
cost–utility. However, cost-effectiveness ratios such as incremental cost per additional patient in remission
could typically be calculated and presented. In contrast to results generated by cost–utility analyses, there is no
stated threshold to determine whether or not treatments are likely to be deemed to be cost-effective using
different metrics. Where the results are sufficiently robust to allow conclusions on likely cost-effectiveness, the
authors have done so. Although a more limited approach to cost-effectiveness, our aim was to provide
evidence that portrays the limited evidence base in its most useful form.
We adopted a pragmatic approach to costing health resources consumed by patients in the identified studies.
Studies rarely report data in a form that would allow an estimate of the timing or dosages of drug change for
cDMARDs, steroids, immunosuppressants and anti-inflammatory painkillers. For these types of drugs, it was
assumed that the costs would be approximately equal in each treatment strategy arm and, therefore, not
included in the cost analysis. This is not believed to introduce significant inaccuracy as a result of the relatively
inexpensive unit costs for the drugs, but will be favourable to those treatments that start with combination
treatment rather than monotherapy. Where there were differences reported between study arms in terms of
hospital inpatient and outpatient care, appointments with rheumatologists and other health-care professionals,
or other aids and applications, these were costed at 2014/15 values.89,90 For studies which allowed the use of
bDMARDs, a more precise estimation of the additional drug costs was undertaken as these drugs are markedly
more expensive, having been estimated to incur an annual cost of £9200:91 exact costs could not be used
because of the commercial-in-confidence patient access schemes for some bDMARDs.
The following section details the TTT studies identified and the cost-effectiveness ratios reported in the
original papers or calculated by the authors of this report. These studies are presented in chronological
order of the last paper within the study, with papers relating to the same study grouped together. To avoid
repetition, the exact components of the treatment arm have not been detailed. Readers are referred to
Independent economic assessment for further information.
Results
Estimation of cost-effectiveness for each of the 16 TTT studies identified within the literature review of
clinical evidence is provided here. We report results separately for studies considering patients with early,
established disease or mixed populations.
Early rheumatoid arthritis populations
Fin-RACo (Mottonen et al., 1999)
The paper by Mottonen et al.46 reports on a 2-year multicentre RCT set in Finland. A total of 199 early
RA patients were randomly allocated to one of two treatment arms: four patients did not start treatment.
A total of 97 patients, 58% female, with a mean age of 47 year received combination drug therapy.
The remaining 98 patients, 66% female, with a mean age of 48 years, received single-drug therapy. The
target was remission.
The primary outcomes were the percentages of patients achieving remission after 1 and 2 years. After
1 year, 25% of patients receiving combination drug therapy and 11% of patients receiving single-drug
therapy achieved remission (p = 0.011). After 2 years, both of these values increased: to 37% of patients
receiving combination drug therapy and 18% of patients receiving single-drug therapy (p = 0.003).
Both the results at 1 year and the results at 2 years are statistically significant.
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This study presents the percentage of patients who experienced a drug-induced AE. Seventy per cent of
those patients on combination therapy experienced an AE, compared with 71% of those on single therapy
(p = 0.840). There was a statistically significant difference only in the percentage of patients with alanine
aminotransferase and alkaline phosphatase levels double that of normal patients, with fewer events in the
combination therapy arm (p = 0.026).
From the evidence contained in this paper, it would appear that combination drug therapy is more
effective than single-drug therapy in inducing remission without having a significant effect on costs. Thus,
in terms of cost-effectiveness it would appear, from the evidence of this study, that combination drug
therapy either dominates single-drug therapy or would be highly likely to have a cost per QALY below the
values published by NICE,92 of £20,000–30,000, compared with monotherapy.
CAMERA (Verstappen et al., 2007)
The paper by Verstappen et al. 36 reports on a 2-year randomised open-label prospective trial, which was set
in the Netherlands. A total of 299 patients were randomly allocated to one of two treatment arms, with one
patient dropping out after randomisation. A total of 151 patients, 69% female, with a mean age of 54 years
received intensive therapy. A total of 148 patients, 66% female, with a mean age of 53 years, received
routine therapy. During the 2-year duration of the study, 94 patients withdrew, 59 in the intensive therapy
arm and 35 in the conventional therapy arm, including 10 shortly after inclusion (two in the intensive
therapy arm and eight in the conventional therapy arm). The target was complex and multidimensional in
both treatment arms.
Patients receiving conventional therapy attended appointments with their treating rheumatologist every
3 months and were treated in accordance the study protocol, whereas patients receiving intensive therapy
attended appointments with their treating rheumatologist every 4 weeks. Rheumatology visits are assumed
to cost £12893 in the UK; thus, intensive therapy will be associated with an additional cost of £2315 per
patient completing the study compared with conventional therapy. Intensive therapy also includes performing
specific clinical measurements, although these costs were assumed small enough to omit.
The primary outcome was the number of patients who achieved and maintained remission for a period
of 3 months during the trial. During the first year, 53 patients (35%) in the intensive therapy arm and
21 patients (14%) in the conventional therapy arm achieved, and maintained, at least one 3-month period of
remission (p < 0.001). Over 2 years these numbers increased to 76 patients (55%) in the intensive therapy
arm and 55 patients (37%) in the conventional therapy arm (p = 0.029). The mean duration patients spent
in the study until remission was 10.4 months for patients receiving intensive therapy and 14.3 months for
patients receiving conventional therapy (p < 0.001). The duration of remission was also significantly longer
for patients receiving intensive therapy (11.6 months) than for patients receiving conventional therapy
(9.1 months) (p = 0.025).
After 1 year, 87 patients (58%) receiving intensive therapy and 64 patients (43%) receiving conventional
therapy had achieved an ACR 50 response (p = 0.018). At 2 years, these numbers were 69 patients (46%)
in the intensive therapy arm and 67 patients (45%) in the conventional therapy arm (p = 1.00). Results
for ESR, morning stiffness, SJC, TJC, VAS scores for general well-being and pain and functional disability
(as measured using the HAQ) for participants on an intention-to-treat basis using a last observation carried
forward methodology basis are also presented. Patients receiving intensive therapy score significantly
better in all measures after 3 months of therapy (p < 0.01), except functional disability (p = 0.8). After
1 year of therapy statistical significant differences are maintained for SJC, TJC and VAS scores for general
well-being and pain. After 2 years of therapy a statistical difference is shown only for the VAS scores for
general well-being and pain, with the mean differences in these categories diminishing. Thus, it appears
that intensive therapy produces a more rapid response than conventional therapy.
Broadly similar mean AEs per appointment are presented: 0.745 in the intensive therapy arm and 0.771 in
the conventional therapy arm (p-value not reported).
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If it is assumed that all patients completed the study, then the estimated cost per incremental patient in
remission would be £36.18 at the end of year 1, increasing to £110.26 at the end of year 2. Dropouts from
the study mean that these values should be taken as indicative rather than definitive. However, given the
potential for increased patient utility and a reduction in costs for a patient being in remission, we believe
that the intensive therapy is likely to have a cost per QALY gained below thresholds published by NICE.92
Saunders et al., 200854
The paper by Saunders et al.54 reports on a 12-month RCT set in the UK. A total of 96 patients with early
RA were randomly allocated to one of two treatment arms. A total of 49 patients, 76% female, with a
mean age of 55 years, received parallel triple therapy. The remaining 47 patients, 79% female, with
a mean age of 55 years, received step-up therapy. The target in both arms was a DAS28 of < 3.2.
The primary study outcome was the mean decrease in DAS28 at 12 months. Secondary outcomes, also
measured at 12 months, were based on the percentage of patients in each arm achieving good response
(EULAR definition) and the percentage of patients achieving remission (EULAR definition) together with
the percentage of patients experiencing an ACR 20, ACR 50 and ACR 70 response. These outcomes are
presented in Table 37.
These study outcomes indicate that there is no statistically significant difference in the effectiveness of
parallel triple therapy compared with step-up therapy in terms of the mean reduction in the DAS28, the
percentage of patients achieving a good EULAR response or the percentage of patients achieving remission
(as defined by EULAR). The results also indicate that there is no statistically significant difference between
the two therapies in terms of the percentage of patients experiencing an ACR 20, ACR 50 or ACR 70
response. The step-up therapy approach has a numerical advantage compared with parallel triple therapy:
it is possible that step-up therapy is better, but this was not observed because of the small sample size.
Saunders et al.54 acknowledged in the paper that their results were at odds with previous studies which
had demonstrated the superiority of triple therapy in achieving clinical improvement among patients with
early RA. However, they state that these results were seen mainly in studies which compared triple therapy
with single or dual cDMARD therapy in non-intensive treatment strategies. The authors hypothesise that
the outcomes could also be as a result of using a relatively low dose of MTX (7.5 mg per week), SSZ
(500 mg twice a day) and HCQ (200 mg daily) in the triple-therapy arm compared with the dose of SSZ
used as the first treatment in the step-up therapy arm (40 mg/kg/day or maximally tolerated dose). The
authors also state that the outcomes of the FIN-RACo trial,46 which was the only other published study
comparing a triple-therapy treatment regimen with a monotherapy treatment regimen in early RA patients,
were measured after 24 months of treatment rather than after just 12 months of treatment. Patients in the
triple-therapy arm of the FIN-RACo study46 were also prescribed oral prednisolone, which was not part of
the treatment regimen in this study.




Number of participants 49 47 –
Mean reduction in the DAS28 –3.3 –4.0 0.16
EULAR good response 41% 60% 0.47
EULAR remission 33% 45% 0.6
ACR 20 response 76% 77% 0.9
ACR 50 response 51% 60% 0.7
ACR 70 response 20% 30% 0.6
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From the data in this paper there is no evidence of statistically significant differences in the effectiveness
of the two therapies and only a minor difference in terms of the costs of the two therapies. Therefore,
no firm conclusion can be drawn between parallel triple-therapy and step-up therapy in terms of
cost-effectiveness or cost–utility.
STREAM (van Eijk et al., 2011)
The paper by van Eijk et al.55 reports on a 2-year RCT set in the Netherlands. A total of 82 patients were
randomly allocated to one of two treatment arms. Forty-two patients, 58% female, with a mean age of
48 years, received aggressive therapy under a tight control treatment regimen. Forty patients, 79% female,
with a mean age of 46 years, received conventional therapy. Patients assigned to aggressive therapy were
able to receive ADA; however, patients assigned to the conventional therapy were not. The target was
remission, defined as a DAS44 score of < 1.6.
The primary outcome was the Sharp/van der Heijde radiographic score. There was a numerical advantage
favouring aggressive therapy, although this was not statistically significant at 2 years (p = 0.17).
Secondary outcomes, which were again measured at 2 years, included differences in the DAS28; the percentage
of patients in clinical remission (a DAS28 of < 1.6); the percentage of patients in pharmaceutical-free clinical
remission; HAQ score; and AEs. A total of 66% of patients in the aggressive therapy group and 49% of patients
in the conventional therapy group achieved remission; the authors report that this is not statistically significant,
but do not report a p-value. In the aggressive therapy group, 17.9% of patients achieved a period of
pharmaceutical-free remission, compared with 15.8% of patients in the conventional therapy group (p= 0.08).
The mean duration of pharmaceutical-free remission in the aggressive therapy group was 6 months and the
mean duration of pharmaceutical-free remission in the conventional therapy group was 7.5 months. Analysis of
HAQ score changes did not show a clear benefit of either treatment arm.
AE occurrence was recorded, with 62 events among patients receiving aggressive therapy patients,
compared with 35 events in the conventional therapy patients within the follow-up period (p = 0.034).
Thus, there is a statistically significant difference in the AE rate, with patients receiving aggressive therapy
more likely to experience an AE than patients receiving conventional therapy.
Based on the evidence contained in this study, aggressive therapy is associated with greater costs than
conventional therapy as a result of the use of a bDMARD in 19 out of 42 patients in the aggressive arm
and the need to record the DAS28. There is not a statistically significant difference in the efficacy of the
two therapies, although a beneficial effect may not have been observed because of the small sample sizes.
Therefore, it is possible that the aggressive therapy is dominated by conventional therapy as a result of
achieving the same outcomes at a considerably higher cost. However, there remains some uncertainty
because of the numerical advantage of patients reaching remission in the aggressive arm: it was not
possible to calculate a robust cost per incremental patient reaching remission as a result of the lack of data
provided by van Eijk et al.55 on the treatment duration with bDMARDs. Therefore, no definitive conclusion
on the cost-effectiveness of the aggressive therapy arm can be made.
The T-4 study (Urata et al., 2011; and Urata et al., 2012)
The more recent paper by Urata et al.57 reports on a 56-week trial set in Japan and supersedes an earlier
abstract.56 A total of 243 patients with early RA were randomly allocated to one of four treatment arms. A
total of 62 patients were allocated to routine care, 60 patients were allocated to a regimen in which treatment
decisions were made based on DAS28, 60 patients were allocated to a regimen in which treatment decisions
were based on MMP-3 scores and 61 patients were allocated to a regimen in which treatment decisions were
based on both the DAS28 and MMP-3 scores.
A total of 21 patients dropped out during the trial as a result of AEs. Seven patients dropped out of
routine care, leaving 55 patients in the routine care group, 76% female, with a mean age of 62 years.
Four patients dropped out of the DAS therapy group, leaving 56 patients in this group, 77% female, with a
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mean age of 60 years. Seven patients dropped out of the MMP-3 therapy group, leaving 53 patients, 83%
female, and a mean age of 62 years. The remaining three patients dropped out of the combination therapy
group, leaving 58 patients, 84% female, with a mean age of 56 years. Baseline patient characteristics
were reported for only those patients who completed the study. There was no target for routine care; the
target for the DAS28-driven therapy was a DAS28 of < 2.6. The target for the MMP-3-driven therapy was a
MMP-3 concentration of < 121 ng/ml in men and < 59.7 ng/ml in women and the targets for both the
DAS28 and MMP-3-driven therapies were those for the individual components.
Patients in all the arms of the trial could receive bDMARD pharmaceuticals, which included a first-line
anti-TNF, a second-line anti-TNF and TOC. The times of bDMARD initiation in each of the four treatment
arms is presented in table 3 of Urata et al.,57 although the numbers provided for each arm (55 for routine
care, 59 for DAS28-driven therapy, 59 for MMP-3-driven therapy and 61 for both the DAS28 and MMP-3-
driven therapy) do not match either the intention-to-treat population or the numbers who completed the
trial. We have assumed that those patients who would be included in the intention-to-treat analysis did
not receive a bDMARD.
A number of primary and secondary outcomes were presented for the study; these include clinical
remission (defined by a DAS28 of < 2.6), radiographic non-progression [defined by a change in modified
total Sharp score (mTSS) of ≤ 0.5], normal physical function (as defined by a mHAQ = 0), a combination of
all three of the above conditions and clinical remission (as defined by a SDAI of ≤ 3.3). These results are
presented in Table 38.
There appear to be errors in the marking of statistical significance between groups in figure 2 of the Urata
et al.57 paper. The correct markings are not easy to interpret, so no further comment will be made on
these. However, it is reported in the results section of the paper’s abstract that clinical remission at
56 weeks was achieved by more patients in the DAS28 and MMP-3-driven group than in either the routine
therapy group (p < 0.0005) or the MMP3-driven group (p < 0.0005).
From the numbers in Table 38 it is seen that the DAS28 and MMP-3-driven group is the most efficacious
treatment in all categories bar prevention of radiographic progression.
Table 39 presents the estimated total treatment duration with bDMARD received by patients in each arm
of the trial. From this the estimated average cost per patient associated with bDMARDs in each arm of the
study could be calculated. It was assumed that the annual cost of all bDMARDs was £9200, which will
result in a daily cost of bDMARD treatment of £25.19, in line with a recent publication.91 The exact costs
could not be used because of the commercial-in-confidence patient access schemes. It has been assumed
that any costs associated with providing MMP-3-driven therapy and/or DAS28-driven therapy are not
excessive and can be ignored for simplicity.















SDAI of ≤ 3.3
Routine care 21 27 44 6 15
DAS28-driven therapy 38 42 60 15 32
MMP-3-driven therapy 13 62 43 7 13
Both DAS28- and
MMP-3-driven therapy
56 59 72 34 46
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From our calculations the most expensive treatment is combined DAS28 and MMP-3-driven therapy,
which has a per-patient cost of £4833, followed by DAS28-driven therapy, which has a per-patient cost of
£2833, followed by routine care, which has a per-patient cost of £2417, with MMP-3-driven therapy being
the cheapest, at £2351 per patient.
The cost per additional patient in remission is approximately £167 when combined DAS28 and MMP-3-driven
therapy is used (Table 40). Given the long-term benefits associated with remission (in terms of both costs
incurred and health-related quality of life accrued), we believe that it is highly likely that the cost per QALY of
the strategy would be below those quoted by NICE as thresholds for cost-effectiveness.92
COBRA-light (den Uyl et al., 2013)
The paper by den Uyl et al.69 reports on a 6-month randomised controlled non-inferiority study set in the
Netherlands. A total of 164 early RA patients were randomly allocated to one of two treatment arms.
A total of 81 patients, 67% female, with a mean age of 53 years, were allocated to COBRA therapy. A
total of 83 patients, 70% female, with a mean age of 51 years, were allocated to COBRA-light therapy.44,45
The target was a DAS44 score of < 1.6.
A summary of key outcomes from the study is presented in Table 41.
There were no significant differences in any outcome measure presented in Table 41 and there was no
clear indication that one treatment strategy was better than the other. Therefore, no firm conclusion can
be made regarding which strategy is the more cost-effective.
The TEAR study
The TEAR study,58–60 set in the Netherlands, evaluated two treatment options [ETN plus MTX and triple therapy
(MTX+ SSZ+HCQ)] and two timings regarding the initiation of therapy (immediately or step-up from MTX
monotherapy if the DAS28-ESR was ≥ 3.2 at week 24). A total of 755 patients with early RA (symptom duration




Days of bDMARD treatment
Cost of arm
per patient (£)First TNF Second TNF TOC Total
Routine care 62 5950 0 0 5950 2417
DAS28-driven therapy 60 5432 560 756 6748 2833
MMP-3-driven therapy 60 5012 0 588 5600 2351
Combined DAS28 and
MMP-3-driven therapy
61 10,136 784 784 11,704 4833




ICER (£)aNumber Incremental Per patient Incremental
MMP-3-driven therapy 8 – 2351 – –
Routine care 13 5 2417 66 13
DAS28-driven therapy 22 9 2833 416 46
Combined DAS28 and MMP-3-driven therapy 34 12 4833 2000 167
a This ICER is measured in terms of the incremental cost per patient achieving remission.
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of < 3 years) were randomly allocated to one of four treatment arms. A total of 245 patients, 74.2% female,
with a mean age of 50.7 years, received immediate MTX plus ETN. A total of 132 patients, 76.5% female, with
a mean age of 48.8 years, received immediate triple therapy. A total of 255 patients, 69.0% female, with a
mean age of 48.6 years, received step-up therapy from MTX monotherapy to MTX plus ETN. The remaining
124 patients, 70.2% female, with a mean age of 49.3 years, received step-up therapy from MTX monotherapy
to triple therapy.
The TEAR study: results after 102 weeks (Moreland et al., 2010)
This abstract by Moreland et al.59 provided preliminary data on radiographic scores by treatment type
and by the timing of treatment initialisation; these data came from 297 participants. At week 102, the
baseline-adjusted change in mTSSs in the ETN plus MTX group was 0.6 (SD 3.3) and for the triple-therapy
group was 2.4 (SD 10.1), which was significantly different (p = 0.0180). No significant differences were
found when analysing the timing of treatment (immediate vs. step-up; p = 0.8059), the percentage of
patients with no damage (p = 0.30 by treatment group), JSN (p = 0.15 by treatment group) or the number
of patients with no erosions (p-value not reported). It is unlikely that the benefit in the reduced progression
of mTSSs would warrant the increased costs associated with ETN.
The TEAR study: 2-year results (Moreland et al., 2012; and O’Dell et al., 2013)
At 2 years, 67.9% of participants completed the study, with the authors reporting that there was no
differential dropout rate across the treatment arms (p = 0.73) or according to the timing of intensive
treatment (p = 0.61) or medication type (ETN plus MTX or triple therapy) (p = 0.18). Of those completing
the study, only 476 had sufficient data for the DAS28-ESR to be determined at week 102.
At week 24, 72% of the patients in the step-up group had a DAS28-ESR of ≥ 3.2 and treatment was
intensified. In contrast, the proportion of patients with a DAS28-ESR of ≥ 3.2 in the immediate-intensified
treatment groups was 59% for those receiving ETN plus MTX and 57% for those receiving triple therapy.




Number of participants 81 83 –
Change in the DAS44 2.50 2.18 0.19a
Percentage of patients achieving ACR response
ACR 20 response 74 72 NRb
ACR 50 response 57 62 NRb
ACR 70 response 38 49 NRb
Percentage of patients achieving EULAR response
Good response 75 65 NRb
Moderate response 19 24 NRb
Non-response 6 11 NRb
Percentage of patients achieving remission
(ACR/EULAR definition)
16 20 NRb
Percentage of patients achieving minimal disease
activity (a DAS44 of < 1.6)
49 41 NRb
NR, not reported.
a Once corrected for baseline values (p-value of 0.08 uncorrected).
b Although the p-value is not reported, the authors do report that the result is not statistically significant.
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Combining the two immediate treatment groups showed a statistically significant benefit in the DAS28-ESR
reduction compared with those in the step-up arms (p < 0.0001). However, by week 48 the DAS28-ESR
was similar in all groups and there was no significant difference across the four treatment groups between
week 48 and week 102 (p = 0.28). This conclusion held when the results were analysed by treatment type
(p = 0.48) and timing of intensified treatment (p = 0.55).
There was no difference in those patients achieving clinical remission (defined as a DAS28-ESR of < 2.6)
between groups (p = 0.93), by timing of intensification (p = 0.36) or by type of treatment received (p = 0.43).
A similar pattern was seen with ACR responses, with both immediate treatment groups achieving better ACR
20/50/70 responses than the step-up groups (p < 0.0001), but few results were statistically significant at
week 102. The only significant comparison from all tested was an improvement in ACR 70 responses
between ETN plus MTX and triple-therapy groups (p = 0.01).
With respect to mTSSs, there was no difference in the change between baseline and week 102 when
comparing immediate with step-up treatment (p = 0.74), although those allocated to ETN plus MTX had
better results than those allocated to triple therapy (p = 0.047). Using a definition of progression of a
radiographic score of > 0.5, 33.6% of patients showed progression, although this did not differ significantly
across the groups (p = 0.33) or according to the timing of intensified treatment (p = 0.56). However, there
was a difference between those allocated to ETN plus MTX and those receiving triple therapy (p = 0.02),
although this became non-significant when an outlier (with a mTSS increase of 78.5) was removed
(p = 0.069). No significant differences across treatment groups were reported for GC use or for those
experiencing AEs or SAEs.
The evidence presented in this study prompted the authors to state that:
Initial use of MTX monotherapy with the addition of SSZ plus HCQ (or ETN, if necessary, after
6 months) is a reasonable therapeutic strategy for patients with early RA.
The authors of this report would concur and additionally point out that the use of ETN is considerably
more expensive than SSZ or HCQ, and it is highly unlikely that the costs could justified an improvement in
radiographic damage.
O’Dell et al.60 presented very similar results to those provided in Moreland et al.58 It was reported that no
statistically significant difference was observed between the percentage of patients in each treatment modality
(immediate combination treatment vs. step-up treatment) who discontinued treatment by week 24 (p = 0.84).
Nor was any statistically significant difference observed between the percentage of patients in each treatment
modality (immediate combination treatment vs. patients who stepped up treatment at week 24 vs. patients
who remained on MTX monotherapy at week 24) who discontinued treatment between weeks 24 and 102
(p = 0.86). At 102 weeks, 159 patients remained in the immediate MTX plus ETN treatment arm, 76 patients
remained in the immediate triple-therapy treatment arm, 166 patients remained in the step-up MTX plus ETN
treatment arm and 75 patients remained in the step-up triple-therapy treatment arm.
The authors conclude that radiographic outcomes for those who started on MTX monotherapy and then
stepped up to combination therapy if the DAS28-ESR was ≥ 3.2 at 24 weeks were ‘indistinguishable from
week 48 to week 102’. The authors further report that the advantage of initial combination of ETN plus
MTX compared with the addition of MTX in those that did not meet the goal of a DAS28-ESR of < 3.2
had ‘no clinical or radiographic advantage’. The authors discuss the economic consequences of the results,
stating that 28% of those patients started on MTX monotherapy had a very good outcome and thus the
expense of ETN need not be incurred. We concur with this view and believe that the use of ETN before
intensive treatment with cDMARDs would not be justified economically and the ICER for such a strategy
would be significantly higher than published NICE thresholds.92
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The BehandelStrategieën in Reumatoïde Artritis trial
The BeSt trial30,33,34,68 is a multicentre RCT set in the Netherlands. A total of 508 patients were randomly
allocated to one of four treatment arms. A total of 126 patients, 68% female, with a mean age of
54 years, received sequential monotherapy; 121 patients, 71% female, with a mean age of 54 years,
received step-up combination therapy; 133 patients, 65% female, with a mean age of 55 years, received
initial combination therapy with PDN; and 128 patients, 66% female, with a mean age of 54 years,
received initial combination therapy with IFX. The target was a DAS44 score of ≤ 2.4.
The BehandelStrategieën in Reumatoïde Artritis trial: results at 1 year
(Goekoop Ruiterman et al., 2005)
Study outcomes measured at 1 year included the D-HAQ, a lower score on which indicates better patient
functioning.30 Radiological damage was assessed in terms of mean total SHS, mean erosion score and
mean JSN. These outcomes are presented in Table 42.
These outcomes show a statistically significant difference between patients receiving initial combination therapy
with PDN and patients receiving initial combination therapy with IFX compared with patients receiving sequential
monotherapy and patients receiving step-up combination therapy for mean total SHS at every time point; mean
erosion score at every time point; and mean D-HAQ score at 3, 6 and 9 months. At 12 months, D-HAQ was
statistically significant between patients receiving initial combination therapy with PDN and patients receiving
initial combination therapy with IFX compared with patients receiving sequential monotherapy.
A statistically significant difference in mean JSN was observed between patients receiving initial
combination therapy with PDN or IFX and patients receiving sequential monotherapy and also between
patients receiving combination therapy with IFX and patients receiving step-up combination therapy.















Percentage of patients achieving LDAa 53 (50) 64 (60) 71 (65) 74 (70) b
Mean D-HAQ score
Baseline 1.4 1.4 1.4 1.4 –
3 months 1.0 1.0 0.6 0.6 < 0.001c
6 months 0.9 0.9 0.5 0.5 < 0.001c
9 months 0.8 0.8 0.6 0.5 < 0.001c
12 months 0.7 0.7 0.5 0.5 < 0.009d
Progression of radiological damage
Mean total SHS 7.1 4.3 2.0 1.3 < 0.001c
Mean erosion score 3.5 2.6 0.9 0.7 < 0.001c
Mean JSN score 3.6 1.6 1.0 0.6 < 0.001e
a Percentage of patients achieving LDA as presented in the paper (percentage of patients achieving LDA using the number
of patients randomised to each therapy as the denominator).
b p-value = 0.004 between groups 1 and 3; p-value = 0.001 between groups 1 and 4; and p-value not significant for
other comparisons.
c p-value < 0.05 between groups 1 and 2 vs. groups 3 and 4.
d p-value < 0.05 between group 1 vs. 3 and 4.
e p-value < 0.05 between group 1 and groups 3 and 4; and between groups 2 and 4.
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A statistically significant difference was observed in the D-HAQ scores at 3, 6 and 9 months between
patients receiving initial combination therapy with PDN or IFX and patients receiving step-up combination
therapy or sequential monotherapy.
Table 43 provides data on AEs observed in the first year of the BeSt trial.26–34,65,68 No statistically significant
difference was observed in the rate of AEs. However, numerically the combination strategies had fewer
patients with AEs, although the combination strategy with PDN had the numerically largest number
of SAEs.
Given the statistically significant better efficacy results for the strategy of combination therapy with PDN
compared with sequential monotherapy and with step-up combination therapy, it is plausible that the first
strategy would have a cost per QALY ratio compared with the last two strategies that was below published
NICE thresholds,92 although this would be dependent on the D-HAQ gains being translated into clinically
meaningful outcomes.
Given the similar efficacy data observed for the combination with PDN and the combination with IFX therapies,
it is anticipated that, because of the relatively large costs of IFX, the cost per QALY gained associated with the
use of IFX rather than PDN would be markedly higher than the published NICE thresholds.92
The BehandelStrategieën in Reumatoïde Artritis trial: results at 2 years (Allaart et al., 2006)
The results presented in Allaart et al.27 included clinical data at 2 years for each of the four study arms.
These data are summarised in Table 44.
The results indicate that at 2 years many of the key clinical outcomes are not significantly different between
the four arms. The two initial combination arms, however, had a quicker effect on the HAQ score and had
less radiographic progression at 2 years than the two remaining arms. Given the significant costs associated
with bDMARDs it is anticipated that the initial combination therapy with IFX arm would have a cost per
QALY in excess of that published by NICE92 when compared with initial combination therapy with PDN.
The BehandelStrategieën in Reumatoïde Artritis trial: results at 3 years (Allaart et al., 2007)
The paper by Allaart et al.26 provided information additional to that of the previous year.27 Data were
provided on the HAQ scores, DAS28, ESR and SHSs for the sequential monotherapy arm and the step-up














SAEs 6 7 13 5 0.438
At least one AE 43 47 37 39 0.367
Gastrointestinal AEs 16 15 8 11 NR
Dermatological AEs 10 12 9 6 NR
Upper RTI AEs 4 7 8 8 NR
Vascular AEs 2 2 6 2 NR
Reaction in infusion 0 0 0 8 NR
Latent tuberculosis 0 0 0 7 NR
NR, not reported; RTI, respiratory tract infection.
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combination therapy arm at 1 year, with a conclusion that the benefits of DAS-adjusted treatment was
clear, with statistically significant improvements for all comparisons. Drug-free clinical remission at 3 years
was reported: 11% for those started on sequential monotherapy, 6% for those started with step-up
combination therapy, 7% for those started with initial combination therapy with PDN and 16% for those
started with combination therapy with IFX. The comparison between the IFX combination and both the
step-up therapy and PDN combination was statistically significant. Radiological damage progression was
significantly lower in the initial combination therapy arms than in the remaining arms. The data provided in
this paper are more favourable to an initial IFX combination therapy arm, but would not change our
conclusions regarding the likely cost-effectiveness of initial IFX combination therapy compared with initial
PDN combination therapy.
The BehandelStrategieën in Reumatoïde Artritis trial: results at 2 years
(van der Kooij et al., 2009)
Study outcomes measured at 2 years were patient-reported outcomes, including changes in the
McMaster–Toronto Arthritis Patient Preference Disability Questionnaire (MACTAR), SF-36 Physical Component
score, SF-36 Mental Component score and the VAS scores for pain, disease progression and global general
health.68 These results are presented in Table 45.
At 2 years there was no significant difference in SF-36 Physical Component (p= 0.95), SF-36 Mental Component
(p= 0.97), VAS pain (p= 0.33), VAS disease activity (p= 0.19) and VAS global health (p= 0.10), although some
scores were statistically significant at 1 year, as was the MACTAR score. However, there is a difference in costs,
with those patients in the combination therapy with IFX anticipated to be more expensive and thus unlikely to
be cost-effective compared with the remaining arms.















HAQ improvement compared with baseline: mean (SD)
6 months 0.5 (0.7) 0.5 (0.7) 0.9 (0.7) 0.8 (0.6) < 0.001
12 months 0.7 (0.7) 0.7 (0.7) 0.9 (0.7) 0.9 (0.7) 0.03
18 months 0.7 (0.7) 0.8 (0.7) 0.8 (0.8) 0.9 (0.7) 0.26
24 months 0.7 (0.7) 0.8 (0.7) 0.9 (0.7) 0.9 (0.7) 0.26
Progression of SHS compared with baseline at 2 years: mean (SD)
Total SHS 9.0 (17.9) 5.2 (8.1) 2.6 (4.5) 2.5 (4.6) < 0.001
Erosion score 4.7 (9.0) 3.1 (5.0) 1.1 (2.2) 1.3 (2.7) < 0.001
JSN score 4.3 (9.8) 2.1 (3.8) 1.5 (3.2) 1.2 (2.9) 0.07
Relative risk for SHS progression of radiographic joint at 2 years: mean (95% CI)







Patients achieving a DAS44 of < 2.4
Percentage 75 81 78 82 NS
Patients achieving a DAS44 of < 1.6
Percentage 46 38 41 42 NS
NS, not significant.
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SF-36 Physical Component score
Baseline 32.9 32.9 32.8 33.4 0.93
6 months 8.0 8.5 12.5 12.4 < 0.001a
1 year 8.9 11.2 11.9 12.0 0.10
2 years 11.9 12.3 12.3 12.7 0.95
SF-36 Mental Component score
Baseline 47.5 46.3 47.6 47.6 0.73
6 months 3.1 3.5 1.2 4.1 0.17
1 year 4.3 4.4 3.2 4.3 0.83
2 years 4.3 4.6 4.6 4.0 0.97
VAS pain
Baseline (0–100) 53.1 53.4 54.1 54.1 0.98
6 months –17.4 –25.5 –30.3 –30.2 < 0.001b
1 year –21.3 –26.0 –28.9 –30.5 0.05c
2 years –28.2 –27.3 –26.9 –32.6 0.33
VAS disease activity
Baseline (0–100) 59.2 59.4 59.5 61.8 0.77
6 months –22.3 –28.0 –32.0 –35.9 0.003b
1 year –27.5 –29.8 –32.8 –38.3 0.03c
2 years –33.2 –33.0 –31.5 –39.0 0.19
VAS global health
Baseline (0–100) 51.9 51.9 50.6 55.0 0.36
6 months –17.7 –21.3 –21.5 –28.4 0.01c
1 year –21.7 –23.2 –22.7 –30.0 0.06
2 years –26.4 –25.6 –23.9 –31.8 0.10
MACTAR
Baseline 47.5 47.1 47.3 47.0 0.77
6 months 12.6 15.4 16.4 19.1 < 0.001d
1 year 15.2 16.3 16.9 19.3 0.02c
a p< 0.05 between groups 1 and 2 vs. groups 3 and 4.
b p< 0.05 between group 1 vs. groups 3 and 4.
c p< 0.05 between groups 1 and 4.
d p< 0.05 between groups 1 and 2 vs. group 4 and between groups 1 and 3.
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The BehandelStrategieën in Reumatoïde Artritis trial: results at 7 years (Dirven et al. 2010)
This abstract, by Dirven et al.,29 presented clinical results at 7 years. These are summarised in Table 46.
It is seen that there is a statistically significant difference neither in the DAS categories nor in SHS
progression. Although there has been a statistically significant reduction in mean HAQ score, equating to
approximately one HAQ level, this is not believed to provide sufficient clinical benefit to make the use
of initial combination with IFX cost-effective given that the number of people using IFX at 7 years is
significantly higher in the initial IFX combination therapy arm.
The BehandelStrategieën in Reumatoïde Artritis trial: results at 8 years (Dirven et al. 2011)
This abstract, by Dirven et al.,28 presented clinical results at 8 years and was very similar to the abstract
presented in 2010.29 The results are summarised in Table 47. It is not stated how the number of
completers was higher in the 8-year results than in the 7-year results.
The conclusions remain the same as for the 7-year results. Namely, it is seen that there is a statistically
significant difference neither in the DAS categories nor in SHS progression. Although there has been a
statistically significant reduction in mean HAQ score, equating to approximately one HAQ level, this is not
believed to provide sufficient clinical benefit to make the use of initial combination with IFX cost-effective
given that the number of people using IFX at 7 years is significantly higher in the initial IFX combination arm.
The BehandelStrategieën in Reumatoïde Artritis trial: results at 5 years
(Klarenbeek et al., 2011)
The paper by Klarenbeek et al.31 presented clinical and radiological outcomes at 5 years and focused on
functional status, quality of life, joint damage, AEs and the percentage of patients in remission (DAS44 of
< 1.6). As previously reported, the beneficial impacts of the two initial combination arms were quicker than
for the remaining arms, but these gains did not persist over time. The results are presented in Table 48.














Number recruited 126 121 133 128 –
Completers 83 72 79 97 –
Completers analyses
A DAS of ≤ 2.4 (%) 82 76 82 76 0.64
A DAS of < 1.6 (%) 49 39 53 45 0.35
A DAS of < 1.6 drug free (%) 16 18 17 17 0.96
SHS progression over 7 years:
median (mean)
3.8 (15.1) 3.5 (10.7) 2.0 (8.4) 2.0 (5.5) 0.205
Intention-to-treat analyses
Use of IFX at 7 years 14 6 11 21 < 0.05
Mean HAQ score over 7 years 0.70 0.71 0.63 0.57 < 0.001
Non-completers (%) 26 33 26 17 0.04
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At 5 years there was no significant difference in HAQ score (mean value 0.58), although there was a
significant difference in mean HAQ score over the 5 years for the combination therapy arms compared
with the sequential monotherapy and the step-up combination arms (p < 0.001) and for the initial
combination therapy with IFX arm compared with initial combination therapy with PDN. There was no
significant difference in either of the quality of life measurements recorded. Radiological progression was
least in the initial combination arms (p < 0.01), although after the first year the authors reported no
difference between the arms. The authors report that 48% of patients were in clinical remission and were
equally distributed between arms, although the initial combination therapy with IFX arm had the greatest
proportion (81%) achieving this on the treatment to which they were initially allocated, with the lowest















Number recruited 126 121 133 128 –
Completers 85 78 86 98 –
A DAS of ≤ 2.4 (%) 79 76 84 76 0.49
A of DAS < 1.6 (%) 49 56 57 47 0.48
A of DAS < 1.6 drug free (%) 18 19 17 15 0.90
SHS progression over 8 years:
median (mean)
3.0 (14.6) 4.3 (13.9) 2.0 (8.5) 2.0 (8.3) 0.567
Intention-to-treat analyses
Use of IFX at 8 years 21 10 13 24 0.06
Mean HAQ score over 8 years 0.69 0.71 0.63 0.57 < 0.05
Non-completers (%) 33 36 35 23 0.13














Drug-free remission (%) 14 16 10 19 0.18
SHS progression over 5 years:
median (mean)
3.5 (14.0) 2.5 (11.0) 1.0 (7.6) 1.0 (6.0) NR
Mean HAQ score over 5 years 0.70 0.70 0.62 0.54 NR
Mean SF-36 Physical Component
score over 5 years: area under
the curve per month
43.5 43.3 44.1 45.0 NS
Mean SF-36 Mental Component
score over 5 years: area under
the curve per month
51.8 51.0 50.9 51.2 NS
NR, not reported; NS, not significant.
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value being that for sequential monotherapy (46%). No significant difference was observed in the
proportion with drug-free remission (p = 0.18). The authors report that 86% of patients had at least one
AE and 30% of patients had SAEs, which were equally distributed across treatment groups.
The data from this paper do not alter the conclusions that the use of initial IFX treatment is unlikely to be
cost-effective.
The BehandelStrategieën in Reumatoïde Artritis trial: results at 7 years
(van den Broek et al., 2012)
The paper by van den Broek et al.65 reports clinical results at 7 years of follow-up. It was reported that there
was no statistically significant difference between the four treatment arms after the first year, although 36%
of patients in the initial combination therapy with PDN arm and 53% of patients in the initial combination
therapy with IFX arm had been tapered to monotherapy after year 2 because of persistent low DAS44 score.
A statistically significant difference was observed between the initial combination therapy with IFX or PDN
groups and the remaining two groups. At the end of the seventh year the percentages of patients across the
groups with drug-free remission were similar: 13% for sequential monotherapy; 16% for step-up combination
treatment; 16% for initial combination with PDN; and 14% with initial combination therapy with IFX.
The data from this paper do not alter the conclusions that the use of initial IFX treatment is unlikely to be
cost-effective.
The BehandelStrategieën in Reumatoïde Artritis trial: results at 5 years
(Koevoets et al., 2013)
The paper by Koevoets et al.32 focused on the relationship between erosions and JSN with the D-HAQ. The
analysis used generalised estimating equations regression models, as these are relatively robust to violations of
normality. Covariates of the DAS44, sex, treatment arm and body mass index were used. In univariate analyses,
the effects of erosions and JSN were similar (erosions: β = 0.003, 95% CI –0.001 to 0.006; JSN: β= 0.004,
95% CI 0.001 to 0.008), although erosions were not statistically significant whereas JSN was significant. The
variables that have the greatest influence on HAQ score when analysed univariately were DAS44, female sex
and DAS44 at baseline. Compared with the initial combination treatment with IFX, sequential monotherapy
(β 0.176, 95% CI 0.047 to 0.578) and step-up combination treatment (β 0.148, 95% CI 0.017 to 0.279)
were associated with significantly worse HAQ scores, although initial combination therapy with PDN was not
(β 0.076, 95% CI –0.035 to 0.188). When a multivariate model was used, the impact of both erosions and JSN
was reduced and neither was a statistically significant predictor of HAQ score.
The BehandelStrategieën in Reumatoïde Artritis trial: results at 8 years
(van den Broek et al., 2013)
The study outcomes measured at 8 years were the percentage of patients achieving LDA (as defined as a
DAS28 of ≤ 2.4), the percentage of patients achieving remission (as defined as a DAS28 of < 1.6), the
percentage of patients maintaining remission while pharmaceutical free, the percentage of patients in each
treatment arm who are still on their initial treatment, the mean HAQ score over the 8-year period of the
study, the percentage of patients in each arm who were receiving IFX after 8 years (patients in all arms
could progress to treatment with IFX during the 8-year period of the study) and the mean SHS over the
8-year period of the study.34 These results are presented in Table 49.
No statistically significant difference between the groups was observed in any of the DAS28 outcomes or
in mean SHS. The mean HAQ score over the 8-year period was statistically significantly different across all
groups when analysed simultaneously, with the authors additionally reporting that initial combination
therapy with IFX group had statistically significant better results against the step-up combination therapy
group and had borderline statistically significantly better results than the sequential monotherapy group.
None of the other comparisons were statistically significantly different. Current use of IFX analysed across
all groups approached statistical significance, with the greatest use being in the initial combination therapy
with IFX group and in the sequential monotherapy group.
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Based on van den Broek et al.,34 there is no evidence to suggest that the initial combination with PDN
group has worse outcomes than the initial combination with IFX group. Owing to the relatively high price
of IFX, it is assumed that the initial combination with IFX group would either be dominated by the initial
combination therapy with PDN group or have a cost per QALY ratio greater than those published
by NICE.92
The use of IFX in the sequential monotherapy group is numerically higher (21%) than for those who began
on combination therapy with PDN (13%), although this finding did not reach statistical significance. There
was, however, a significant difference in the mean D-HAQ score and radiological progression in the first
year (see Table 42). No firm conclusions can be made on the relative cost-effectiveness of the sequential
monotherapy and the initial combination therapy with PDN group, although it is plausible that initiating
combination therapy with PDN is more cost-effective than initiating sequential monotherapy.
The results of those in the step-up combination group and those in the initial combination therapy with
PDN were broadly comparable, although there was a significantly quicker change in D-HAQ score at
3 months in the combination therapy with PDN group (see Table 42). No firm conclusions can be made
regarding which out of the initial step-up combination therapy group and the initial combination therapy
with PDN group is more cost-effective.
The BehandelStrategieën in Reumatoïde Artritis trial: results at 10 years
(Markusse et al., 2014)
The results at 10 years report only mortality rates33 and these rates are presented in Table 50.
It can be seen that there is a numerical advantage for patients who receive initial combination therapy with
PDN and patients who receive initial combination therapy with IFX compared with patients who receive
sequential monotherapy and patients who receive step-up combination therapy. However, these
differences are not statistically significant (p = 0.805) and are contrary to the mean HAQ score over the
initial 8 years (see Table 49), so this difference is likely to be by chance.
For this reason, the results presented by Markusse et al.33 would not influence the conclusions on
cost-effectiveness generated by the data from van den Broek et al.34














A DAS28 of ≤ 2.4 (%) 79 76 84 76 0.5
A DAS28 of < 1.6 (%) 49 56 57 47 0.5
A DAS28 of < 1.6 pharmaceutical
free (%)
18 19 17 15 0.9
Still on initial treatment step (%) 29 22 45 66 < 0.001
Mean HAQ score over the study
period (8 years)
0.69 0.71 0.63 0.57 < 0.05a
Current use of IFX (%) 21 10 13 24 0.06
Mean SHS progression (years 0–8) 14.6 13.9 8.5 8.3 0.6
a According to a linear mixed model: group 2 vs. group 4, p< 0.05; group 1 vs. group 4, p= 0.055; and all others, p> 0.05.
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The BehandelStrategieën in Reumatoïde Artritis trial: results at 10 years
(Markusse et al., 2016)
The paper by Markusse et al.64 reports on the results at 10 years and comments that there was a
significant difference in dropout rates among the four arms, with 28% dropping out of the initial
combination therapy with IFX arm, compared with 40–45% in the remaining arms (p = 0.031). Of those
patients dropping out, 39% were in clinical remission. No significant differences were observed in the
number of AEs (p = 0.159), SAEs (p = 0.47) or deaths (p = 0.81). Survival was stated to be comparable to
that of the Dutch population. The 10-year results have been included in Table 51.
These 10-year results do not change the previously reached conclusions that no firm conclusions can be
made regarding which of sequential monotherapy, initial step-up combination therapy and initial
combination therapy with PDN group is the most cost-effective. However, initiation with IFX is not likely to
be cost-effective.
Hodkinson et al., 2015
The paper by Hodkinson et al,51 reports on a prospective 12-month study set in South Africa. A total of
102 patients, 94% black Africans, 83% female, with a mean symptom duration of 3.0 years and a mean
DAS28 of 6.2, were randomly allocated to one of two monitoring methodologies: CDAI or SDAI. This
study cites post hoc analyses,94–96 which have shown both indexes to be valid instruments in monitoring
disease activity in patients receiving treatment under a tight control strategy. The target in the SDAI arm
was a score of ≤ 11 and the target in the CDAI arm was a score of ≤ 10, both of which represented LDA.














Number of patients 126 121 133 128 –
Number of deaths 16 15 21 20 –
Percentage mortality at the years 12.70 12.40 15.79 15.63 0.805
















8.7 9.1 9.0 10.2 NR
Remission (%) 51 49 53 53 0.94
A DAS28 of ≤ 2.4 (%) 84 77 83 84 0.72
Use of initial treatment at 10 years:
intention to treat (%)
17 11 25 41 NR
Use of IFX at 10 years: study
completers (%)
18 12 13 25 NR
Mean HAQ score over 10 years 0.69 0.72 0.64 0.58 0.12
NR, not reported.
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The authors state that SDAI is based on a summation of five variables and that CDAI is based on a similar
summation. However, SDAI requires an acute-phase reactant test at each monitoring visit, whereas CDAI
does not. Thus, SDAI will be associated with a marginally greater cost than CDAI.
Two patients were lost to follow-up and two patients died during the study period. The analyses presented
by the authors were based predominantly on 98 patients: 57 patients receiving CDAI monitoring and 41
patients receiving SDAI monitoring.
The study outcomes at 12 months are presented in Table 52. However, the definitions for remission, LDA,
moderate disease activity and high disease activity are not provided. It can be seen from the p-values that
there is no statistically significant difference between the treatments in terms of the percentage of patients
in the four disease categories or the percentage of patients achieving a good response, as defined by EULAR.
The p-values of 1.00 appear to have been miscalculated, but this would not affect the broad conclusion.
No firm conclusion can be made regarding the cost-effectiveness of the treatments; however, current
evidence suggests that the treatment strategies are broadly comparable, but that SDAI will cost more than
CDAI. These data would suggest that, in the absence of further data, CDAI would be preferable.
The Care in early Rheumatoid Arthritis trial
The CareRA study38–43 was a 52-week randomised, pragmatic, open-label, superiority trial set in Belgium.
Patients were assigned to either the high- or low-risk group based on the presence of erosions, disease
activity, rheumatoid factor and anti-citrullinated protein antibody. The risk for which patients were
reported to be high or low was not stated, but we presume it is of RA progression. The target for all
patients in all arms was LDA, defined as a DAS28-CRP of ≤ 3.2.
The Care in early Rheumatoid Arthritis trial: results at 16 weeks (De Cock et al., 2013)
The results from this abstract38 were also reported in a full paper by Verschueren et al.,42 although slight
differences were noted. It is assumed that the later, full, paper would contain the correct results. For this
reason, no further comment will be provided on this abstract.
The Care in early Rheumatoid Arthritis trial: results at 16 weeks (Verschueren et al., 2014)
The results from this abstract41 were also reported in a full paper by Verschueren et al.42 We have focused
on the full paper.
The Care in early Rheumatoid Arthritis trial: results at 16 weeks (Verschueren et al., 2015)
The results provided in this paper, by Verschureren et al.,42 compared the use of COBRA Classic with
COBRA Slim and COBRA Avant-Garde in patients at high risk following 16 weeks of treatment. A total of
98 patients were allocated to COBRA Classic, 65.3% female, with a mean age of 53.2 years; 98 patients
were allocated to COBRA Slim, 64.3% female, with a mean age of 51.8 years; and 94 patients were




Percentage of patients in remission 34.1 33.3 1.00
Percentage of patients with LDA 31.7 29.8 1.00
Percentage of patients with moderate disease activity 31.7 31.6 1.00
Percentage of patients with high disease activity 2.4 5.3 0.64
EULAR good response 56.1 50.9 0.68
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allocated to COBRA Avant-Garde, 69.1% female, with a mean age of 51.2 years. Four outcomes were
assessed: DAS28-CRP remission defined as a score of < 2.6, cumulative disease activity, HAQ scores and
AEs. These results are reported in Table 53.
There was only one statistically significant difference among the three groups at 16 weeks, which related
to therapy-related AEs with COBRA Slim having fewer events than the remaining arms. Given the
comparable costs and efficacy it is likely that COBRA Slim would be the most cost-effective of the three
strategies given the 16-week data.
The Care in early Rheumatoid Arthritis trial: results at 16 weeks for low-risk patients
(De Cock et al., 2014)
The results from this abstract39 were also reported in a full paper by Verschueren et al.40 For this reason,
no further comment will be provided on this abstract.
The Care in early Rheumatoid Arthritis trial: results at 16 weeks for low-risk patients
(Verschueren et al., 2015)
The results provided in the paper40 by Verschueren et al. compared the use of MTX-TSU with COBRA Slim
in patients at low risk following 16 weeks of treatment. A total of 47 patients were allocated to MTX-TSU,
80.9% female, with a mean age of 51.02 years, and 43 patients were allocated to COBRA Slim, 76.7%
female, with a mean of 51.42 years. Four outcomes were assessed: DAS28-CRP remission defined as a
score of < 2.6, cumulative disease activity, HAQ scores and AEs. These results are reported in Table 54.
COBRA Slim was observed to have a statistically significant benefit in terms of both the area under the
curve of DAS28-CRP in the 16-week period and the proportion of patients with a HAQ score of zero.
Although not reaching significance, there were numerical advantages for COBRA Slim in key clinical
outcomes such as remission, change in DAS28-CRP, change in HAQ score and EULAR response.











Change in DAS28-CRP 2.80 2.60 2.40 0.140
Area under the curve of DAS28-CRP in
weeks 0–16
10.66 11.05 10.72 0.521
Remission (%) 70.4 73.5 68.1 0.713
LDA (%) 84.7 86.7 87.2 0.863
Good EULAR response (%) 79.6 79.6 76.6 0.844
Moderate or good EULAR response (%) 98.0 95.9 93.6 0.320
Reduction in HAQ score 0.8 0.6 0.7 0.081
HAQ clinically meaningful change (%) 84.7 76.5 76.6 0.271
HAQ = 0 45.9% 42.9% 48.9% 0.700
(n= 91) (n= 96) (n= 91)
Patients with therapy-related AEs (%) 61.2 46.9 69.1 0.006
Number of therapy-related AEs per ITT
patient
1.63 0.73 1.43 NR
Patients with therapy-related SAEs (%) 2.2 1.0 3.3 NR
ITT, intention to treat; NR, not reported.
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Given the likely comparability of costs for the two arms, but the superior efficacy for the COBRA Slim arm,
it is likely that COBRA Slim would be more cost-effective than MTX-TSU given the 16-week data.
The Care in early Rheumatoid Arthritis trial: 52-week results (Verscheuren et al., 2015)
The results from this abstract, by Verscheuren et al.,40 were also reported in a full paper by Verschueren
et al.,43 although slight differences were noted. It is assumed that the later, full, paper, would contain the
correct results and, therefore, no further comment will be provided on this abstract.
The Care in early Rheumatoid Arthritis trial: 52-week results (Verschueren et al., 2016)
Two analyses were described within this paper by Verscheuren et al.:43 one assessed three interventions for
high-risk patients and one assessed two interventions for low-risk patients.
High-risk patients A total of 289 high-risk patients were randomly allocated to one of three treatment
strategies. Ninety-eight patients, 65.3% female, with a mean age of 53.2 years, received COBRA Classic
therapy; 98 patients, 64.3% female, with a mean age of 51.8 years, received COBRA Slim therapy; and
93 patients, 68.8% female, with a mean age of 51.1 years, received COBRA Avant-Garde therapy. Note
that this number of patients is one fewer in the COBRA Avant-Garde arm than previously reported.38,42
Study outcomes, measured at 54 weeks, were the percentage of patients achieving LDA, the change in
DAS28-CRP, the percentage of patients achieving remission (defined as DAS28-CRP < 2.6), the percentage
of patients achieving a good EULAR response and the percentage of patients achieving a moderate EULAR
response. The results for these outcomes are presented in Table 55.
Study outcomes indicate that there are no statistically significant differences in the efficacy of the three
interventions. Indeed, each treatment possesses a numerical advantage in at least one outcome measure.
No firm conclusions can be made regarding the cost-effectiveness of the three treatment strategies.
In the absence of other data, it is noted that COBRA Slim was associated with significantly fewer AEs.
This conclusion is consistent with the 16-week results.
TABLE 54 Clinical outcomes at week 16 for low-risk patients as reported by Verschueren et al.40
Outcome
Therapy
p-valueMTX-TSU (n= 47) COBRA Slim (n= 43)
Change in DAS28-CRP 1.76 2.12 0.192
Area under the curve DAS28-CRP in weeks 0–16 13.84 11.18 0.006
Remission (%) 46.8 65.1 0.081
LDA (%) 72.3 79.1 0.458
Good EULAR response (%) 44.7 58.1 0.202
Moderate or good EULAR response (%) 72.3 86.0 0.111
Reduction in HAQ score 0.40 0.58 0.267
Clinically meaningful reduction in HAQ (%) 53.2 62.8 0.357
HAQ score of 0 (%) 23.4 51.2 0.006
Patients with therapy-related AEs (%) 44.7 39.5 0.622
Number of therapy-related AEs per ITT patient 0.681 0.698 NR
Patients with therapy-related SAEs (%) 0 0 NR
ITT, intention to treat; NR, not reported.
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Low-risk patients A total of 90 low-risk patients were randomly assigned to one of two treatment
strategies. Forty-seven patients, 80.9% female, with a mean age of 51.0 years, received MTX-TSU; and
43 patients, 76.7% female, with a mean age of 51.4 years, received COBRA Slim (low-risk) therapy.
The results for low-risk patients are presented in Table 56.
There were no statistically significant differences in the efficacy of the two interventions. However, COBRA Slim
therapy does possess a numerical advantage in all outcomes except that of obtaining at least a moderate EULAR
response. The possibility that a true difference was not observed because of a small sample size cannot be
discounted. However, there were two SAEs in the COBRA Slim arm and zero in the MTX-TSU group.
TABLE 55 Study outcomes at 52 weeks for high-risk patients reported by Verschueren et al.43
Outcome
Therapy
p-valueCOBRA Classic COBRA Slim COBRA Avant-Garde
Number of participants 98 98 93 –
DAS28-CRP reduction 2.5 2.3 2.3 0.329
Remission (%) 64.3 60.2 62.4 0.840
LDA (%) 74.5 75.5 79.6 0.684
Good EULAR response (%) 67.3 68.4 67.7 0.995
Moderate or good EULAR response (%) 84.7 88.8 88.2 0.654
Patients with therapy-related AEs (%) 67.3 66.3 78.5 0.125
Number of therapy-related AEs per ITT patient 1.9 1.3 1.9 0.028
Patients with therapy-related SAEs (%) 2.0 2.0 2.2 NR
ITT, intention to treat; NR, not reported.




Number of participants 47 43 –
DAS28-CRP change 2.1 2.1 0.990
Remission (%) 57.4 67.4 0.329
LDA (%) 76.6 81.4 0.577
Good EULAR response (%) 57.4 60.5 0.771
Moderate or good EULAR response (%) 78.7 76.7 0.822
Patients with therapy-related AEs (%) 63.8 51.2 0.224
Number of therapy-related AEs per ITT patient 1.2 1.2 0.737
Patients with therapy-related SAEs (%) 0.0 4.3 NR
ITT, intention to treat; NR, not reported.
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No firm conclusions can be made regarding which treatment strategy was more cost-effective. COBRA
Slim has a numerical advantage on key clinical outcomes and AEs, but not SAEs; however, this was not
statistically significant. This conclusion differs from that which was formed when only the results at
16 weeks were known.
The U-Act-Early trial (Bijlsma et al., 2016)
The paper by Bijlsma et al.62 reports on a 2-year RCT which was set in the Netherlands. A total of 317 patients
with early RA were randomly allocated to one of three treatment arms. One hundred and six patients, 61%
female, with a mean age of 53.0 years, received TOC plus MTX; 103 patients, 76% female, with a mean age
of 55 years, received TOC monotherapy; and the remaining 108 patients, 64% female, with a mean age of
53.5 years, received MTX monotherapy. The target was to achieve sustained remission defined as a period of
at least 24 weeks with a DAS28 of < 2.6 and a SJC of < 5.
The primary study outcome was the percentage of patients achieving sustained remission at 104 weeks.
Secondary outcomes, measured at 24, 52 and 104 weeks, included the percentage of patients achieving
a good or moderate EULAR response, the percentage of patients achieving an ACR 20/50/70/90 response
and the mean physical function score (the D-HAQ adjusted for centre and baseline). A measure of the
progression of radiological joint damage using the SHS was also assessed at 52 and 104 weeks. These
outcomes are presented in Table 57.
Patients were allowed to add HCQ to their initial allocated treatment. If sustained remission was not
achieved, then subsequent treatment regimens were allowed. These included alternative TNFis for those
who were initially on TOC treatment, and TOC and an alternative TNFi for those patients who were
allocated to MTX monotherapy.
No statistically significant difference was observed between TOC plus MTX and TOC monotherapy in terms
of the percentage of patients achieving sustained remission. However, statistically significant differences were
observed between both TOC arms compared with patients receiving MTX monotherapy. The same pattern
exists in terms of EULAR response and ACR 20/50/70 responses at week 24. However, by week 52 most of
these differences had become non-significant and by week 104 no statistically significant differences existed
between treatment groups. In terms of physical function, a statistically difference between treatment groups
as present at week 24 (p = 0.0275). However, again by week 52 this difference had become non-significant
(week 52, p = 0.14; week 104, p = 0.06). In terms of the progression of radiological joint damage, measured
by the SHS, there was a statistically significant difference at week 52 (patients receiving TOC+MTX vs.
patients receiving MTX monotherapy; p = 0.0164) and week 104 [patients receiving TOC+MTX vs. patients
receiving MTX monotherapy (p = 0.0207) and patients receiving TOC monotherapy vs. patients receiving
MTX monotherapy (p = 0.0381)].
The study presents the percentage of patients who experienced AEs, SAEs and serious infections. However,
there appear to be no statistically significant differences in AE frequency between treatment arms.
The study also reports results for patients at the end of the study, when patients could move on to
subsequent treatments. At the end of the study, 88% of the TOC arm, 86% of the TOC plus MTX arm
and 77% of the MTX arm had achieved sustained remission, with only the comparison between TOC
monotherapy and MTX monotherapy being significant (p = 0.0356). It is stated that ‘roughly 50%’ of
patients in the MTX monotherapy arm received TOC.
Without further details on the costs for each patient in each of the allocated treatment arms, it is not
possible to estimate a robust cost per QALY for the interventions. What is known is that the use of TOC
produces a statistically significantly higher percentage of patients who achieve sustained remission and that
TOC is markedly more expensive than MTX. Given that 44% of patients on MTX monotherapy achieved
sustained remission without the use of a bDMARD, there can be considerable savings by not starting
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TABLE 57 Outcomes reported by Bijlsma et al.62 as measured at 24, 52 and 104 weeks
Outcome














104 weeks on initial
treatment, n (%)
91 (86) 81 (83) 48 (44) < 0.0001/2.0a < 0.0001/1.86a 0.62/1.03a
Week 24
Good EULAR response (%) 89 87 49 < 0.0001 < 0.0001 0.43
Moderate EULAR response (%) 5 11 32
ACR 20 response (%) 75 75 59 0.0099 0.0343 NS
ACR 50 response (%) 64 59 34 < 0.0001 0.0009 NS
ACR 70 response (%) 44 37 15 < 0.0001 0.0003 NS
ACR 90 response (%) 18 12 5 0.0027 NS NS
Mean physical function score 0.50 0.63 0.65 0.0275
Week 52
Good EULAR response (%) 75 88 72 0.26 0.0074 0.06
Moderate EULAR response (%) 6 4 7
ACR 20 response (%) 75 72 69 NS NS NS
ACR 50 response (%) 62 59 51 NS NS NS
ACR 70 response (%) 44 44 33 NS NS NS
ACR 90 response (%) 19 21 7 0.0045 0.0026 NS
Mean physical function score 0.46 0.48 0.55 0.14
SHSb 0.50 0.79 0.96 0.0164 0.06 0.49
Week 104
Good EULAR response (%) 66 76 68 0.87 0.13 0.10
Moderate EULAR response (%) 8 8 8
ACR 20 response (%) 63 65 61 NS NS NS
ACR 50 response (%) 49 55 48 NS NS NS
ACR 70 response (%) 36 39 35 NS NS NS
ACR 90 response (%) 21 20 14 NS NS NS
Mean physical function score 0.48 0.61 0.62 0.06
SHSb 1.18 1.45 1.53 0.0207 0.0381 0.53
NS, not significant.
a Cochran–Mantel–Haenszel test stratified/relative risk; testing sequence for the intention-to-treat analysis defined a priori.
b Change from baseline.
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patients on bDMARDs and in potentially increasing the intensity of cDMARDs before progressing to
biologic use. It is the opinion of the authors of this report that the use of bDMARDs initially would produce
a cost per QALY greater than the thresholds published by NICE.92
Established disease rheumatoid arthritis populations
Fransen et al., 2005
The paper by Fransen et al.50 reports on a 24-week multicentre cluster RCT set in the Netherlands. A total
of 384 RA patients were included with a subgroup of 142 patients who had DAS28 assessed were
included. Twenty-four rheumatology outpatient centres were randomly allocated to provide DAS28-guided
care (61 patients) or usual care (81 patients). A summary of the patients’ characteristics are tabulated in
Table 58. The target in the systematic therapy arm was a DAS28 of ≤ 3.2: there was no target in the
usual-care arm.
The frequency of appointments with treating rheumatologists was no different between patients receiving
systematic therapy and patients receiving usual-care therapy. However, rheumatologists would perform a
joint count and calculate the DAS28 during appointments with patients in the systematic monitoring arm,
which are likely to be associated with a cost. However, this cost is unlikely to be significant and has been
omitted from this analysis.
Outcomes included the percentage of patients achieving LDA (defined as a DAS28 of ≤ 3.2) at 24 weeks
and the mean DAS28. These results are also presented in Table 58.
The authors state that the difference between the results in terms of the percentage of patients achieving
LDA was statistically significant at the 5% level (p = 0.028). However, the difference in DAS28 was not
statistically significant at the 5% level (p = 0.36).
It was found that, in terms of treatment-induced adverse reactions, a statistically significant difference
between the treatment arms was observed only for rash or itching, with 4% of patients in the systematic
monitoring therapy arm and 11% of patients in the usual-care therapy arm reporting this adverse reaction
to treatment. However, it was assumed that this difference would not have a substantial effect on costs.
The evidence in the study appears to indicate that the systematic monitoring of patients is more effective
without having a significant effect on costs. Thus, in terms of cost-effectiveness, the evidence in this paper
would appear to indicate that usual-care therapy is dominated by the systematic monitoring of patients.
TABLE 58 Baseline patient characteristics in Fransen et al.50
Characteristic
Therapy
Systematic monitoring Usual care
Mean age (years) 57 58
Patients who are female (%) 62 77
Baseline
Mean DAS28 4.6 4.5
Patients with LDA (%) 13 12
24 weeks
Mean DAS28 4.2 4.4
Patients with LDA (%) 31 16
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The BROSG trial (Symmons et al., 2005)
This Health Technology Assessment (HTA) report9 presents the methodology and results of the BROSG RCT set
in the UK. This study compared a shared-care treatment methodology, with patients treated predominantly
within a primary care setting, with a hospital-based treatment modality, with patients treated predominantly
within a hospital clinical setting. In the shared-care treatment methodology, the aims were to reduce joint pain,
stiffness and related symptoms, whereas in the hospital-based methodology these aims were supplemented by
an additional aim, to reduce clinical and laboratory evidence of inflammation.
A total of 466 patients were randomly allocated to one of the two treatment arms. Two hundred and
thirty-three of these patients, 68.2% female, with a mean age of 60.4 years and mean duration of
symptomatic RA of 12.6 years received shared care. The remaining 233 patients, 67.8% female, with a
mean age of 60.8 years and mean duration of symptomatic RA of 12.5 years, received hospital-based care.
The target was controlling joint pain, stiffness and related symptoms.
Health-related quality of life values were evaluated using the EQ-5D instrument at baseline and every 4 months,
finishing at 36 months. The discounted QALYs were accrued by patients in each cohort of the study for three
time periods: baseline to 12 months, 12–24 months and 24–36 months. The QALYs are presented in Table 59
together with the total QALYs accrued by patients in both arms of the study across the entire study period.
Thus, according to the authors, the incremental QALYs accrued by patients in the shared-care cohort
compared with patients in the hospital-based treatment cohort is 0.07 QALYs. A sensitivity analysis was
conducted, which adjusted the calculation for differences in baseline utilities between arms.
The undiscounted costs incurred by patients in the shared-care cohort and the hospital-based treatment
cohort across the 36-month period of the study are presented in Table 60. The authors report an incremental
discounted cost of the shared-care treatment compared with hospital-based treatment of £106.
The authors conclude that the ICER of shared-care compared with hospital-based treatment is £1517 per
QALY. A sensitivity analysis was conducted in which the calculation was adjusted for baseline utility values
and this produced an ICER of £7571.
From the evidence presented in this study, shared-care treatment appears cost-effective when compared
with hospital-based care.
The Optimisation of Adalimumab study (Pope et al., 2010; and Pope et al., 2013)
Both of the documents by Pope et al.52,53 report results from the Optimisation of Adalimumab study. The
Optimisation of Adalimumab study is an 18-month cluster RCT set in Canada that investigated whether
or not TTT produced better results than routine care in established RA. Pope et al.53 was an abstract that
has been superseded by a full paper.52 A total of 308 patients were randomly allocated to one of three
treatment arms. One hundred and nine patients, 83.5% female, with a mean age of 56.0 years and mean
TABLE 59 Discounted QALYs accrued by patients in each cohort of the BROSG RCT9
Assessment period
Treatment
Shared care Hospital based
Baseline to 12 months 0.60 0.57
12–24 months 0.55 0.53
24–36 months 0.52 0.50
Entire study period 1.67 1.60
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baseline DAS28 of 5.7 received routine care with no target. One hundred patients, 82.0% female, with a
mean age of 55.3 years and mean baseline DAS28 of 5.7 received treatment in which the target was a
DAS28 of < 2.6. The remaining 99 patients, 77.8% female, with a mean age of 51.5 years and mean
baseline DAS28 of 5.8 received treatment in which the target was to achieve a SJC of 0.
Study outcomes measured at 6, 12 and 18 months were the DAS28, the percentage of patients achieving
LDA (defined as a DAS28 of < 3.2), the percentage of patients achieving remission (defined as a DAS28
of < 2.6), the percentage of patients achieving a good/moderate EULAR response (undefined) and the
percentage of patients achieving a SJC of 0. Analyses were undertaken using an intention-to-treat basis.
These outcomes are presented in Table 61.
At all of the time points the strategy of treating to a target of a DAS28 of < 2.6 had a numerical advantage
in terms of the percentage of patients achieving the following criteria: achieving remission; LDA; good or
moderate EULAR response; and no swollen joints. Statistical significance was not reached given an adjustment
in the significance level as a result of multiple testing, but was borderline at 18 months for EULAR response
and approached significance at 18 months for remission and for LDA. Thus, there may be a true beneficial
effect that has not been observed as a result of the small sample size.
The dose of ADA was not changed across arms, although the paper reports that there were more intensifications
of other drugs in the targeted arms. The incremental cost of treatment between the arms of the study was
therefore assumed to be negligible. However, the paper reports that there were more physician visits in the
targeted groups, 4.3 in the routine care arm and 6.5 in each of the targeted arms. The additional 2.2 visits were
assumed to cost £128,93 resulting in additional costs of £281.60 for the two targeted arms.
Given the numerical advantage of the targeted treatment strategies, which may have failed to reach
reached significance only because of small sample sizes, no firm conclusion on the cost-effectiveness or
cost–utility of the treatment strategies can be made.
Mixed, early and established disease populations
TIght COntrol for Rheumatoid Arthritis trial (Grigor et al., 2004)
The paper by Grigor et al.61 reports on an 18-month single-blind RCT set in the UK. A total of 111 RA
patients were randomly allocated to one of two treatment arms, with one patient dropping out after
randomisation. Fifty-five patients, 71% female, with a mean age of 51 years, received intensive therapy.
The remaining 55 patients, 69% female, with a mean age of 54 years, received routine therapy. The target
in the intensive management arm was a DAS44 score of ≤ 2.4: there was no target in the routine
therapy arm.
TABLE 60 Undiscounted mean costs for the 36-month period of the study in the BROSG RCT9
Cost category
Treatment (£)
Shared care Hospital based
Inpatient care 1575 1261
Outpatient care 997 1369
Primary care 502 395
Other health care 98 90
Drug therapy 1475 1403
Aids and appliances 68 76
Total 4700 4581
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The primary outcome was the mean reduction in DAS and the proportion of patients with a good EULAR
response (a DAS44 of < 2.4 and a fall from baseline of > 1.2) over the 18-month study period. Secondary
outcomes included the percentage of patients achieving remission, defined as a DAS28 of < 1.6. These
results are presented in Table 62. The results indicate that there are statistically significant differences in
the effectiveness of intensive care compared with routine care.
Costs, using 2001/2 prices, were taken directly from the paper (Table 63). All costs except prescription
costs were uplifted to 2014/15 values using inflation indices from Unit Costs for Health & Social Care
201589 and Unit Costs for Health & Social Care 201090 (as the 2015 version did not include the inflation
index for 2001/2). It was assumed that the annual increase in the cost of pharmaceuticals is not in line
with the inflation indices given in the Unit Costs for Health & Social Care 2015.89 Ideally, the total
pharmaceutical cost for each arm would have been calculated using current costs; however, the paper did
not specify either the total or the individual pharmaceutical use in each arm and so this was not possible.
These values were left at their 2001/2 values assuming that the incremental pharmaceutical or prescription
cost would not differ considerable between 2001/2 and 2014/15.
TABLE 61 Outcomes from the Optimisation of Adalimumab study at 6, 12 and 18 months reported by Pope et al.52




DAS28 of < 2.6 SJC of 0
Mean DAS28a
6 months 3.26 3.72 3.49 0.460
12 months 3.12 3.38 3.18 0.619
18 months 3.27 3.40 3.16 0.273
Intention-to-treat analyses
Percentage of patients achieving remission (DAS28 of < 2.6)
6 months 17.4 24.0 16.2 0.564b
12 months 21.1 28.0 26.3 0.697b
18 months 15.6 38.0 22.2 0.027b
Percentage of patients achieving LDA (DAS28 of < 3.2)
6 months 28.4 33.0 30.3 0.880b
12 months 32.1 39.0 31.3 0.672b
18 months 22.9 47.0 27.3 0.022b
Percentage of patients achieving a good or moderate EULAR response
6 months 56.9 62.0 62.5 0.634b
12 months 51.4 61.0 50.5 0.508b
18 months 35.8 63.0 53.5 0.018b
Percentage of patients achieving an SJC of 0
6 months 22.0 27.0 24.2 0.839b
12 months 22.9 29.0 26.3 0.780b
18 months 21.1 34.0 26.3 0.331b
a Least square mean estimates based on linear mixed model.
b Between-group comparisons were assessed using a chi-squared clustered test with a significance level of 0.017 to
account for multiple comparisons.
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The incremental mean savings per patient, using 2014/15 values, was £1089. There were 55 participants
in both the intensive care arm and the routine care arm of this study and the total savings associated with
intensive care were £59,892.
Given that the intensive care arm was associated with better patient outcomes and cost savings, intensive
care is estimated to dominate routine care.
van Hulst et al., 2010
The paper by van Hulst et al.63 reports on an 18-month randomised pilot study set in the Netherlands. A
total of 248 patients were randomly allocated to one of two treatment arms. One hundred and forty-four
patients, 68% female, with a mean age of 60 years, were allocated to a nurse-led intervention. In this
intervention, treating rheumatologists were informed of a patient’s DAS28 before each consultation with a
target of reducing a patient’s DAS28 to ≤ 3.2 (mean age 60 years and 68% were female). One hundred
and four patients, 60% female, with a mean age of 59 years, were allocated to a usual-care arm. These
patients had their DAS28 calculated at each consultation, to allow a comparison of efficacies between
arms to be evaluated, but the DAS28 was not communicated to the treating rheumatologists. The target
in the intensive management arm was a DAS28 of ≤ 3.2: there was no target in the routine therapy arm.
In this study, participants underwent an assessment by a rheumatology nurse each time they were seen by
their treating rheumatologist. In practice, usual-care patients would not be assessed by a rheumatology
nurse at each consultation and, therefore, it is anticipated that the nurse-led intervention would be
associated with a higher cost.
Study outcomes that were measured at 18 months were based on the change in DAS28 and the
percentage of patients exhibiting a good, moderate or no EULAR response. These outcomes are presented
in Table 64.
TABLE 62 Outcomes of the Grigor et al.61 study at 18 months
Outcome
Treatment group
p-valueRoutine care Intensive care
Number in study arm 55 55 –
Mean reduction in DAS44 –1.9 –3.5 < 0.0001
Patients achieving a good EULAR response (%) 44 82 < 0.0001
Number achieving remission (%) 16 65 < 0.0001
TABLE 63 Mean cost per patient reported in Grigor et al.61 and their updated equivalents
Cost category
Cost year calculation (£)
Original paper (2001/2) Uplifted to current costs (2014/15)
Routine care Intensive care Routine care Intensive care
Outpatient cost 401 698 569 991
Inpatient cost 1611 571 2287 810
Prescription costs 452 649 452 649
Health professional visits 1249 859 1773 1219
Diagnostic tests 341 568 484 806
Total 4054 3345 5565 4476
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There was no evidence of a statistically significant difference in the effectiveness of a nurse-led intervention
compared with usual care. Given the anticipated higher costs, it is highly likely that the nurse-led approach
would be dominated by usual care or have an estimated cost per QALY greater than those published
by NICE.92
Discussion
Literature relating to 16 studies was found. In papers relating to six of these studies [i.e. Saunders et al.,54
van Eijk et al.,55 Pope et al.,52,53 den Uyl et al.,69 Hodkinson et al.51 and CareRA39,40,43 (low risk, presumably of
progression, patient subgroup)], no clear conclusions could be made regarding comparative cost-effectiveness.
In the remaining 10 studies and for the high-risk patient subgroup in the CareRA trial,39,42,43 the authors
believe that conclusions could be made with some confidence. In Mottonen et al.,46 combination drug therapy
was estimated to be more cost-effective than single-drug therapy; in Grigor et al.,61 intensive care was
associated with both better outcomes and lower costs than routine care; in Fransen et al.,50 systematic
monitoring produced significantly more patients with LDA than usual care for similar costs; in Symmons et al.,9
the paper concludes that the ICER of shared-care treatment compared with hospital-based treatment is
£1517 per QALY or £7571 per QALY when accounting for different baseline utility; in Verstappen et al.,36 it
was concluded that intensive therapy would be more cost-effective than conventional therapy; in van Hulst
et al.,63 usual care was deemed more cost-effective than a nurse-led approach as the additional resources
required were not translated into health benefits; in Urata et al,57 a policy of using both DAS28 and MMP-3
to drive treatment decisions has been estimated by the authors of this report to be < £170 per additional
person in remission compared with strategies of MMP-3-driven treatment or DAS28-driven treatment alone
or routine care; in the TEAR58–60 study, the additional costs of immediate ETN, or the use of ETN before triple
therapy, would not be justified by any clinical gain; whereas in the BeSt trial,26–34,42,64,65,68 the additional
costs of initial combination therapy with IFX has not been shown to produce health benefits above initial
combination therapy with PDN despite the markedly higher costs; in the CareRA trial,38,42,43 for high-risk
(presumably of progression) patients, efficacy was similar across the three arms but there were significantly
fewer AEs in the COBRA Slim arm; and in Bijlsma et al.,62 although TOC produced a statistically significantly
higher percentage of people who achieved sustained remission, it would likely be associated with markedly
higher costs than MTX and it is believed that the cost per QALY of using bDMARDs prior to treatment with
intensive cDMARDs would have a cost per QALY greater than those published by NICE.92
There were too few studies in established RA to discern a pattern regarding cost-effectiveness: in two
studies it was believed that a clear conclusion on cost-effectiveness could be made,9,50 and in one no clear
conclusion could be drawn.52,53
As previously stated, the regimens used within the studies were too heterogeneous to draw conclusions
that compared all of the tested strategies simultaneously. Furthermore, it is unclear how routine care has
changed over time and setting; for example, recent data97 have shown that the intensity of cDMARD




Number of participants 144 104 –
Change in DAS28 –0.69 –0.66 0.7
Good EULAR response (%) 21.5 18.3 NR
Moderate EULAR response (%) 22.9 26.9 NR
No EULAR response (%) 55.6 54.8 NR
NR, not reported.
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treatment has increased since the publication of results from the TICORA trial,61 which indicated that an
intensive approach was both more beneficial for patients and saved money. However, there appears to be a
pattern that treating intensively with cDMARDs was likely to be more cost-effective than treating with
routine practice: the extent and degree to which this result was attributable to treating to a specific target is
uncertain. A further pattern was that treating with bDMARDs prior to intensive treatment with cDMARDs
would not produce sufficient benefit to justify the additional costs, given published NICE thresholds.92 Of
course, caution in the interpretation of these results is required because of the fact that cost estimates for
some papers had to be undertaken on the basis of very limited data and outcomes could not always be
expressed in standard metrics.
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Chapter 5 Assessment of factors relevant to the
NHS and other parties
For people with newly diagnosed RA, NICE clinical guideline number 79,4 published in 2009, recommendsa combination of cDMARDs (including MTX and at least one other DMARD plus short-term GCs) as
first-line treatment, ideally beginning within 3 months of the onset of persistent symptoms. In early disease,
this element of more intensive treatment of patients is often part of TTT strategies that have been tested in
clinical studies. It is therefore the case that some elements of TTT are likely to be already in widespread NHS
practice. It is not clear the extent to which other elements of TTT (the setting of explicit treatment goals and
more frequent assessments of patients) are practised in the NHS or if such approaches are consistently
followed in all areas of the UK.
Treat to target is typically more resource intensive during the early management of disease, until LDA or
remission is achieved. There is a requirement for more frequent assessments and monitoring. Therefore, if
there was a more widespread adoption of this form of TTT than is currently the case, this may place
demands on rheumatology services.
It is also feasible that some patients whose disease progresses rapidly will be identified earlier via TTT
management approaches and move to bDMARD therapies more rapidly than would otherwise be the case.
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Statement of principal findings
Treat to target refers not to a single concept, but to a spectrum of broad approaches to the treatment of
patients. TTT requires, at a minimum, the specification of a treatment objective. However, TTT commonly
combines the specifying of a patient target with more frequent assessment of the target and adjustments
to treatments by the clinician in response to those assessments. Those treatment adjustments can be
entirely at the discretion of the clinician or may be protocolised. Clinical studies included in this report
exhibit marked heterogeneity in each of the aforementioned aspects of TTT. Studies also differ in terms
of the patient populations they examine, with the distinction between early and established disease being
particularly important. Owing to these differences, it was not possible to quantitatively synthesise evidence
across the studies and the number of studies where valid comparisons can be made, even qualitatively,
is reduced.
Compared with usual care, there is no clear evidence either in favour of, or against, the clinical effectiveness
of a TTT approach, in terms of the proportion of patients meeting the target, attaining LDA and attaining
remission. In early RA, two studies found evidence in favour of the TTT approach. TTT was more effective
in terms of the proportion of patients meeting the target and attaining remission. The T-4 study56,57 found
usual care to be more effective than the MMP-3-targeted arm, but the combined DAS28 of < 2.6- and
MMP-3-targeted arm to be more effective than usual care [OR 0.21 (95% CI 0.10 to 0.47) at 1 year in the
T-4 study56,57], in terms of the proportion of patients attaining remission. In trials with an established RA
population, there was evidence in favour of a TTT approach compared with usual care in the Fransen et al.
trial50 in terms of the proportion of patients meeting the target or attaining LDA, but no difference between
TTT and usual care in the Optimisation of Adalimumab study52 in terms of the proportion of patients
meeting the target or attaining LDA or remission. The TICORA trial61 demonstrated evidence in favour of a
TTT approach in a population containing both early and established RA patients in terms of the proportion
of patients attaining remission.
The evidence is also mixed when comparing TTT to usual care in terms of other outcomes (DAS44
response, SJC, TJC, EULAR response, HAQ, erosions and quality of life). In early RA, there were mixed
findings for DAS28/DAS4455,57 and joint erosion,55,57 and no difference between TTT arms and usual care
on HAQ score.55,57 In established RA, there was evidence in favour of in terms of EULAR response in the
Optimisation of Adalimumab study.52 There was, however, no difference between TTT and usual care in
terms of DAS28,50,52 SJC,52 TJC52 or HAQ response. In a mixed population, a TTT approach was favoured
compared with usual care in terms of ACR 20/50/70 response in the TICORA61 trial. The evidence,
however, was equivocal for DAS28/DAS44 score,61,63 SJC,61,63 TJC,61,63 EULAR response,61,63 HAQ
response,61,63 joint erosion61 and quality of life.61
Few differences in outcomes were found in relation to different targets within TTT strategies. Only the T-4
study56,57 (early RA) found differences between targets: the DAS28 of < 2.6 target was more effective than
the MMP-3 target, and the combined DAS28 of < 2.6 and MMP-3 target was more effective than both
the DAS28 of < 2.6 target and the MMP-3 target, in terms of the proportion of patients in remission.
Among trials examining an early RA population, there was no difference in the clinical effectiveness of
different targets on DAS28/DAS44,51,57,58 TJC,51,58 EULAR response51 and HAQ score response.51,57,58
Findings relating to SJC,51,58 ACR 20/50/70 response58 and joint erosion57,58 were equivocal. In established
RA populations, there is evidence in favour of TTT, using a LDA target (DAS28 of ≤ 3.2),50 but evidence is
mixed with regard to remission (DAS28 of < 2.6) and SJC (SJC of 0) targets.52 For other outcomes, only
the Optimisation of Adalimumab study52 demonstrated the benefit of a DAS28 of < 2.6 target over a SJC
of 0 target. Both trials examining populations containing both early and established RA patients (i.e. the
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TICORA trial61 and van Hulst et al.63) examined a LDA target (DAS44 of ≤ 2.461 or DAS28 of ≤ 3.263), and
demonstrated evidence in favour of a TTT approach on most outcomes, with ambiguous evidence on some
clinical outcomes. It is also important to note that all trials comparing different targets were rated as being
at high risk of bias.
Only a small number of studies report data on AEs. Among trials examining an early RA population, there
was no difference in the proportion of patients experiencing any AE, SAE, death, withdrawals as a result of
AEs or specific AEs, although more events were experienced in the TTT arm compared with the usual-care
arm in the STREAM trial.55 Among trials examining established RA populations, a smaller proportion of
patients withdrew as a result of AEs52 and experienced specific AEs (dermatological and gastrointestinal
AEs50) in the TTT arm, compared with usual care. The only trial reporting on these outcomes in a
population containing both early and established RA patients, the TICORA trial,61 which was also the only
trial examining TTT compared with usual care rated as being at a low risk of bias, reported that a smaller
proportion of patients reported any AE and specific AEs (dermatological, gastrointestinal and infectious
AEs, significance not reported) in the TTT arm than in the usual-care arm. Overall, comparing trials by
target on AEs, there is no clear evidence in favour of any target being more or less safe, compared with
usual care.
Overall, we consider that the evidence for TTT is mixed but, in early RA, there does seem to be some
limited support for TTT, in general, on some clinical outcomes. This is particularly true if the TICORA trial
results, which was the only study in the review considered at low risk of bias, are interpreted as providing
evidence relevant to the early RA population. The inclusion criterion for the TICORA trial was that patients
had to have a disease duration of < 5 years.
There is also evidence to suggest that, in early RA, the components of care that together constitute TTT
are likely to form a cost-effective approach. Conclusions relating to cost-effectiveness could be drawn for
10 studies, and for the high-risk patient subgroup in the CareRA trial. Almost all of the estimates from
these studies indicated that TTT would be considered cost-effective other than when the TTT strategy
included the use of bDMARDs in early disease. No conclusions could be made in relation to TTT in
established disease.
Patient and public involvement representatives stated that if a TTT strategy were to be implemented, it
would be beneficial that the patient was explicitly informed of this and made aware of the planned
escalation of medication and the proposed target.
Strengths and limitations of the assessment
The current systematic review is the most comprehensive review to date to examine the clinical
effectiveness of TTT. We have synthesised findings on TTT compared with usual care and a comparison of
different targets. However, TTT is a broad term covering a spectrum of different treatment strategies.
Clinical studies test TTT strategies that are heterogeneous. It was not felt justified to pool these strategies
and make comparisons based on a synthesis of the evidence base.
Synthesis of different treatment protocols was precluded (even in terms of a narrative synthesis) by
heterogeneity and lack of comparability between treatment protocols, although we have provided a
comprehensive summary of the findings of trials that compare different treatment protocols. The current
review is also the only systematic review to examine findings by population, which is important in this
context as the recommendations for TTT differ slightly for early and established RA patients, as the
treatment prognosis and implications of TTT may be different in these populations.17,18 Another strength of
the current review is the focus on RCTs, which reduces the impact of selection bias on the review findings.
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A further strength of the work undertaken is in assessing the likely cost-effectiveness implications of
each study identified in the clinical review. These results, which help inform the conclusions on the
cost-effectiveness of TTT, also serve as a source of information for fellow researchers.
The main limitation of the current review is the small number of trials within in each comparison, in each
population group. There was much heterogeneity in terms of targets, treatment protocols and frequency
of contact between trials, even within each population group, in each comparison. Risk of bias was rated
as being high in the majority of included trials.
The heterogeneity in identified studies, inter alia, placed additional constraints on the cost-effectiveness
analysis. We adopted a pragmatic approach to estimate costs and outcomes from data reported alongside
each clinical study. The required assumptions to optimise the use of limited resource use data and often
also required the expression of outcomes in non-standard terms.
Uncertainties
It is unclear from the current review if there are specific elements of TTT that drive clinical effectiveness
and cost-effectiveness, as TTT strategies tested in the identified clinical studies are varied and variously
include the formal assessment of patients, clear protocols for drug treatment changes in response to
patient assessments and more frequent assessment of patients. Existing NICE guidelines, based on
systematic review of the literature, already recommend combination non-biologic drug treatment in
early disease. This review is unable to establish if the adding in of other elements of TTT represents a
cost-effective approach to care.
There is more limited evidence relating to TTT as a concept in established disease.
DOI: 10.3310/hta21710 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 71
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Wailoo et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science




Implications for service provision
For people with newly diagnosed RA, NICE Clinical Guideline 794 recommends a combination of cDMARDs
(including MTX and at least one other DMARD plus short-term GCs) as first-line treatment. For patients with
early disease, this element of more intensive treatment for patients is often part of TTT strategies that have
been tested in clinical studies. Furthermore, it is likely that rheumatologists would monitor patients more
frequently if treating with a more intense drug strategy. It is therefore likely that many rheumatologists, if
compliant with NICE guidance, would experience little impact on their services were they to switch to a
formal TTT strategy. It is also likely that many are already providing TTT in some form.
It is likely that more widespread adoption of TTT principles, particularly those TTT approaches that combine
a treatment target with intensive drug protocols and frequent assessment of patients, would require more
intense management of patients with early disease during their initial treatment period. It is also feasible
that some patients whose disease progresses rapidly will be identified earlier via TTT management
approaches, and move to bDMARD therapies more rapidly than would otherwise be the case.
Suggested research priorities
We highlight substantial uncertainty in the evidence base for TTT in RA. In part, this stems from the
relatively low quality of the clinical trials identified. Only one study, the TICORA trial,61 was rated as having
a low risk of bias. However, there is also significant uncertainty that stems from the fact that TTT describes
a broad concept, used to describe a spectrum of ways to treat patients, rather than a clearly defined,
individual technology. Clinical studies reflect this and exhibit a wide degree of heterogeneity in the types
of TTT they seek to examine. This results in a series of studies that cannot feasibly be pooled quantitatively,
diminishing the strength of any conclusions. This heterogeneity also means that it is difficult to disentangle
the effect of different elements of TTT strategies: the target itself, whether or not there is a treatment
protocol to be followed in the light of assessment of the target and the frequency of patient assessment.
The design of any future clinical trials needs to be carefully assessed to ensure that aspects of these
uncertainties will be resolved by the data they generate. If such research is to be conducted, there should
be a focus on well-conducted trials comparing TTT with usual care and/or different TTT targets, which are
adequately blinded (in terms of participants, study personnel and outcome assessment), with low rates of
attrition and adequate allocation concealment, reporting on the proportion of patients meeting the target
and being in remission. It is imperative that the design of such trials is mindful of the contribution results
may make to the overall body of existing evidence on the subject. This requires comparability between
trials. For example, remission, defined in a consistent manner, should be the target of choice for future
studies. This extends to considerations of cost-effectiveness. As well as conducting cost-effectiveness
analyses alongside the trial, methods for ensuring long-term extensions studies, that allow some of the key
uncertainties in this area to be addressed, are critical (e.g. the rate at which patients move to bDMARD
therapies in the long term).
Patient and public involvement representatives stated that future research into the fatigue that is associated
with RA would be beneficial, as it was not only swollen joints and pain that were of concern to the patient.
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Appendix 1 Cost-effectiveness review: Preferred




Records excluded at full-text stage
(n = 131)
Records excluded at title and
abstract stage
(n = 1098)
Records screened at full text
(n = 133)
Records identified through database
searching
(n = 1231)
Records screened by title and abstract
(n = 1231)
DOI: 10.3310/hta21710 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 71
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Wailoo et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
163

Appendix 2 Literature search strategies
Phase I search strategies
MEDLINE(R) In-Process & Other Non-Indexed Citations and MEDLINE(R)
Date searched: 19 May 2015.
Search strategy




5. (strateg$ or aim$ or goal$ or target$ or tight$ or aggressiv$ or intens$ or control$).ti.
6. ((strateg$ or aim$ or goal$ or target$ or tight$ or aggressiv$ or control$) adj2 (treat$ or therap$)).mp.
7. (optim$ or switch$ or add$ or chang$ or expand$ or step$ or combin$ or intensif$ or escalat$).ti.
8. (adapt$ or titrat$ or adjust$ or response-based).tw.





14. 10 or 11 or 12 or 13
15. 9 and 14
16. ((strateg$ or proced$ or consequ$ or therap$ or halt$ or stop$ or revers$ or dela$ or arrest$ or detain$ or slow$
or preven$ or retard$ or avoid$) adj3 (structural or functional or erosi$ or progre$ or disabilit$ or invalidity or
impediment or disablement or radiograph$ or radiolog$)).mp.
17. (remission adj3 (strateg$ or optimi$ or adapt$ or control$ or frequency or dose$ or dosing)).mp.
18. (((low$ or moderate or medium or high) and activity) adj3 (strateg$ or optimi$ or adapt$ or control$ or frequency
or dose$ or dosing)).mp.
19. 4 or 5 or 6 or 15 or 16 or 17 or 18
20. 3 and 19
21. randomized controlled trial.pt.
22. randomized controlled trial.mp.
23. 21 or 22
24. 20 and 23





30. 20 and 29
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31. limit 30 to yr=‘2008 -Current’
32. ec.fs.
33. cost.tw.
34. health care costs.sh.
35. or/32-34
36. 20 and 35
37. limit 36 to yr=‘2013 -Current’
EMBASE
Date searched: 19 May 2015.
Search strategy
1. exp rheumatoid arthritis
2. rheumatoid arthritis.tw.
3. 1 or 2
4. remission/
5. (strateg$ or aim$ or goal$ or target$ or tight$ or aggressiv$ or intens$ or control$).ti.
6. ((strateg$ or aim$ or goal$ or target$ or tight$ or aggressiv$ or control$) adj2 (treat$ or therap$)).tw.
7. (optim$ or switch$ or add$ or chang$ or expand$ or step$ or combin$ or intensif$ or escalat$).ti.
8. (adapt$ or titrat$ or adjust$ or response-based).tw.






15. 9 and 14
16. ((strateg$ or proced$ or consequ$ or therap$ or halt$ or stop$ or revers$ or dela$ or arrest$ or detain$ or slow$
or preven$ or retard$ or avoid$) adj3 (structural or functional or erosi$ or progre$ or disabilit$ or invalidity or
impediment or disablement or radiograph$ or radiolog$)).tw.
17. (remission adj3 (strateg$ or optimi$ or adapt$ or control$ or frequency or dose$ or dosing)).tw.
18. (((low$ or moderate or medium or high) and activity) adj3 (strateg$ or optimi$ or adapt$ or control$ or frequency
or dose$ or dosing)).tw.
19. 4 or 5 or 6 or 15 or 16 or 17 or 18





25. 20 and 24
26. limit 25 to yr=‘2008 -Current’
APPENDIX 2




29. 27 or 28
30. 20 and 29
31. limit 30 to yr=‘2008 -Current’
32. cost.tw.
33. costs.tw.
34. 32 or 33
35. 20 and 34
36. limit 35 to yr=‘2013 -Current’
Cochrane Database of Systematic Reviews; Cochrane Central Register of Controlled
Trials; Health Technology Assessment Database; Database of Abstracts of Reviews of
Effects; and NHS Economic Evaluation Database
Date searched:19 May 2015.
Search strategy
#1 MeSH descriptor: [Arthritis, Rheumatoid] explode all trees
#2 rheumatoid arthritis:ti,ab,kw
#3 #1 or #2
#4 MeSH descriptor: [Remission Induction] explode all trees
#5 (strateg* or aim* or goal* or target* or tight* or aggressiv* or intens* or control*):ti,ab,kw
#6 ((strateg* or aim* or goal* or target* or tight* or aggressiv* or control*) next/2 (treat* or therap*)):ti,ab,kw
#7 (optim* or switch* or add* or chang* or expand* or step* or combin* or intensif* or escalat*):ti,ab,kw
#8 (adapt* or titrat* or adjust* or response-based):ti,ab,kw
#9 #7 or #8
#10 MeSH descriptor: [Disease Progression] this term only
#11 MeSH descriptor: [Disease Management] this term only
#12 MeSH descriptor: [Disease Outbreaks] this term only
#13 MeSH descriptor: [Disease] explode all trees
#14 #10 or #11 or #12 or #13
#15 #9 and #14
#16 ((strateg* or proced* or consequ* or therap* or halt* or stop* or revers* or dela* or arrest* or detain* or slow*
or preven* or retard* or avoid*) next/3 (structural or functional or erosi* or progre* or disabilit* or invalidity or
impediment or disablement or radiograph* or radiolog*)):ti,ab,kw
#17 (remission next/3 (strateg* or optimi* or adapt* or control* or frequency or dose* or dosing)):ti,ab,kw
#18 (((low* or moderate or medium or high) and activity) next/3 (strateg* or optimi* or adapt* or control* or frequency
or dose* or dosing)):ti,ab,kw
#19 #4 or #5 or #6 or #15 or #16 or #17 or #18
#20 #3 and #19
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Web of Science Citation Index Expanded and Web of Science Citation Index and
Conference Proceedings Index
Date searched: 19 May 2015.
Search strategy
# 19 #18 AND #13
Indexes=SCI-EXPANDED,
CPCI-S Timespan=2013-2015
# 18 TOPIC: ((cost* and (effective* or utilit* or benefit* or minimi*))) OR TITLE: (costs) OR TOPIC:
(((economic* or pharmacoeconomic* or pharmaco-economic*))) OR TITLE: (economic*)
# 17 #16 AND #13
# 16 TS=((meta-analysis or meta analy* or metaanaly*)) OR TS=(systematic review*)
# 15 #14 AND #13
# 14 TS=(randomi* controlled trial*) OR TS=(placebo*)
# 13 #12 AND #1
# 12 #11 OR #10 OR #9 OR #8 OR #3 OR #2
# 11 TS=(((low* or moderate or medium or high) and activity)) AND TS=((strateg* or optimi*
or adapt* or control* or frequency or dose* or dosing))
# 10 TS=(((remission NEAR/3 (strateg* or optimi* or adapt* or control* or frequency or dose*
or dosing))))
# 9 TS=(((strateg* or proced* or consequ* or therap* or halt* or stop* or revers* or dela*
or arrest* or detain* or slow* or preven* or retard* or avoid*) NEAR/3 (structural or
functional or erosi* or progre* or disabilit* or invalidity or impediment or disablement or
radiograph* or radiolog*)))
# 8 #7 AND #6
# 7 TOPIC: (disease)
# 6 #5 OR #4
# 5 TOPIC: ((adapt* or titrat* or adjust* or response-based))
# 4 TITLE: ((optim* or switch* or add* or chang* or expand* or step* or combin* or
intensif* or escalat*))
# 3 TS=(((strateg* or aim* or goal* or target* or tight* or aggressiv* or control*) NEAR/2
(treat* or therap*)))
# 2 TITLE: ((strateg* or aim* or goal* or target* or tight* or aggressiv* or intens* or control*))
# 1 TOPIC: (rheumatoid arthritis*)
ClinicalTrials.gov: US National Institutes of Health
URL: http://clinicaltrials.gov/.
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European League Against Rheumatism Abstract Archive; published in the Annals of the
Rheumatic Diseases and searched via the Web of Science
URL: www.abstracts2view.com/eular/sessionindex.php
Date searched: 21 May 2015.
Search strategy
# 15 #14 AND #13
Indexes=SCI-EXPANDED, CPCI-S Timespan=2008-2015
# 14 PUBLICATION NAME: (ann rheum dis)
# 13 #12 AND #1
# 12 #11 OR #10 OR #9 OR #8 OR #3 OR #2
# 11 TS=(((low* or moderate or medium or high) and activity)) AND TS=((strateg* or optimi* or adapt* or control* or
frequency or dose* or dosing))
# 10 TS=(((remission NEAR/3 (strateg* or optimi* or adapt* or control* or frequency or dose* or dosing))))
# 9 TS=(((strateg* or proced* or consequ* or therap* or halt* or stop* or revers* or dela* or arrest* or detain* or
slow* or preven* or retard* or avoid*) NEAR/3 (structural or functional or erosi* or progre* or disabilit* or
invalidity or impediment or disablement or radiograph* or radiolog*)))
# 8 #7 AND #6
# 7 TOPIC: (disease)
# 6 #5 OR #4
# 5 TOPIC: ((adapt* or titrat* or adjust* or response-based))
# 4 TITLE: ((optim* or switch* or add* or chang* or expand* or step* or combin* or intensif* or escalat*))
# 3 TS=(((strateg* or aim* or goal* or target* or tight* or aggressiv* or control*) NEAR/2 (treat* or therap*)))
# 2 TITLE: ((strateg* or aim* or goal* or target* or tight* or aggressiv* or intens* or control*))
# 1 TOPIC: (rheumatoid arthritis*)
American College of Rheumatology and Association of Rheumatology Health
Professionals; published in Arthritis and Rheumatology and searched via the Web
of Science
URL: http://acrabstracts.org/
Date searched: 21 May 2015.
Search strategy
# 15 #14 AND #13
Indexes=SCI-EXPANDED, CPCI-S Timespan=2008-2015
# 14 SO=(ARTHRITIS ‘AND’ RHEUMATISM)
# 13 #12 AND #1
# 12 #11 OR #10 OR #9 OR #8 OR #3 OR #2
# 11 TS=(((low* or moderate or medium or high) and activity)) AND TS=((strateg* or optimi* or adapt* or control* or
frequency or dose* or dosing))
# 10 TS=(((remission NEAR/3 (strateg* or optimi* or adapt* or control* or frequency or dose* or dosing))))
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# 9 TS=(((strateg* or proced* or consequ* or therap* or halt* or stop* or revers* or dela* or arrest* or detain* or
slow* or preven* or retard* or avoid*) NEAR/3 (structural or functional or erosi* or progre* or disabilit* or
invalidity or impediment or disablement or radiograph* or radiolog*)))
# 8 #7 AND #6
# 7 TOPIC: (disease)
# 6 #5 OR #4
# 5 TOPIC: ((adapt* or titrat* or adjust* or response-based))
# 4 TITLE: ((optim* or switch* or add* or chang* or expand* or step* or combin* or intensif* or escalat*))
# 3 TS=(((strateg* or aim* or goal* or target* or tight* or aggressiv* or control*) NEAR/2 (treat* or therap*)))
# 2 TITLE: ((strateg* or aim* or goal* or target* or tight* or aggressiv* or intens* or control*))
# 1 TOPIC: (rheumatoid arthritis*)
Phase II randomised controlled trials search strategies
MEDLINE(R) In-Process & Other Non-Indexed Citations and MEDLINE(R)
Date searched: 8 January 2016.
Search strategy




5 (remission adj2 induc$).ti,ab.
6 (strateg$ or aim$ or goal$ or target$ or tight$ or aggressiv$ or intens$ or control$ or optim$ or adapt$ or switch$
or add$ or chang$ or expand$ or step$ or combin$ or intensif$ or escalat$).ti.
7 ((strateg$ or aim$ or goal$ or target$ or tight$ or aggressiv$ or control$) adj2 (treat$ or therap$)).tw.
8 (ttt or t2t).tw.
9 (treat$ and target$).ti.
10 ((disease activity score or das28) adj3 (driven or step$ or strateg$ or therap$ or treat$)).tw.
11 (optim$ or switch$ or add$ or chang$ or expand$ or step$ or combin$ or intensif$ or escalat$).ti.







19 13 and 18
20 ((strateg$ or proced$ or consequ$ or therap$ or halt$ or stop$ or revers$ or dela$ or arrest$ or detain$ or slow$
or preven$ or retard$ or avoid$) adj3 (structural or functional or erosi$ or progre$ or disabilit$ or invalidity or
impediment or disablement or radiograph$ or radiolog$)).tw.
21 ((remission or activ$) adj3 (strateg$ or optimi$ or adapt$ or control$ or frequency or dose$ or dosing)).tw.
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22 (((low$ or moderate or medium or high) and activity) adj3 (strateg$ or optimi$ or adapt$ or control$ or frequency
or dose$ or dosing)).tw.
23 4 or 5 or 6 or 7 or 8 or 9 or 10 or 19 or 20 or 21 or 22
24 3 and 23
25 Randomized controlled trials/
26 Randomized controlled trial.pt.
27 Controlled clinical trial.pt.
28 Random Allocation/
29 Double blind method/
30 Single Blind Method/
31 Clinical trial.pt.
32 exp Clinical Trial/
33 (clin$ adj25 trial$).ti,ab.













47 45 not (45 and 46)
48 or/40-44,47
49 39 not 48
EMBASE
Date searched: 8 January 2016.
Search strategy




5 (remission adj2 induc$).ti,ab.
6 (strateg$ or aim$ or goal$ or target$ or tight$ or aggressiv$ or intens$ or control$ or optim$ or adapt$ or switch$
or add$ or chang$ or expand$ or step$ or combin$ or intensif$ or escalat$).ti.
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7 ((strateg$ or aim$ or goal$ or target$ or tight$ or aggressiv$ or control$) adj2 (treat$ or therap$)).tw.
8 (treat$ and target$).ti.
9 ((disease activity score or das28) adj3 (driven or step$ or strateg$ or therap$ or treat$)).tw.
10 (optim$ or switch$ or add$ or chang$ or expand$ or step$ or combin$ or intensif$ or escalat$).ti.
11 (adapt$ or titrat$ or adjust$ or response-based).tw.






18 12 and 17
19 ((strateg$ or proced$ or consequ$ or therap$ or halt$ or stop$ or revers$ or dela$ or arrest$ or detain$ or slow$
or preven$ or retard$ or avoid$) adj3 (structural or functional or erosi$ or progre$ or disabilit$ or invalidity or
impediment or disablement or radiograph$ or radiolog$)).tw.
20 ((remission or activ$) adj3 (strateg$ or optimi$ or adapt$ or control$ or frequency or dose$ or dosing)).tw.
21 4 or 5 or 6 or 7 or 8 or 9 or 18 or 19 or 20
22 3 and 21
23 Randomized controlled trial/
24 clinical trial/
25 Randomization/
26 Single blind procedure/
27 Double blind procedure/
28 Crossover procedure/
29 Placebo/
30 randomi?ed controlled trial$.tw.
31 (clin$ adj25 trial$).ti,ab.











43 41 not (41 and 42)
44 37 or 38 or 39 or 40 or 43
45 36 not 44
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Cochrane Central Register of Controlled Trials
Date searched: 14 January 2016.
Search strategy
#1 MeSH descriptor: [Arthritis, Rheumatoid] explode all trees
#2 rheumatoid arthritis:ti,ab,kw
#3 #1 OR #2
#4 MeSH descriptor: [Remission Induction] explode all trees
#5 (remission next/2 induc*):ti,ab,kw
#6 (strateg* or aim* or goal* or target* or tight* or aggressiv* or intens* or control* or optim* or adapt* or
switch* or add* or chang* or expand* or step* or combin* or intensif* or escalat*):ti
#7 (strateg* or aim* or goal* or target* or tight* or aggressiv* or control*) next/2 (treat* or therap*):ti,ab,kw
#8 (ttt or t2t):ti,ab,kw
#9 (treat* and target*):ti
#10 ((disease activity score or das28) near/3 (driven or step* or strateg* or therap* or treat*)):ti,ab,kw
#11 (optim* or switch* or add* or chang* or expand* or step* or combin* or intensif* or escalat*):ti
#12 (adapt* or titrat* or adjust* or response-based):ti,ab,kw
#13 #11 or #12
#14 MeSH descriptor: [Disease Progression] this term only
#15 MeSH descriptor: [Disease Management] this term only
#16 MeSH descriptor: [Disease Outbreaks] this term only
#17 MeSH descriptor: [Disease] this term only
#18 #14 or #15 or #16 or #17
#19 #13 and #18
#20 (strateg* or proced* or consequ* or therap* or halt* or stop* or revers* or dela* or arrest* or detain* or slow*
or preven* or retard* or avoid*) n3 (structural or functional or erosi* or progre* or disabilit* or invalidity or
impediment or disablement or radiograph* or radiolog*):ti,ab,kw
#21 ((remission or activ*) near/3 (strateg* or optimi* or adapt* or control* or frequency or dose* or dosing)):ti,ab,kw
#22 (((low* or moderate or medium or high) and activity) near/3 (strateg* or optimi* or adapt* or control* or
frequency or dose* or dosing)):ti,ab,kw
#23 #4 or #5 or #6 or #7 or #8 or #9 or #10 or #19 or #20 or #21 or #22
#24 #3 and #23
Web of Science Citation Index Expanded and Web of Science Citation Index and
Conference Proceedings Index
Date searched: 26 January 2016.
Search strategy
S1 TOPIC=(Rheumatoid arthritis)
S2 TOPIC=(remission near/2 induc*)
S3 TITLE=(strateg* or aim* or goal* or target* or tight* or aggressiv* or intens* or control* or optim* or adapt* or
switch* or add* or chang* or expand* or step* or combin* or intensif* or escalat*)
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S4 TS=((strateg* or aim* or goal* or target* or tight* or aggressiv* or intens* or control*) near/2 (treat* or therap*))
S5 TOPIC=(ttt or t2t)
S6 TITLE=(treat* and target)
S7 TOPIC=(‘disease activity score’ or das28)
S8 TI=(optim* or switch* or add* or chang* or expand* or step* or combin* or intensif* or escalat*)
S9 TOPIC=(adapt* or titrat* or adjust* or response-based)





S15 S14 OR S13 OR S12 OR S11
S16 S15 AND S10
S17 TOPIC=((strateg* or proced* or consequ* or therap* or halt* or stop* or revers* or dela* or arrest* or detain*
or slow* or preven* or retard* or avoid*) near/3 (structural or functional or erosi* or progre* or disabilit* or
invalidity or impediment or disablement or radiograph* or radiolog*))
S18 TOPIC=((remission or activ*) near/3 (strateg* or optimi* or adapt* or control* or frequency or dose* or dosing))
S19 TOPIC=((low* or moderate or medium or high) and (activity) near/3 (strateg* or optimi* or adapt* or control* or
frequency or dose* or dosing))
S20 S19 OR S18 OR S17 OR S16 OR S7 OR S6 OR S5 OR S4 OR S3 or S2
S21 S20 AND S1
S22 TOPIC=(randomi?ed controlled trial)
S23 TOPIC=(rct)
S24 TOPIC=(random allocation)
S25 TOPIC=(allocated near/2 random*)
S26 TOPIC=single blind*
S27 TOPIC=(double blind*)
S28 TOPIC=((treble or triple) near/1 (blind*))
S29 TOPIC=(placebo*)
S30 S29 OR S28 OR S27 OR S26 OR S25 OR S24 OR S23 OR S22
S31 S30 AND S21
Bioscience Information Service Previews
Date searched: 14 January 2016.
Search strategy
S1 TOPIC=Rheumatoid arthritis
S2 TOPC=(remission near/2 induc*)
S3 TITLE=(strateg* or aim* or goal* or target* or tight* or aggressiv* or intens* or control* or optim* or adapt* or
switch* or add* or chang* or expand* or step* or combin* or intensif* or escalat*)
S4 TOPIC=((strateg* or aim* or goal* or target* or tight* or aggressiv* or intens* or control*) near/2 (treat* or therap*))
S5 TOPIC=(ttt or t2t)
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S6 TITLE=(treat* and target)
S7 TOPIC=(‘disease activity score’ or das28)
S8 TITLE=(optim* or switch* or add* or chang* or expand* or step* or combin* or intensif* or escalat*)
S9 TOPIC=(adapt* or titrat* or adjust* or response-based)





S15 #14 OR #13 OR #12 OR #11
S16 #15 AND #10
S17 TOPIC=((strateg* or proced* or consequ* or therap* or halt* or stop* or revers* or dela* or arrest* or detain*
or slow* or preven* or retard* or avoid*) near/3 (structural or functional or erosi* or progre* or disabilit* or
invalidity or impediment or disablement or radiograph* or radiolog*))
S18 TOPIC=((remission or activ*) near/3 (strateg* or optimi* or adapt* or control* or frequency or dose* or dosing))
S19 TOPIC=((low* or moderate or medium or high) and (activity) near/3 (strateg* or optimi* or adapt* or control* or
frequency or dose* or dosing))
S20 #19 OR #18 OR #17 OR #16 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2
S21 #20 AND #1
S22 TOPIC=(randomi?ed controlled trial
S23 TOPIC=(rct)
S24 TOPIC=(random allocation)
S25 TOPIC=(allocated near/2 random*)
S26 TOPIC=(single blind*)
S27 TOPIC=(double blind*)
S28 TOPIC=((treble or triple) near/1 (blind*))
S29 TOPIC=(placebo*)
S30 S29 OR S28 OR S27 OR S26 OR S25 OR S24 OR S23 OR S22
S31 S30 AND S21
Cumulative Index to Nursing and Allied Health Literature
Date searched: 13 January 2016.
Search strategy
S1 (Mesh Heading ‘Arthritis, Rheumatoid+’)
S2 TX rheumatoid arthritis
S3 (S1 OR S2)
S4 TI (remission n2 induc*) or AB (remission n2 induc*)
S5 TI (strateg* or aim* or goal* or target* or tight* or aggressiv* or intens* or control* or optim* or adapt* or
switch* or add* or chang* or expand* or step* or combin* or intensif* or escalat*)
S6 TX (strateg* or aim* or goal* or target* or tight* or aggressiv* or control*) n2 (treat* or therap*)
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S7 TX (ttt or t2t)
S8 TITLE (treat* and target*)
S9 TX (disease activity score or das28) n3 (driven or step* or strateg* or therap* or treat*)
S10 TITLE (optim* or switch* or add* or chang* or expand* or step* or combin* or intensif* or escalat*)
S11 TX (adapt* or titrat* or adjust* or response-based)
S12 S10 OR S11
S13 (Major concept ‘Disease Progression’)
S14 (Major concept ‘Disease Outbreaks’)
S15 (Mesh Heading ‘Disease’)
S16 S13 OR S14 OR S15
S17 S12 AND S16
S18 TX (strateg* or proced* or consequ* or therap* or halt* or stop* or revers* or dela* or arrest* or detain* or slow*
or preven* or retard* or avoid*) n3 (structural or functional or erosi* or progre* or disabilit* or invalidity or
impediment or disablement or radiograph* or radiolog*)
S19 TX ((remission or activ*) n3 (strateg* or optimi* or adapt* or control* or frequency or dose* or dosing)
S20 TX (((low* or moderate or medium or high) and activity) n3 (strateg* or optimi* or adapt* or control* or frequency
or dose* or dosing))
S21 S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S17 OR S18 OR S19 OR S20
S22 S3 AND S21
S23 (Mesh Heading ‘Randomized Controlled Trials’)
S24 Publication Type Randomized controlled trial
S25 TX clinic* n1 trial*
S26 TX (Singl* n1 blind*) OR TX (singl* n1 mask*) OR TX (doubl* n1 blind*) OR TX (doubl* n1 mask*) OR TX (tripl* n1
blind*) OR TX (tripl* n1 mask*) OR TX (trebl* n1 blind*) OR TX (trebl* n1 mask*)
S27 (Mesh Heading ‘Clinical Trials+’)
S28 Publication Type Clinical trial
S29 TX Randomi* control* trial*
S30 (MeSH heading ‘Random Assignment’)
S31 TX Random* allocat*
S32 TX Placebo*
S33 (MeSH heading ‘Placebos’)
S34 (MeSH heading ‘Quantitative Studies’)
S35 (S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34)
S36 S22 AND S35
S37 Publication Type commentary
S38 Publication Type Letter
S39 Publication Type Editorial
S40 TX Case report
S41 (MH ‘Animals’)
S42 S37 OR S38 OR S39 OR S40 OR S41
S43 S36 NOT S42
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ClinicalTrials.gov: US National Institutes of Health
URL: http://clinicaltrials.gov/
Date searched: 18 January 2016.
Search strategy
Remission induction | rheumatoid arthritis
‘TTT’ | rheumatoid arthritis
International Clinical Trials Registry Platform (URL: www.who.int/ictrp/en/)
Date searched: 18 January 2016.
Search strategy
Remission induction | rheumatoid arthritis
‘TTT’ | rheumatoid arthritis
National Institute for Health and Care Excellence Evidence (URL: www.nice.org.uk/)
Date searched: 18 January 2016.
Search strategy
‘TTT’ filtered by type of information – commissioning guide
‘TTT’ filtered by type of information – ongoing trials
‘Remission induction’ rheumatoid arthritis filtered by type of information – ongoing trials
‘Remission induction’ rheumatoid arthritis filtered by type of information – commissioning guide
Phase II cost-effectiveness search strategies
MEDLINE(R) In-Process & Other Non-Indexed Citations and MEDLINE(R)
Date searched: 14 January 2016.
Search strategy




5 (remission adj2 induc$).ti,ab.
6 (strateg$ or aim$ or goal$ or target$ or tight$ or aggressiv$ or intens$ or control$ or optim$ or adapt$ or switch$
or add$ or chang$ or expand$ or step$ or combin$ or intensif$ or escalat$).ti.
7 ((strateg$ or aim$ or goal$ or target$ or tight$ or aggressiv$ or control$) adj2 (treat$ or therap$)).tw.
8 (ttt or t2t).tw.
9 (treat$ and target$).ti.
10 ((disease activity score or das28) adj3 (driven or step$ or strateg$ or therap$ or treat$)).tw.
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11 (optim$ or switch$ or add$ or chang$ or expand$ or step$ or combin$ or intensif$ or escalat$).ti.







19 13 and 18
20 ((strateg$ or proced$ or consequ$ or therap$ or halt$ or stop$ or revers$ or dela$ or arrest$ or detain$ or slow$
or preven$ or retard$ or avoid$) adj3 (structural or functional or erosi$ or progre$ or disabilit$ or invalidity or
impediment or disablement or radiograph$ or radiolog$)).tw.
21 ((remission or activ$) adj3 (strateg$ or optimi$ or adapt$ or control$ or frequency or dose$ or dosing)).tw.
22 (((low$ or moderate or medium or high) and activity) adj3 (strateg$ or optimi$ or adapt$ or control$ or frequency
or dose$ or dosing)).tw.
23 4 or 5 or 6 or 7 or 8 or 9 or 10 or 19 or 20 or 21 or 22
24 3 and 23
25 Economics/





31 Cost of illness/
32 Cost sharing/
33 “Deductibles and coinsurance”/
34 Health care costs/
35 Direct service costs/
36 Drug costs/




41 Value of life/
42 exp Economics, hospital/
43 exp Economics, medical/
44 Economics, nursing/
45 Economics, pharmaceutical/
46 exp "fees and charges"/
47 exp budgets/
48 (low adj cost).mp.
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49 (high adj cost).mp.
50 (health?care adj cost$).mp.
51 (fiscal or funding or financial or finance).tw.
52 (cost adj estimate$).mp.
53 (cost adj variable).mp.
54 (unit adj cost$).mp.
55 (economic$ or pharmacoeconomic$ or price$ or pricing).tw.
56 exp models, economic/
57 or/25-56








66 64 not (64 and 65)
67 or/59-63,66
68 58 not 67
EMBASE
Date searched: 14 January 2016.
Search strategy




5 (remission adj2 induc$).ti,ab.
6 (strateg$ or aim$ or goal$ or target$ or tight$ or aggressiv$ or intens$ or control$ or optim$ or adapt$ or switch$
or add$ or chang$ or expand$ or step$ or combin$ or intensif$ or escalat$).ti.
7 ((strateg$ or aim$ or goal$ or target$ or tight$ or aggressiv$ or control$) adj2 (treat$ or therap$)).tw.
8 (treat$ and target$).ti.
9 ((disease activity score or das28) adj3 (driven or step$ or strateg$ or therap$ or treat$)).tw.
10 (optim$ or switch$ or add$ or chang$ or expand$ or step$ or combin$ or intensif$ or escalat$).ti.
11 (adapt$ or titrat$ or adjust$ or response-based).tw.
12 10 or 11
13 *disease course/
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18 12 and 17
19 ((strateg$ or proced$ or consequ$ or therap$ or halt$ or stop$ or revers$ or dela$ or arrest$ or detain$ or slow$
or preven$ or retard$ or avoid$) adj3 (structural or functional or erosi$ or progre$ or disabilit$ or invalidity or
impediment or disablement or radiograph$ or radiolog$)).tw.
20 ((remission or activ$) adj3 (strateg$ or optimi$ or adapt$ or control$ or frequency or dose$ or dosing)).tw.
21 4 or 5 or 6 or 7 or 8 or 9 or 18 or 19 or 20
22 3 and 21
23 Socioeconomics/
24 Cost benefit analysis/
25 Cost effectiveness analysis/




30 Health care cost/
31 Health care financing/
32 Health economics/
33 Hospital cost/
34 (fiscal or financial or finance or funding).tw.
35 cost minimization analysis/
36 (cost adj estimate$).mp.
37 (cost adj variable$).mp.
38 (unit adj cost$).mp.
39 or/23-38





45 43 not (43 and 44)
46 or/41-42,45
47 40 not 46
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NHS Economic Evaluation Database
Date searched: 14 January 2016.
Search strategy
#1 MeSH descriptor: [Arthritis, Rheumatoid] explode all trees
#2 rheumatoid arthritis:ti,ab,kw
#3 #1 OR #2
#4 MeSH descriptor: [Remission Induction] explode all trees
#5 (remission next/2 induc*):ti,ab,kw
#6 (strateg* or aim* or goal* or target* or tight* or aggressiv* or intens* or control* or optim* or adapt* or
switch* or add* or chang* or expand* or step* or combin* or intensif* or escalat*):ti
#7 (strateg* or aim* or goal* or target* or tight* or aggressiv* or control*) next/2 (treat* or therap*):ti,ab,kw
#8 (ttt or t2t):ti,ab,kw
#9 (treat* and target*):ti
#10 ((disease activity score or das28) near/3 (driven or step* or strateg* or therap* or treat*)):ti,ab,kw
#11 (optim* or switch* or add* or chang* or expand* or step* or combin* or intensif* or escalat*):ti
#12 (adapt* or titrat* or adjust* or response-based):ti,ab,kw
#13 #11 or #12
#14 MeSH descriptor: [Disease Progression] this term only
#15 MeSH descriptor: [Disease Management] this term only
#16 MeSH descriptor: [Disease Outbreaks] this term only
#17 MeSH descriptor: [Disease] this term only
#18 #14 or #15 or #16 or #17
Cumulative Index to Nursing and Allied Health Literature
Date searched: 14 January 2016.
Search strategy
S1 (MeSH Heading “Arthritis, Rheumatoid+”)
S2 TX rheumatoid arthritis
S3 (S1 OR S2)
S4 TI (remission n2 induc*) OR AB (remission n2 induc*)
S5 TITLE (strateg* or aim* or goal* or target* or tight* or aggressiv* or intens* or control* or optim* or adapt* or
switch* or add* or chang* or expand* or step* or combin* or intensif* or escalat*)
S6 TX (strateg* or aim* or goal* or target* or tight* or aggressiv* or control*) n2 (treat* or therap*)
S7 TX (ttt or t2t)
S8 TI (treat* and target*)
S9 TX (disease activity score or das28) N3 (driven or step* or strateg* or therap* or treat*)
S10 TI (optim* or switch* or add* or chang* or expand* or step* or combin* or intensif* or escalat*)
S11 TX (adapt* or titrat* or adjust* or response-based)
S12 S10 OR S11
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S13 (MeSH descriptor “Disease Progression”)
S14 (MeSH descriptor "Disease Outbreaks")
S15 (Mesh Heading “Disease”)
S16 S13 OR S14 OR S15
S17 S12 AND S16
S18 TX (Strateg* or proced* or consequ* or therap* or halt* or stop* or revers* or dela* or arrest* or detain* or
slow* or preven* or retard* or avoid*) N3 (structural or functional or erosi* or progre* or disabilit* or invalidity or
impediment or disablement or radiograph* or radiolog*)
S19 TX ((Remission or activ*) N3 (strateg* or optimi* or adapt* or control* or frequency or dose* or dosing)
S20 TX (((Low* or moderate or medium or high) and activity) N3 (strateg* or optimi* or adapt* or control* or
frequency or dose* or dosing))
S21 S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S17 OR S18 OR S19 OR S20
S22 S3 AND S21
S23 (MeSH Heading “Economics+”)
S24 (MeSH Heading "Financial Management+")
S25 (MeSH Heading “Financing, Organized+”)
S26 (MeSH Heading "Business+")
S27 S24 OR S25 OR S26
S28 S23 NOT S27
S29 MeSH Heading Health resource allocation
S30 MeSH Heading Health resource utilization
S31 S29 OR S30
S32 S28 OR S31
S33 TX (cost or costs or economic* or pharmacoeconomic* or price* or pricing*)
S34 S32 OR S33
S35 S22 AND S34
S36 Publication Type Editorial
S37 Publication Type letter
S38 (MeSH Heading “Animal Studies”)
S39 S36 OR S37 OR S38
S40 S35 NOT S39
American Economic Association’s electronic bibliography
Date searched: 14 January 2016.
Search strategy
1 Rheumatoid arthritis.tw.
2 (remission adj2 induc$).ti,ab.
3 (strateg$ or aim$ or goal$ or target$ or tight$ or aggressiv$ or intens$ or control$ or optim$ or adapt$ or switch$
or add$ or chang$ or expand$ or step$ or combin$ or intensif$ or escalat$).ti.
4 ((strateg$ or aim$ or goal$ or target$ or tight$ or aggressiv$ or control$) adj2 (treat$ or therap$)).tw.
5 (ttt or t2t).tw.
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6 (treat$ and target$).ti.
7 ((disease activity score or das28) adj3 (driven or step$ or strateg$ or therap$ or treat$)).tw.
8 (optim$ or switch$ or add$ or chang$ or expand$ or step$ or combin$ or intensif$ or escalat$).ti.
9 (adapt$ or titrat$ or adjust$ or response-based).tw.






16 10 and 15
18 ((Remission or activ$) adj3 (strateg$ or optimi$ or adapt$ or control$ or frequency or dose$ or dosing)).tw.
19 (((low$ or moderate or medium or high) and activity) adj3 (strateg$ or optimi$ or adapt$ or control$ or frequency
or dose$ or dosing)).tw.
20 2 or 3 or 4 or 5 or 6 or 7 or 16 or 17 or 18 or 19
21 1 and 20
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Appendix 3 Table of excluded studies with
rationale
Study Reason
ACT-RAY98,99 Not a trial of TTT
Alemao et al., 2014100 Conference abstract: insufficient detail
ARCTIC101 Conference abstract: insufficient detail
Bijlsma et al., 2015102 No new data (from update search): U-Act-Early62
CAMERA II37,103–106 Not a trial of TTT
Carubbi et al., 2016107 Not a trial of TTT
Charles-Schoeman 2016108 No relevant outcomes (from update search): TEAR58–60
CIMESTRA109–111 Not a trial of TTT
COBRA112–116 Not a trial of TTT
Dale 2015117 Not a RCT
De Cock et al., 2013;118 and 2014119 Not a RCT
De Cock et al., 2015120 No new data (from update search): CareRA40,42,43
DRESS121 Not a trial of TTT
Dumitru et al., 2016122 No study results yet
Emery et al., 2009;123 2010;124,125 and 2011126 Not a RCT
Fedorenko et al., 2013127 Not a trial of TTT
Ferraccioli et al., 2002128 Numbers stepping up not reported
Fiehn et al., 2007129 Not a trial of TTT
Galloway et al., 2015130 Not a trial of TTT
Giacomelli et al., 2002131 Not a trial of TTT
Harrold et al., 2015132 No relevant outcomes
Hørslev-Petersen et al., 2011133 Not a trial of TTT
Hwang et al., 2016134 No relevant outcomes (from update search): TEAR58–60
IDEA135,136 Not a trial of TTT
IMAGINE-RA137 No study results yet
Jalal et al., 2016138 Not a RCT
Korthals-de Bos et al., 2004113 Unobtainable
Kume et al., 2013139 Conference abstract: insufficient detail
Kuusalo et al., 2015140 Not a trial of TTT: Neo-RACo (from update search)
Li et al., 2016141 Not a trial of TTT
Marchesoni et al., 2002142 Not a trial of TTT
Markusse et al., 2015143 No new data (from update search): BeSt26–34,64–66
Markusse et al., 2016144 Not a RCT
MASCOT145,146 Not a trial of TTT
Menon et al., 2014147 Not a trial of TTT
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Study Reason
Moller-Bisgaard et al., 2015148 Not a trial of TTT: CIMESTA (from update search)
Montecucco et al., 2012149 Not a trial of TTT
Neo-RACo140,150–157 Not a trial of TTT
OPERA158–162 Not a trial of TTT
OPTIMA163–168 Not a trial of TTT
OSRA169,170 Conference abstract: insufficient detail
Pablos et al., 2015171 Not a trial of TTT
Pavelka et al., 2015172 Not a RCT
Pavelka et al., 2016173 Not a trial of TTT
PREMIER174–186 Not a trial of TTT
PRESERVE187–200 Not a trial of TTT
Proudman et al., 2000201 Not a trial of TTT
Scott and Kowalczyk, 2010202 Not a RCT
Scott et al., 2016203 Not a RCT
Solomon et al., 2016204 Not a RCT
STRASS205–213 Not a trial of TTT
TaSER214–216 No data available for the DAS28-targeted group
Todoerti et al., 2010217 Not a trial of TTT
tREACH218–224 Not a trial of TTT
Van der Elst et al., 2016225 Not a RCT
van Tuyl et al., 2008226 Separate data not reported for the two arms
Verschueren et al., 2008227 Not a RCT
Verschueren et al., 2015228 No new data (from update search): CareRA40,42,43
Yoo et al., 2016229 Not a trial of TTT
ACT-RAY, ACTemra (tocilizumab) RAdiographic studY; ARCTIC, Aiming for Remission in rheumatoid arthritis: a randomised
trial examining the benefit of ultrasound in a Clinical TIght Control regimen; CAMERA II, Computer Assisted Management
in Early Rheumatoid Arthritis trial-II; CIMESTRA, Ciclosporine, Methotrexate, Steroid in RA; DRESS, Dose REduction Strategy
of Subcutaneous TNF inhibitors in rheumatoid arthritis; IDEA, Infliximab as Induction Therapy in Early Rheumatoid Arthritis;
IMAGINE-RA, An MRI-guided Treatment Strategy to Prevent Disease Progression in Patients With Rheumatoid Arthritis;
MASCOT, Methotrexate And Sulfasalazine Combination Therapry; Neo-RACo, Neo Rheumatoid Arthritis Combination
Therapy; OPERA, OPtimized treatment algorithm for patients with Early Rheumatoid Arthritis; OPTIMA, Optimal Protocol for
Treatment Initiation with Methotrexate and Adalimumab; OSRA, Objectives Study Rheumatoid Arthritis; PREMIER, Patients
REceiving Methotrexate and Infliximab for the treatment of Early Rheumatoid arthritis; PRESERVE, Maintenance, reduction,
or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid
arthritis; STRASS, Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study; TaSER, Targeting Synovitis in Early
Rheumatoid Arthritis; tREACH, treatment in the Rotterdam Early Arthritis Cohort.
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Appendix 4 Tables of treatment adaptations and
drug dosing
TABLE 65 Treatment adaptations and drug dosing: comparison of TTT vs. usual care – early RA population
Trial acronym Treatment arms Treatment adaptations
Total dose of each drug
given over trial period
STREAM55 Aggressive group NR NA
Conventional care NR NA
Aggressive group 29 patients stepped up to 25mg/week of
MTX
19 patients stepped up to 40mg/2 weeks of
ADA+MTX 25mg/week
15 patients stepped up to 40mg/week of
ADA+ 25mg/week of MTX
11 patients converted to triple cDMARDs
3 patients stepped up to triple
cDMARDs+ PDN
1 patient converted to LEF
NR
Conventional care 24 patients started on HCQ:
l 5 switched to SSZ (then 1 to MTX and
1 to HCQ)
l 6 switched to MTX
l 2 started on SSZ and ended up on
MTX at 2 years
14 started on MTX:
l 1 ended up on no medication
l 3 ended up on MTX + SSZ+ HCQ at
2 years
Mean dose of MTX
among MTX users was
19 mg/week
T-4 study56,57 Routine care Number initiating:
l MTX, n= 36
l DMARD (except SSZ), n = 13
l Triamcinolone acetonide , n = 65
l IA GC, n= 7
l First TNFi, n= 20
l Second TNFi, n= 0
l TOC, n = 0
NR
(N = 55)
DAS28-driven therapy Number initiating:
l MTX, n= 40
l DMARD (except SSZ), n = 16
l Triamcinolone acetonide, n = 72
l IA GC, n= 24
l First TNFi, n= 22
l Second TNFi, n= 2
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TABLE 65 Treatment adaptations and drug dosing: comparison of TTT vs. usual care – early
RA population (continued )
Trial acronym Treatment arms Treatment adaptations
Total dose of each drug




l MTX, n= 29
l DMARD (except SSZ), n = 9
l Triamcinolone acetonide, n = 186
l IA GC, n= 84
l First TNFi, n= 19
l Second TNFi, n= 0






l MTX, n= 46
l DMARD (except SSZ), n = 8
l Triamcinolone acetonide, n = 61
l IA GC, n= 26
l First TNFi, n= 38
l Second TNFi, n= 3
l TOC, n = 3
NR
(N = 61)
IA, intra-articular; NA, not applicable; NR, not reported.
TABLE 66 Treatment adaptations and drug dosing: comparison of TTT vs. usual care – established RA population
Trial acronym; first
author and year of
publication Treatment arm Treatment adaptations
Total dose (mg/week)
of each drug given
over trial period
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TABLE 66 Treatment adaptations and drug dosing: comparison of TTT vs. usual care – established
RA population (continued )
Trial acronym; first
author and year of
publication Treatment arm Treatment adaptations
Total dose (mg/week)




Routine care NR NR
DAS28 target NR NR
SJC target NR NR
Routine care NR NR
DAS28 target NR NR
SJC target NR NR
Routine care Changes per 100 patient-months: 5.1c,d NR
DAS28 target Changes per 100 patient-months: 6.2b,c NR
SJC target Changes per 100 patient-months: 3.3c NR
NR, not reported.
a More changes occurred in the DAS28 group (p = 0.013).
b p< 0.001 vs. routine care.
c Mean.
d p= 0.035 vs. routine care.
TABLE 67 Treatment adaptations and drug dosing: comparison of TTT vs. usual care – trials with a combined early
and established RA population
Trial acronym; first
author and year of
publication Treatment arm Treatment adaptations
Total dose of each drug
given over trial period
TICORA61 Intensive
management
Combination DMARD initiation: 37 (67)a MTX: 17.6 mg/weekb
Numbers receiving by 18 months:
l SSZ or MTX monotherapy: 16/53
l Triple therapy (MTX, SSZ, HCQ): 27/53
l MTX + ciclosporin: 2/53
l Other DMARD combinations: 5/53





Routine management Combination DMARD initiation: 6 (11)a MTX: 13.6 mg/weekb
Numbers receiving by 18 months:
l Triple therapy (MTX, SSZ, HCQ): 2/51
l Other DMARD combinations: 4/51




van Hulst et al.,
201063
Intervention group Medication changed in 35% (263/760)
clinic visits:
l Adding corticosteroid (injections)
without DMARD change, 13.5%
l Start, add on or switch DMARD, 14%
l Increasing dosage of DMARD, 5%
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TABLE 67 Treatment adaptations and drug dosing: comparison of TTT vs. usual care – trials with a combined early
and established RA population (continued )
Trial acronym; first
author and year of
publication Treatment arm Treatment adaptations
Total dose of each drug
given over trial period
Usual-care group Medication changed in 33% (133/406)
clinic visits:
l Adding corticosteroid (injections)
without DMARD changes, 15%
l Start, add on or switch DMARD, 11%
l Increasing dosage of DMARD, 5%






TABLE 68 Treatment adaptations and drug dosing: comparison of different targets – early RA population
Trial acronym; first
author and year of
publication Treatment arm Treatment adaptations
Total dose of each drug
given over trial period
Hodkinson et al.,
201551
SDAI arm NR NR
CDAI arm NR NR
T-4 study56,57 Routine care Number initiating:
l MTX, n= 36
l DMARD (except SSZ), n = 13
l Triamcinolone acetonide, n = 65
l IA GC, n= 7
l First TNFi, n= 20
l Second TNFi, n= 0
l TOC, n = 0
NR
(N = 55)
DAS28-driven therapy Number initiating:
l MTX, n= 40
l DMARD (except SSZ), n = 16
l Triamcinolone acetonide, n = 72
l IA GC, n= 24
l First TNFi, n= 22
l Second TNFi, n= 2






l MTX, n= 29
l DMARD (except SSZ), n = 9
l Triamcinolone acetonide, n = 186
l IA GC, n= 84
l First TNFi, n= 19
l Second TNFi, n= 0
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TABLE 69 Treatment adaptations and drug dosing: comparison of different targets – established RA population
Trial name Treatment arm Treatment adaptations
Total dose of each drug
given over trial period
Optimisation of
Adalimumab study52,53
Routine care NR NR
DAS28 target NR NR
SJC target NR NR
Routine care NR NR
DAS28 target NR NR
SJC target NR NR
Routine care Changes per 100 patient-months: 5.1a,b NR
DAS28 target Changes per 100 patient-months: 6.2a,c NR
SJC target Changes per 100 patient-months: 3.3a NR
NR, not reported.
a Mean.
b p= 0.035 vs. routine care.
c p< 0.001 vs. routine care.
TABLE 68 Treatment adaptations and drug dosing: comparison of different targets – early RA population
(continued )
Trial acronym; first
author and year of
publication Treatment arm Treatment adaptations
Total dose of each drug




l MTX, n= 46
l DMARD (except SSZ), n = 8
l Triamcinolone acetonide, n = 61
l IA GC, n= 26
l First TNFi, n= 38
l Second TNFi, n= 3
l TOC, n = 3
NR
(N = 61)




Step-up ETN NR NR
Step-up triple therapy NR NR
Immediate ETN NR For all four groups,
the mean MTX dosage:








Step-up triple therapy NR
IA, intra-articular; NR, not reported.
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TABLE 70 Treatment adaptations and drug dosing: other comparisons – early RA population
Trial acronym Treatment arm Treatment adaptations
Total dose of each drug
given over trial period
CAMERA35,36,67 Intensive strategy group NR NR
Conventional strategy group NR NR
Intensive strategy group 55 patients converted to subcutaneous
MTX as a result of reaching the maximum
dose of MTX or toxicity. Ciclosporin given
to 38 patients after the maximum MTX
dose reached
MTX: 16.1 (14.8 to 17.3)
mg/weeka (in completers)
Conventional strategy group 12 patients converted to subcutaneous
MTX as a result of reaching the maximum
dose of MTX or toxicity. Ciclosporin given
to four patients after the maximum MTX
dose reached
MTX: 14.0 (13.1 to 14.8)
mg/weeka (in completers)
NR, not reported.
a Mean (95% CI).
TABLE 71 Treatment adaptations and drug dosing: other comparisons – established RA population
Trial Treatment arm Treatment adaptations
Total dose of each drug
given over trial period
BROSG trial9 Symptomatic treatment
(shared care)
131/234 (56%) of patients had some
change in their disease-suppressive
treatment [including patients who had the
dose changed, but not those who only
had joint injection(s)]
NR
Aggressive therapy (hospital) 179/232 (77%) of patients had some
change in their disease-suppressive
treatment [including patients who had the
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Appendix 5 Quality assessment of the
economic papers
As some of the authors of this report were key members of the team undertaking the HTA ofbDMARDs, it was deemed that a review of economic models that did not focus on TTT was
unnecessary. Systematic reviews that were identified had references checked to see if any of the included
studies were assessments of TTT.





Title 1 Identify the study as an economic evaluation or use more specific terms, such
as ‘cost-effectiveness analysis’, and describe the interventions compared
Abstract 2 Provide a structured summary of objectives, perspective, setting, methods
(including study design and inputs), results (including base-case and
uncertainty analyses) and conclusions
Background and objectives
Background and objectives 3 Provide an explicit statement of the broader context for the study





4 Describe characteristics of the base-case population and subgroups analysed,
including why they were chosen
Setting and location 5 State relevant aspects of the system(s) in which the decision(s) need(s) to be
made
Study perspective 6 Describe the perspective of the study and relate this to the costs being
evaluated
Comparators 7 Describe the interventions or strategies being compared and state why they
were chosen
Time horizon 8 State the time horizon(s) over which costs, and consequences, are being
evaluated and say why appropriate
Discount rate 9 Report the choice of discount rate(s) used for costs and outcomes and say
why appropriate
Choice of health outcomes 10 Describe what outcomes were used as the measure(s) of benefit in the
evaluation and their relevance for the type of analysis performed
Measurement of
effectiveness
11a Single study-based evaluation: describe fully the design features of the single
effectiveness study and why the single study was a sufficient source of clinical
effectiveness data
11b Synthesis-based estimates: describe fully the methods used for identification




12 If applicable, describe the population and methods used to elicit preferences
for outcomes
continued
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13a Single study-based evaluation: describe the approaches used to estimate
resource use associated with the alternative interventions. Describe primary or
secondary research methods for valuing each resource item in terms of its unit
cost. Describe any adjustments made to approximate to opportunity costs
13b Model-based evaluation: describe the approaches and data sources used to
estimate resource use associated with model health states. Describe primary
or secondary research methods for valuing each resource item in terms of its
unit cost. Describe any adjustments made to approximate to opportunity costs
Currency, price date and
conversion
14 Report the dates of the estimated resource quantities and unit costs. Describe
methods for adjusting estimated unit costs to the year of reported costs if
necessary. Describe methods for converting costs into a common currency
base and the exchange rate
Choice of model 15 Describe and give reasons for the specific type of decision-analytical model
used. Providing a figure to show model structure is strongly recommended
Assumptions 16 Describe all structural or other assumptions underpinning the decision-analytical
model
Analytical methods 17 Describe all analytical methods supporting the evaluation. This could include
methods for dealing with skewed, missing or censored data; extrapolation
methods; methods for pooling data; approaches to validate or make
adjustments (such as half cycle corrections) to a model; and methods for
handling population heterogeneity and uncertainty
Results
Study parameters 18 Report the values, ranges, references and, if used, probability distributions for
all parameters. Report reasons or sources for distributions used to represent




19 For each intervention, report mean values for the main categories of
estimated costs and outcomes of interest, as well as mean differences
between the comparator groups. If applicable, report ICERs
Characterising uncertainty 20a Single study-based economic evaluation: describe the effects of sampling
uncertainty for the estimated incremental cost and incremental effectiveness
parameters, together with the impact of methodological assumptions (such as
discount rate, study perspective)
Incremental costs and
outcomes
20b Model-based economic evaluation: describe the effects on the results of
uncertainty for all input parameters and uncertainty related to the structure of
the model and assumptions
Characterising
heterogeneity
21 If applicable, report differences in costs, outcomes, or cost-effectiveness that
can be explained by variations between subgroups of patients with different
baseline characteristics or other observed variability in effects that are not
reducible by more information
Discussion
Discussion 22 Summarise key study findings and describe how they support the conclusions
reached. Discuss limitations and the generalisability of the findings and how
the findings fit with current knowledge
Other
Source of funding 23 Describe how the study was funded and the role of the funder in the
identification, design, conduct and reporting of the analysis. Describe other
non-monetary sources of support
Conflicts of interest 24 Describe any potential for conflict of interest of study contributors in
accordance with journal policy. In the absence of a journal policy, we
recommend authors comply with the recommendations of the International
Committee of Medical Journal Editors
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TABLE 73 The CHEERS checklist for the Vermeer et al. study85
Item
number Response
1 The study is identified in the title as an economic evaluation. However, the names of the interventions being
compared were not identified in the title
2 The study includes a structured summary or abstract
3 The study provides a rationale and context for the research question
The study identifies and clearly states the research question to be answered, but does not state the relevance
that answering the research question will have in health policy or practice decisions
4 The cost-effectiveness analysis was based on the results achieved by patients entered into the DREAM registry
which began in 2006. Patients who received TTT care (n= 261), 61.7% female, had a mean age of 57.9
years (SD = 13.8 years) and a mean DAS28 of 5.0 (SD = 1.1). Patients who received usual care over the same
period (n= 69), 62.3% female, had a mean age of 53.9 years (SD = 13.0 years) and a mean DAS28 of 4.8
(SD = 1.3). However, the number of patients entered into the usual-care cohort was considered insufficient
and thus patients who had received usual care from the year 2000 were entered into a third cohort (n= 213).
These patients, 62% of whom were female, had a mean age of 56.6 years (SD = 13.4 years) and a mean
DAS28 of 4.8 (SD = 1.2). All patients had a symptom duration of < 1 year and had received no previous
DMARD treatment
5 The study was set in Denmark
6 The perspective of the study was direct health-care costs
7 The TTT strategy included a standardised, protocol-based treatment regimen targeted at achieving remission.
Patients were assessed at weeks 0, 8, 12, 20, 36 and 52 and every subsequent 3 months with doctors
informed of each patient’s DAS28 measured by a rheumatology nurse. Treatment consisted of initial MTX
monotherapy followed by MTX/SSZ combination therapy followed by MTX/anti-TNF combination therapy.
Patients achieving remission were maintained on their current treatment for 6 months; if remission persisted
beyond 6 months treatment was gradually reduced and discontinued. NSAID medications, prednisolone and
intra-articular corticosteroid injections were allowed at the discretion of the doctor
The usual-care strategy was a non-standard, non-protocol-based regimen. Patients were assessed every
3 months by a rheumatology nurse, but doctors were not informed of a patient’s DAS28. Treatment
regimen was at the discretion of the doctor, although the usual pathway is MTX monotherapy followed by
either SSZ monotherapy, or combination MTX/SSZ therapy followed by two conventional DMARDs and finally
an anti-TNF agent. NSAID medications and prednisolone were allowed at the discretion of the doctor
8 The reporting of cost-effectiveness analysis was poor; time horizon and cycle length were not reported
9 The annual discount rate used to discount future costs and benefits was not reported
10 The study used DAS28 to assess if a patient has achieved remission (i.e. a DAS28 of < 2.6). The HAQ was
used to assess the heath-related quality of life of registry patients rather than a preference-based measure
such as the EQ-5D. However, HAQ scores were converted to EQ-5D scores using model 5 of the mapping
methodology derived by Bansback et al.230
11a The study was based on the DREAM registry, a quasi-experimental study performed at multiple locations in
eastern Denmark. Patients were allocated to the TTT cohort or the usual-care cohort based on their home
address. Patient characteristics and resource use were recorded for all patients, with the interim results
(at the time of publication the study was ongoing) used to inform this cost-effectiveness analysis
11b N/A
12 See response to item 4
13a See response to item 11a
13b N/A
14 The study states that a cost year of 2011 was used. Costs from other sources were uplifted to 2011 values,
if necessary, using the Dutch price index rate
15 The reporting of cost-effectiveness analysis was poor, no model specification or schematic is reported
16 Not reported
continued
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TABLE 73 The CHEERS checklist for the Vermeer et al. study85 (continued )
Item
number Response
17 Missing data were dealt with through single imputation using a regression method or linear interpolation
using the trapezoid method conditional on missing data occurring at random
18 The reporting of cost-effectiveness analysis was poor, the nature and value of the input parameters is not
specified
19 The economic results were provided for data after a 2-year follow-up period and data after a 3-year
follow-up period
2-year follow-up period:
l TTT: mean total cost €4791 (SD = €7436)
l Usual care: mean total cost €3727 (SD = €5773)
l ICER: €3591 per patient in remission
l ICUR = €19,410 per QALY
3-year follow-up period:
l TTT: mean total cost €6410 (SD = €10,485)
l Usual care: mean total cost €6872 (SD = €11,033)
l ICER: TTT dominates
ICUR: TTT dominates
20a The economic answers were based running the model on 1000 bootstrap replicates. However, there is no
reporting of the data behind this bootstrapping
20b N/A
21 A subgroup analysis was performed using usual-care data collected on patients entering since 2006 (see
response to item 4). After 2 years’ follow-up the ICER was €8709 per patient in remission and after 3 years’
follow-up TTT dominates. However, the 3-year results were based on data for only 45 patients in the
usual-care cohort)
22 A comprehensive discussion of the conclusion, strengths and limitations of the study was provided
23 The study was funded by an unrestricted education grant from Abbott
24 All 10 authors state that they had no competing interests
ICUR, incremental cost–utility ratio; N/A, not applicable.
TABLE 74 The CHEERS checklist for the van den Hout et al. study86
Item
number Response
1 The study is identified in the title as a cost–utility appraisal. However, the names of the interventions being
compared are not identified in the title
2 The study includes a structured summary or abstract
3 The study provides a rationale and context for the research question
The study identifies, and clearly states, the research question to be answered, but does not state the
relevance that answering the research question will have in health policy or practice decisions
4 The cost–utility appraisal was based on the results achieved by patients with recent-onset RA who entered
into treatment at the 20 included sites in the Netherlands between March 2000 and August 2002. Patients
were at least 18 years of age, fulfilled the 1987 criteria of the ACR and had a disease duration of, at most,
2 years. The details of the randomisation groups is as follows:
l Randomisation group 1: initially 126 patients were assigned to treatment strategy 1 with a mean age of
54 years (SD 13 years), 68% of the patients were female and their baseline mean disease activity score
was 4.5 (SD 0.9)
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TABLE 74 The CHEERS checklist for the van den Hout et al. study86 (continued )
Item
number Response
l Randomisation group 2: initially 121 patients were assigned to treatment strategy 2, again with a mean
age of 54 years (SD 13 years), 72% of the patients were female and their baseline mean disease activity
score was 4.5 (SD 0.8)
l Randomisation group 3: initially 133 patients were assigned to treatment strategy 3 with a mean age of
55 years (SD 14 years), 66% of the patients were female and their baseline mean disease activity score
was 4.4 (SD 0.9)
l Randomisation group 4: initially 128 patients were assigned to treatment strategy 4, with a mean age of
54 years (SD 14 years), 66% of the patients were female and their baseline mean disease activity score
was 4.3 (SD 0.9)
5 The study was set in the Netherlands
6 The primary perspective of the study was a societal cost. However, a secondary analysis was conducted with
a health-care cost perspective
7 The study compared four treatment strategies:
l Strategy 1, sequential monotherapy
l Strategy 2, step-up combination therapy
l Strategy 3, initial combination therapy with PDN
l Strategy 4, initial combination therapy with IFX
The actual treatment a patient received was based on their disease activity score, which was measured every
3 months by an experienced research nurse who was unaware of the randomisation group. In addition, all
patients receiving IFX had their disease activity score measured 1 week before infusion. If a patient’s DAS
was > 2.4, the next treatment regimen in their treatment strategy was started; otherwise, patients remained
on their current treatment regimen. After 6 months with a disease activity score of ≤ 2.4, treatment was
tapered until the treatment regimen contained only a single DMARD
Parallel treatment with NSAID containing corticosteroids
8 The time horizon of the analysis was 2 years and the cycle length was 3 months
9 The annual discount rate used to discount future costs and benefits was 3%
10 The study used QALYs to measure the outcome in terms of health-related benefit which was appropriate for
a cost–utility appraisal
11a The study was based on the BeSt trial, which was designed to determine the best treatment regimen for
patients with RA, and was populated to ensure a power of 80% at a significance level of 0.05
11b N/A
12 The study used a number of methods and instruments to elicit health outcomes from the entire study
population, as described in item 4. These included measuring patients’ quality of life using the British EQ-5D
instrument, the Dutch EQ-5D instrument and the SF-6D every 3 months. The time trade-off method was also
used to measure patients’ quality of life at baseline, and at 6, 12 and 24 months
13a Resources used, including pharmaceuticals, were obtained from patient’s case notes with pharmaceutical and
associated unit costs being taken from the Dutch Health Insurance Executive Board. Other health-care unit
costs were based on Dutch standard prices, which were designed to reflect societal costs231,232
The societal cost of absence from paid work was costed using an age- and sex-appropriate standard hourly
rate and ranged between €17 and €41 per hour. The friction method233 was used in the initial 6-month study
period and the human capital method over the entire study period, but did not include the cost of lost
production or the cost of replacement staff
Patients’ out-of-pocket expenses were valued using costs reported by patients in their quarterly cost diaries.
If costs were not specified in the diary, expenses were costed using published cost prices234,235 or current
market prices
Extra time spent by patients on household and voluntary work was estimated by subtracting the average
time taken by an age- and gender-matched population for a task from the time spent on that task by
patients. This extra time was valued at the cost of informal care taken from van Roijen et al.236
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14 A cost year of 2008 was used with all costs converted to euros using the general Dutch price index rate
15 Not reported
16 Not reported
17 A multiple imputation by chained equations method was employed to reduce any bias attributable to missing
data
18 In this instance, all that was required was a statistical analysis of study data rather than health economics
modelling
19 Results of the primary analysis: in the primary analysis, QALY estimates were based on the British EQ-5D
instrument and a societal perspective was taken, with the friction method used to estimate cost of absence
from work. Strategy 4 resulted in the highest number of QALYs but at a considerably higher cost, indeed
the cost–utility ratio of strategy 4 compared with the next best strategy (strategy 3) is €130,000 (95% CI
€27,000 to €3,000,000) per QALY. Strategy 3 had the greatest chance of being optimal at willingness-to-pay
thresholds between €74,000 per QALY and €130,000 per QALY, with strategy 2 having the greatest change
of being optimal at willingness-to-pay thresholds < €74,000 per QALY. Strategy 1 was dominated by
strategies 2 and 3
Results of the secondary analysis: the cost–utility ratio of strategy 4 compared with strategy 3 using the other
utility estimates were:
l Dutch EQ-5D instrument €140,000 (95% CI €30,000 to €2,300,000) per QALY
l SF-6D instrument €250,000 (95% CI €50,000 to €15,000,000) per QALY
l TTO instrument €320,000 (95% CI €40,000 to ∞) per QALY
Costs of pharmaceuticals: the following costs are the mean pharmaceutical costs (SD) for the four strategies
over the 2-year study period:
l Strategy 1: €5202 (SD €8094)
l Strategy 2: €1941 (SD €4723)
l Strategy 3: €3126 (SD €5317)
l Strategy 4: €20,075 (SD €13,491)
20a No deterministic or stochastic sensitivity analyses were performed
20b N/A
21 No subgroup analyses were performed
22 A comprehensive discussion of the conclusion was provided
23 The study was funded by a grant from the Dutch Health Insurance Board. However, additional funding was
also provided by Schering-Plough B.V. and by Centocor Inc.
24 A number of the authors state that they have competing interests
N/A, not applicable; SF-6D, Short Form questionnaire-6 Dimensions; TTO, time trade off.
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Appendix 6 Tables of treat to target and disease
activity outcomes for the comparison of different
treatment protocols
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121 12 months 115/121 (95) l Patient refusal,
n= 4
l AE, n= 1










133 12 months 128/133 (96) l Patient refusal,
n= 4






















l Died, n= 3
l Other, n= 5
NR NR NR 25% still on initial
treatment; 41% started
delayed IFX and 21%










l Died, n= 3
l Other, n= 5d
NR NR NR 21% still on initial
treatment; 12% started
delayed IFX and 5%
were still on it at 5 years.
26% started PDN and










l Died, n= 2
l Other, n= 1
NR NR NR 45% still on initial
treatment; 21% started
delayed IFX and 11%




























































l Died, n= 4
l Other, n= 4
NR NR NR 65% still on initial
treatment; 19% were
still taking delayed






126 7 years29 83/126 (66) NR 68/83
(82)
68/83 (82)
(DAS44 of ≤ 2.4)
41/83 (49)
(DAS44 of < 1.6)
Still on initial treatment
step, 17/83 (21%); IFX





121 7 years 72/121 (60) NR 55/72
(76)
55/72 (76)
(DAS44 of ≤ 2.4)
28/72 (39)
(DAS44 of < 1.6)
Still on initial treatment
step, 12/72 (16%); IFX





133 7 years 79/133 (59) NR 59/79
(82)
59/79 (82)
(DAS44 of ≤ 2.4)
42/79 (53)
(DAS44 of < 1.6)
Still on initial treatment
step, 16/79 (20%); IFX





128 7 years 97/128 (76) NR 74/97
(76)
74/97 (76)
(DAS44 of ≤ 2.4)
44/97 (45)
(DAS44 of < 1.6)
Still on initial treatment
step, 53/97 (55%)





126 8 years28 85/126 (67) NR 67/85
(79)
67/85 (79)
(DAS44 of ≤ 2.4)
42/85 (49)
(DAS44 of < 1.6)
Still on initial treatment
step, 25/85 (29%); IFX





121 8 years 78/121 (64) NR 59/78
(76)
59/78 (76)
(DAS44 of ≤ 2.4)
44/78 (56)
(DAS44 of < 1.6)
Still on initial treatment
step, 17/78 (22%); IFX





133 8 years 86/133 (65) NR 72/86
(84)
72/86 (84)
(DAS44 of ≤ 2.4)
49/86 (57)
(DAS44 of < 1.6)
Still on initial treatment
step, 39/86 (45%); IFX





128 8 years 98/128 (77) NR 74/98
(76)
74/98 (76)
(DAS44 of ≤ 2.4)
46/98 (47)
(DAS44 of < 1.6)
Still on initial treatment
step, 65/98 (66%)















































































































































































































COBRA Classic 98 4 weeks NR NR A DAS28-CRP
of ≤ 3.2
NR NR 63/98 (64)
(DAS28-CRP < 2.6)
NR NA





94 4 weeks NR NR NR NR 60/94 (70)
(DAS28-CRP < 2.6)
NR NA
COBRA Classic 98 8 weeks NR NR NR NR 64/98 (65)
(DAS28-CRP < 2.6)
NR NA





94 8 weeks NR NR NR NR 65/94 (74)
(DAS28-CRP < 2.6)
NR NA
COBRA Classic 98 16 weeks 91/98 (93) l Withdrew consent,
n= 2












Adaptations in 19 out
of 98 (19.4%) patients
over the first 16 weeks
NR
COBRA Slim 98 16 weeks 96/98 (98) l Withdrew consent,
n= 1







Adaptations in 22 out
of 98 (22.4%) patients














Adaptations in 14 out
of 94 (14.9%) patients


















































COBRA Classic 98 52 weeks43 90/98 (92) l Death, n= 1



























COBRA Slim 98 52 weeks 89/98 (91) l Death, n= 1



































































































































































































































































MTX-TSU 47 8 weeks NA NR DAS28-CRP
≤ 3.2
NR NR NR Adaptations in 16 out
of 47 (34%) patients
over the first 8 weeks
NR
COBRA Slim 43 8 weeks NA NR NR NR NR Adaptations in 10 out
of 43 (23%) patients
over the first 8 weeks
NR
MTX-TSU 47 16 weeks Unclear l Patient withdrew
their consent,
n= 1







Adaptations in 11 out
of 47 (21%) patients
over the first 16 weeksi
NR
Intra-articular GC




COBRA Slim 43 16 weeks Unclear l Patients withdrew
consent, n= 3







Adaptations in 7 out of
43 (16%) patients over















































































































































































































































































































































COBRA-light 83 13 weeks NA NR 36/81
(44)
NR 36/81 (44)




COBRA 81 6 months 80/81 (99) l AE (myocardial
infarction), n= 1
NR (49)e NR NR (49)e


















NR (41)e NR NR (41)e





















ETN for 26 weeks














































































l Loss to follow-up,
n= 1





























99 (97 in ITT) 5 years47 78 (80) l Remission, n= 4
l Refused, n= 3
(1 died after
9 years – unclear
what this means)
l Moved, n= 1
l Death, n= 1
18, 41j/
NR (29)h








5 years 82/NR (84) l Remission, n= 5
l AE, n= 1
l Refused, n= 1
(1 died after
6 years – unclear
what this means)
l Moved, n= 1
l Death, n= 5
13, 33j/
NR (22)h












































































































































































































99 (97 in ITT) 11 years47 68/NR (70) l Centre
discontinuation,
n= 2
l Refused, n= 4
l Died, n= 4
(unclear if this
includes the
1 died at 9 years)
26, 49j/
NR (37)k





At some time between
the 2- and 11-year
visits, a combination-
DMARD strategy had













11 years 70/NR (71) l Centre
discontinuation,
n= 2
l Refused, n= 4
l Died, n= 4
(unclear if this
includes the
1 died at 9 years)
11, 29j/
NR (19%)l





At some time between
the 2- and 11-year
visits, a combination-
DMARD strategy had
been used by 56 (80%)
of patients
NR
27 (39%) of patients




























































49 12 months 47/49 (96) l Died, n= 1













withdrawals as a result
of AEs:
l SSZ withdrawn in
eight patients
l MTX withdrawn in
two patients

















withdrawals as a result
of AEs:
l SSZ withdrawn in
17 patients





































































































































































































































124 24 weeks NR NR NR





l Lost to follow-up,
n= 19





l AE, n= 3























l Lost to follow-up,
n= 9





l AE, n= 4




























































l Lost to follow-up,
n= 18





l AE, n= 5
















l Lost to follow-up,
n= 15





l AE, n= 2

















































































































































































































TOC+MTX 106 24 weeks 100/106 (94) l AE, n= 4
l Insufficient
response, n= 1
l Other, n= 1
A DAS28 of
< 2.6 and a
SJC of ≤ 4 of
the 28 joints
assessed
NR NR NR NR NR
TOC+ PBO–MTX 103 24 weeks 101/103 (98) l AE, n= 1
l Other, n= 1
NR NR NR NR NR





l Other, n= 1
NR NR NR NR NR
TOC+MTX 106 52 weeks 87/106 (82) Weeks 24–52:





l Other, n= 3

















































TOC+ PBO–MTX 103 52 weeks 92/103 (89) Weeks 24–52:





l Other, n= 2
NR NR NR NR NR
MTX+ PBO–TOC 108 52 weeks 92/108 (85) Weeks 24–52:





l Other, n= 2
NR NR NR NR NR
TOC+MTX 106 104 weeks 78/106 (74) Weeks 52–104:





l Other, n= 2
91/106
(86)m
NR 91/106 (86)m [a
DAS28 of < 2.6
and a SJC of











































































































































































































TOC+ PBO–MTX 103 104 weeks 81/103 (79) Weeks 52–104









[a DAS28 of < 2.6
and a SJC of





MTX+ PBO–TOC 108 104 weeks 78/108 (72) l Weeks 52–104:









[a DAS28 of < 2.6
and a SJC (28





ITT, intention to treat; NA, not applicable; NR, not reported.
a Randomised.
b p= 0.004 vs. group 3.
c p= 0.001 vs. group 4.
d Discrepancy in flow-chart: total number withdrawing reported as 27.
e n not reported.
f n/N (%).
g p= 0.003.
h Converted from graphical data.
i Data from the Verschueren et al.40 paper have been used; data on treatment adaptations presented within the De Cock et al.39 abstract are discrepant.
j 95% CI.
k p= 0.017.
l Assuming proportion of completers with DAS28.










































126 3 months30 NR NR NR NR NR ACR 20: 29.2%b D-HAQ: 1.0 (0.7)c,d NR SF-36 PCS
improvement: 5.8e,f





121 3 months NR NR NR NR NR ACR 20: 36.9%b D-HAQ: 1.0 (0.6)c,d NR SF-36 PCS
improvement: 3.9e,f





133 3 months NR NR NR NR NR ACR 20: 70.1%b D-HAQ: 0.6 (0.6)c,d NR SF-36 PCS
improvement: 11.2e,f





128 3 months NR NR NR NR NR ACR 20: 60.2 %b D-HAQ: 0.6 (0.6)c,d NR SF-36 PCS
improvement: 9.6e,f




126 6 months30 NR NR NR NR NR ACR 20: 49.4%b D-HAQ: 0.9 (0.7)c,d NR SF-36 PCS
improvement: 8.0e,f





121 6 months NR NR NR NR NR ACR 20: 60.2%b D-HAQ: 0.9 (0.7)c,d NR SF-36 PCS
improvement: 8.5e,f





133 6 months NR NR NR NR NR ACR 20: 70.6%b D-HAQ: 0.5 (0.5)c,d NR SF-36 PCS
improvement: 12.5e,f





























































































































































































128 6 months NR NR NR NR NR ACR 20: 74.2%b D-HAQ: 0.5 (0.5)c,d NR SF-36 PCS
improvement:
12.4e,f























126 12 months30 NR NR NR NR NR ACR 20: 63.4%b D-HAQ: 0.7 (0.7)c,g Progression of SHS:
l Erosion score
(0–280): 3.5 (8.2)f,h,i
l JSN score (0–168):
3.6 (8.4)h,i,j











































121 12 months NR NR NR NR NR ACR 20: 63.3%b D-HAQ: 0.7 (0.6)c Progression of SHS:
l Erosion score
(0–280): 2.6 (4.7)f,h,i
l JSN score (0–168):
1.6 (2.9)h,i,j









133 12 months NR NR NR NR NR ACR 20: 77.3%b D-HAQ: 0.5 (0.5)c,g Progression of SHS:
l Erosion score
(0–280): 0.9 (1.9)f,h,i
l JSN score (0–168):
1.0 (2.4)h,i,j









128 12 months NR NR NR NR NR ACR 20: 79.1%b D-HAQ: 0.5 (0.5)c,g Progression of SHS:
l Erosion score
(0–280): 0.7 (2.1)f,h,i
l JSN score (0–168):
0.6 (2.6)h,i,j












l JSN score (0–168):
4.3 (9.8)h




















































































































































































































l JSN score (0–168):
1.5 (3.2)h













l JSN score (0–168):
1.2 (2.9)h




































































































































































































































































































(SD) Joint erosion Quality of life
Sequential
monotherapy

































121 10 years NR NR NR NR NR NR 0.72 (during
10 years)








133 10 years NR NR NR NR NR NR 0.64 (during
10 years)








128 10 years NR NR NR NR NR NR 0.58 (during
10 years)

































































































COBRA Classic 98 52 weeks43 DAS28-CRP
change: 2.5
(1.5)
NR NR NR Good response:
67.3%
NR HAQ change: 0.7
(0.7)j




































































































































































































(SD) Joint erosion Quality of life
COBRA Slim 98 52 weeks DAS28-CRP
change: 2.3
(1.4)
NR NR NR Good response:
68.4%
NR HAQ change: 0.5
(0.7)
















93 52 weeks DAS28-CRP
change: 2.3
(1.5)
NR NR NR Good response:
67.7%
NR HAQ change: 0.6
(0.7)j



























































NR NR NR Good response:
21/47 (44.7%)

















NR NR NR Good response:
25/43 (58.1%)











MTX-TSU 47 52 weeks43 DAS28-CRP
change: 2.1
(1.7)
NR NR NR Good response:
57.4%
NR HAQ change: 0.5
(0.6)















COBRA Slim 43 52 weeks DAS28-CRP
change: 2.1
(1.9)
NR NR NR Good response:
60.5%;
NR HAQ change: 0.6
(0.7)











































































































































































































COBRA 81 13 weeks NR NR NR NR Good response:
63%i
NR 0.52b,o NR NR
Non-response:
4%i
COBRA-light 83 13 weeks NR NR NR NR Good response:
47%i
NR 0.62b,o NR NR
Non-response:
11%i
COBRA 81 6 months NR 1.62 (0.96)h NR NR Good response:
75%i










COBRA-light 83 6 months NR 1.78 (1.13)h NR NR Good response:
65%i











































(SD) Joint erosion Quality of life
COBRA 81 12 months 2.49 (1.3) 1.70 (1.0) 2.6 (3.6) 5.3 (7.2) NR ACR 70: 25/81
(31%)








l Change in erosion
score: 0.18 (0.4)h
l Change in JSN
score: 0.31 (1.5)h
l Change in total
score: 0.49 (1.6)h
COBRA-light 83 12 months 2.71 (1.3) 1.88 (1.0) 2.3 (2.6) 5.0 (6.0) NR ACR 70: 28/81
(35%)








l Change in erosion
score: 0.30 (0.8)h
l Change in JSN
score: 0.27 (0.8)h

































































































































































































































































NR ACR 20: 78%
(95% CI 69/%
to 80%)
0.27 (0.11)b,w Number of eroded

























NR ACR 20: 84%
(95% CI 75%
to 90%)
0.30 (0.10)b,w Number of eroded













99 (97 in ITT) 5 years47 2.51
(0.28)b,w,x









































(SD) Joint erosion Quality of life
Combination
treatment
99 (97 in ITT) 11 years48,49 2.48
(1.22)x
NR 0 (0–3)s 1 (0–5)s NR NR 0.34 (0.54) Change from baseline
in Larsen score: 17
(95% CI 12–26);y,aa
87% (95% CI 74% to
94%) patients in had
no erosive changes in
large joints
NR
HAQ score of 0:
56%






11 years 2.73 (1.23)x NR 2 (IQR 0–4)s 2 (IQR 0–5)s NR NR 0.38 (0.58) Change from baseline
in Larsen score: 27
(95% CI 22–33);y,aa
72% (95% CI 58% to
84%) patients in had
no erosive changes in
large joints
NR
HAQ score of 0:
43%





























































































































































































































































































































(SD) Joint erosion Quality of life





124 2 years NR NR NR NR NR ACR 20: 47.92%b NR NR NR
ACR 50: 37.15%b
ACR 70: 11.43%b










l JSN: 3.7 (9.8);h
n= 159



















l Total SHS: 7.3
(13.3);h n= 76
NR












l JSN: 2.1 (4.4);h
n= 166

















l JSN: 2.6 (5.0);h n=75






































































































































































































































































































































(SD) Joint erosion Quality of life









































































































































































































































































(SD) Joint erosion Quality of life






















































AUC, area under the curve; ITT, intention to treat; MCS, Mental Components score; NR, not reported; PCS, Physical Components Score.
a Randomised.
b Converted from graphical data.
c n not reported.
d p< 0.05, groups 1 and 2 vs. groups 3 and 4.
e Mean change from baseline.
f p< 0.05, groups 1 and 2 vs. groups 3 and 4.
g p< 0.05, group 1 vs. groups 3 and 4.
h Mean (SD).
i n not reported.
j p< 0.05, group 1 vs. groups 3 and 4 and group 2 vs. group 4.
k Median.
l p= 0.007 group 1 vs. group 4.
m p< 0.001 group 1 vs. group 4.
n p= 0.004 group 2 vs. group 4.
o p< 0.05.
p Mean.
q p< 0.05, groups 1 and 2 vs. group 4.


















u p= 0.017 across low-risk groups.
v p= 0.05.
w Not reported if variance is SD or SE.
x Significant treatment effect over time, p = 0.0022.
y Mean (95% CI).
z p= 0.002.
aa p= 0.037.
ab p< 0.0001, groups 1 and 2 vs. groups 3 and 4.
ac p< 0.0001 across groups.
ad p= 0.0176 across groups.
ae TOC +MTX vs. MTX, p < 0.0001; TOC vs. MTX, p < 0.0001; TOC+MTX vs. TOC, p = 0.43.
af ACR 20: TOC +MTX vs. MTX, p= 0.0099; TOC vs. MTX, p= 0.0343; ACR 50: TOC+MTX vs. MTX, p< 0.0001; TOC vs. MTX, p = 0.0009; ACR 70: TOC+MTX vs. MTX, p< 0.0001;
TOC vs. MTX, p= 0.0003; ACR 90: TOC+MTX vs. MTX, p= 0.0027.
ag p= 0.0275 across groups.
ah Median (range).
ai OC +MTX vs. MTX, p = 0.26; TOC vs. MTX, p= 0.0074; TOC+MTX vs. TOC, p= 0.06.
aj TOC +MTX vs. MTX, p = 0.0164; TOC vs. MTX, p = 0.06; TOC +MTX vs. TOC, p= 0.49.
ak ACR 90: TOC +MTX vs. MTX, p= 0.0045; TOC vs. MTX, p= 0.0026.
al Adjusted for centre and baseline HAQ score and DAS28.
am TOC+MTX vs. MTX, p= 0.87; TOC vs. MTX, p= 0.13; TOC +MTX vs. TOC, p = 0.10.
an p= 0.06 across groups.
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metabolic Cardiovascular Dermatological Ophthalmological Gastrointestinal Infectious Psychological Other
STREAM55 Aggressive
group
NR 2 years NR NR NR NR NR NR NR NR NR
Conventional
care
NR 2 years NR NR NR NR NR NR NR NR NR
T-4 study56,57 Routine care 61 56 weeks NR NR NR NR NR NR 0 (0)b NR NR
DAS28-driven
therapy
59 56 weeks NR NR NR NR NR NR 0 (0)b NR NR
MMP-3-driven
therapy




61 56 weeks NR NR NR NR NR NR 0 (0)b NR NR
NR, not reported.
































metabolic Cardiovascular Dermatological Ophthalmological Gastrointestinal Infectious Psychological Other
Fransen et al.,
200550













Routine care 100 18 months NR NR NR NR NR NR NR NR NR
DAS28 target 109 18 months NR NR NR NR NR NR NR NR NR
SJC target 99 18 months NR NR NR NR NR NR NR NR NR
NR, not reported.




















































































































































































metabolic Cardiovascular Dermatological Ophthalmological Gastrointestinal Infectious Psychological Other
TICORA61 Intensive
management
55 18 months NR NR NR 10 AEs NR 18 AEs 5 AEs NR l Abnormal liver
function, n= 8
l CNS, n= 1
l Haematological,
n= 2
l Others, n= 2
Routine
management
55 18 months NR NR NR 15 AEs NR 25 AEs 7 AEs NR l Abnormal liver
function, n= 16
l CNS, n= 9
l Haematological,
n= 6
l Others, n= 7




NR NR NR NR NR NR NR NR NR NR NR
Usual-care
group
NR NR NR NR NR NR NR NR NR NR NR
CNS, central nervous system; NR, not reported.































metabolic Cardiovascular Dermatological Ophthalmological Gastrointestinal Infectious Psychological Other
Hodkinson et al.,
201551
SDAI arm NR NR NR NR NR NR NR NR NR NR NR
CDAI arm NR NR NR NR NR NR NR NR NR NR NR
T-4 study56,57 Routine care 61 56 weeks NR NR NR NR NR NR 0 (0)b NR NR
DAS28-driven
therapy
59 56 weeks NR NR NR NR NR NR 0 (0)b NR NR
MMP-3-driven
therapy




61 56 weeks NR NR NR NR NR NR 0 (0)b NR NR
TEAR58–60 Immediate
ETN











































































































































































































metabolic Cardiovascular Dermatological Ophthalmological Gastrointestinal Infectious Psychological Other
Immediate
triple therapy






































































metabolic Cardiovascular Dermatological Ophthalmological Gastrointestinal Infectious Psychological Other
Step-up triple
therapy























a Refers to number of patients unless otherwise specified.
b Serious infection.













































































































































































Any AEa Any SAEa,b Death
Withdrawals as a
result of an AEa
BeSt30,31,33 Sequential
monotherapy
126 1 year30 ≥ 1 AE: 54 (43%) 8/126 (6.3) defined as life-threatening
condition or death, a significant or
permanent disability, a malignancy,
hospitalisation or prolongation of
hospitalisation, a congenital abnormality,
or a birth defect
Hospitalised, n= 8:
l Hypertension, n= 1
l Transient ischaemic attack, n= 1
l Pulmonary embolism, n= 1
l Pneumonia, n= 1
l Herpes simplex encephalitis, n= 1
l Hip prosthesis operation, n= 1
l Fever associated with SSZ, n= 1
l For active arthritis with revision of





121 1 year ≥ 1 AE: 57 (47%) 9/121 (7.4)
Hospitalised, n= 10:
l Peripheral bypass operation, n= 1
l Pacemaker implantation, n= 1
l A prolapsed vertebral disk, n= 1
l Neuropathy, n= 1
l Hip prosthesis operation, n= 1
l Diffuse peritonitis, n= 1



























Any AEa Any SAEa,b Death
Withdrawals as a





133 1 year ≥ 1 AE: 49 (37%) 17/133 (12.8)
Hospitalised, n= 20:
l Myocardial infarction, n= 3
l Heart failure, n= 1
l Oral herpes simplex infection, n= 1
l Hip fracture, n= 1
l Hip pain, n= 1
l Granulocytopenia, n= 1
l Urinary tract stone, n= 1
l Temporal arteritis, n= 1
l Exacerbation of RA, n= 2
l Excision of benign
microcalcifications viewed on
mammography, n= 1
l Appendectomy, n= 2
l Malignancies, n= 2:
¢ Breast cancer, n= 1






128 1 year ≥ 1 AE: 50 (39%) 6/128 (4.7)
Hospitalised, n= 6:
l Transient cardiac ischemia, n= 1
l Pulmonary embolism, n= 1
l Peripheral vascular disease, n= 1;
l Pneumonia, n= 1
l Septic arthritis, n= 1






126 5 years31 110 (87%) 42 (33) 3/126 (2.38%):
l Pneumonia
l Pneumonia/encephalitis
















































































































































































Any AEa Any SAEa,b Death
Withdrawals as a




































































Any AEa Any SAEa,b Death
Withdrawals as a




COBRA Classic 91 16 weeks 56/91 (61.2)c (therapy
related)
2 AEsd 0/91 (0) 2/91 (2)
COBRA Slim 96 16 weeks 45/96 (46.9)c (therapy
related)
1 AE 1/96 (1) 0/96 (0)
COBRA Avant-
Garde
91 16 weeks 63/91 (69.1)c (therapy
related)
3 AEsd 0/91 (0) 0/91 (0)
COBRA Classic 98 52 weeks 66/98 (67.3) (therapy
related); mean n AEs per
patient= 1.9 (2.0)e
2 AEs (therapy related)d 1/98 (1) 0
COBRA Slim 98 52 weeks 65/98 (66.3) (therapy
related); mean n AEs per
patient= 1.3 (1.4)e
2 AEs (therapy related)d 1/98 (1) 0
COBRA Avant-
Garde
93 52 weeks 73/93 (78.5) (therapy
related); mean n AEs Per
patient= 1.9 (1.6)e




MTX-TSU 47 16 weeks 32 (68.1) (therapy related) 0/47 NR NR
COBRA Slim 43 16 weeks 30 (69.8) (therapy related) 0/43 NR NR
MTX-TSU 47 52 weeks 30/47 (63.8) (therapy
related); mean n AEs per
patient 1.2 (1.2)
0 0/47 (0) 0
COBRA Slim 43 52 weeks 22/43 (51.2) (therapy
related); mean n AEs per
patient 1.2 (1.5)














































































































































































Any AEa Any SAEa,b Death
Withdrawals as a
result of an AEa
COBRA-
light44,45
COBRA 81 6 months44 ≥ 1 AE: 94% n= 3:
l Myocardial infarction, n= 1
l Planned cataract operation, n= 1
l Planned operation of the cervical
spine, n= 1
NR 1 manic episode
COBRA-light 81 6 months ≥ 1 AE: 90% l n= 6:
l Planned knee replacement, n= 1
l Planned hallux valgus surgery, n= 1
l Planned varicose vein surgery, n= 1
l planned control colonoscopy for
diverticulosis, n= 1
l Hospitalisation for arrhythmia, n= 1






l Myocardial infarction, n= 1
l Pulmonary embolism, n= 1
l Hospitalisation for pneumonia, n= 1
l Planned cataract surgery on both
eyes (2×), n= 2
l Planned surgery of the cervical
spine, n= 1
l Attempted suicide because of
depression, n= 1
l Fibula fracture caused by MTX
osteopathy, n= 1
l Pelvis fracture, n= 1
Numbers of SAEs or patients not


























Any AEa Any SAEa,b Death
Withdrawals as a
result of an AEa
COBRA-light 81 12 months NR n= 16:
l Lung carcinoma, n= 2
l Planned knee replacement
surgery, n= 2
l Planned hallux valgus surgery, n= 1
l Planned varicose vein surgery, n= 1
l Planned control colonoscopy for
diverticulitis, n= 1
l Hospitalisation for arrhythmia, n= 1
l Manic episode, n= 1
l Replacement and hospitalisation for
a retina bleeding, n= 1
l Planned surgery for cyst
removal, n= 1
l Hospitalisation for anaemia caused
by duodenal ulcers, n= 1
l Planned cholecystectomy, n= 1
l Surgery for an inguinal hernia, n= 1
l Hospitalisation and surgery for a hip
fracture after a fall, n= 1
l Surgery for chronic synovitis, n= 1




97 2 years 68 (70) SAEs (necessitating hospital admission,
life-threatening, fatal or malignant




98 2 years 70 (71) SAEs (necessitating hospital admission,
life-threatening, fatal or malignant






NR 12 months 141 AEs, n patients not
reported





NR 12 months 135 AEs, n patients not
reported
















































































































































































Any AEa Any SAEa,b Death
Withdrawals as a
result of an AEa
TEAR58 Immediate ETN 244 102 weeks 193 (79.1) 35 (14.3) 1 12 (4.9):
l SAE, n= 8
l AE, n= 3
l Death, n= 1
Immediate
triple therapy
132 102 weeks 101 (76.5) 18 (13.6) 1 7 (5.3):
l SAE, n= 2;
l AE, n= 4
l Death, n= 1
Step-up ETN 255 102 weeks 187 (73.3) 32 (12.5) 2 9 (3.5):
l SAE, n= 2
l AE, n= 5
l Death, n= 2
Step-up triple
therapy
124 102 weeks 92 (74.2) 16 (12.9) 0 4 (3.2):
l SAE, n= 2
l AE, n= 2
l Death, n= 0
NR, not reported.
a Refers to the number of patients, unless otherwise specified.
b Defined in the trial as a SAE.
c Between-group difference p= 0.006.
d Patient n not reported.































metabolic Cardiovascular Dermatological Ophthalmological Gastrointestinal Infectious Psychological Other
BeSt30,31,33 Sequential
monotherapy














128 1 year NR NR 2 (2) 8 (6) NR 14 (11) 10 (8) NR NR
Sequential
monotherapy
126 5 years31 NR NR 20 (16) Dermal/mucosal:
34 (27)











121 5 years NR NR 21 (17) Dermal/mucosal:
36 (30)












133 5 years NR NR 36 (27) Dermal/mucosal:
39 (29)
































































































































































































128 5 years NR NR 26 (20) Dermal/mucosal:
24 (19)












91 16 weeks NR NR NR Discomfort: 111
AEsb
NR NR 5 AEsb NR Toxicity: 27 AEsb
Others: 4 AEsb
Surgery: 1 AE
COBRA Slim 96 16 weeks NR NR NR Discomfort: 50
AEsb




91 16 weeks NR NR NR Discomfort: 96
AEsb




98 52 weeks NR NR NR Itch and rash: 4
AEsb
0 45 AEsb 11 AEsb NR Malaise: 52 AEsb
Liver function
abnormalities: 17 AEsb
Hair loss: 7 AEsb
Changed in appetite
related: 18 AEsb
GC related: 9 AEsb
Blood level related: 7
AEsb



































metabolic Cardiovascular Dermatological Ophthalmological Gastrointestinal Infectious Psychological Other




48 AEsb 8 AEsb NR Malaise: 22 AEsb
Liver function
abnormalities: 17 AEsb
Hair loss: 10 AEsb
Changed appetite
related: 3 AEsb
GC related: 5 AEsb
Blood level related: 3
AEsb








93 52 weeks NR NR NR Itch and rash: 1
AE b
0 67 AEsb 7 AEsb NR Malaise: 30 AEsb
Liver function
abnormalities: 22 AEsb































































































































































































metabolic Cardiovascular Dermatological Ophthalmological Gastrointestinal Infectious Psychological Other
CareRA: low-risk
patients40,43
MTX-TSU 47 16 weeks NR NR NR NR NR 11/47 (23.4) 1/47 (2) NR NR
COBRA Slim 43 16 weeks NR NR NR NR NR 10/43 (23.3) 0/43 (0) NR NR




20 AEsb 7 AEsb NR Malaise: 11 AEsb
Liver function
abnormalities: 6 AEsb
Hair loss: 3 AEsb
Change in appetite in
related: 0 AEsb
GC related: 0 AEsb
Blood level related: 0
AEsb










15 AEsb 2 AEsb NR Malaise: 12 AEsb
Liver function
abnormalities: 3 AEsb
Hair loss: 5 AEsb
Change in appetite
related: 4 AEsb
GC related: 0 AEsb
Blood level related:
2 AEsb




































COBRA-light44,45 COBRA 81 6 months NR NR 0 37% NR 42% 42% NR ≥ 5-kg gain in weight,
reported as n= 7 (9%)
(suggests safety n of
78). New diagnosis of
type 2 diabetes,
reported as n= 2.
Hypertension reported
as n= 1
COBRA-light 81 6 months NR NR 1 (myocardial
infarction)
43% NR 42% 40% NR ≥ 5-kg gain in weight,







97 2 years 23 (24) NR NR NR NR 29 (30) NR NR l Respiratory,
n= 14 (14)
l Central nervous































































































































































































metabolic Cardiovascular Dermatological Ophthalmological Gastrointestinal Infectious Psychological Other
Single-drug
treatment
98 2 years 16 (16) NR NR NR NR 30 (31) NR NR l Respiratory,
n= 14 (14)
l Central nervous






























l Other, n= 22b
Step-up
therapy













































metabolic Cardiovascular Dermatological Ophthalmological Gastrointestinal Infectious Psychological Other
TEAR58 Immediate
ETN
































































































































































































































metabolic Cardiovascular Dermatological Ophthalmological Gastrointestinal Infectious Psychological Other













































a Refers to the number of patients, unless otherwise specified.




















































NR NR l 88 (59.1) patients
experienced 453
CNS AEs in 3191
evaluationsd





l 58 (38.9) patients
experienced 326
renal AEs in 3191
evaluations




















































































































































































































NR NR l 54 (38.6) patients
experienced 169
CNS AEs in 1132
evaluationsd





l 62 (44.3) patients
experienced 178
renal AEs in 1132
evaluations

















CNS, central nervous system; NR, not reported.
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